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Summary
Serotonin is a naturally occuring amine with vaso-active 
properties; its role in the pathogenesis of hypertension 
is unknown. Serotonin in blood is stored in platelets, and 
is released during platelet aggregation. Normally, only 
negligable amounts of serotonin are present in the plasma. 
Platelets from patients with untreated essential
hypertension (n=22) showed increased serotonin-induced 
aggregation in whole blood in-vitro compared to age and 
sex matched normotensive controls (n=20). Enhanced 
platelet aggregation could contribute to raised arterial 
pressure in hypertension, by increasing free plasma levels 
of vasoconstrictors such as serotonin. However,
spontaneous platelet aggregation in whole blood was not 
enhanced in these hypertensive patients.
Enhanced platelet aggregation in-vivo might be expected 
to cause a reduction in platelet contents, such as 
serotonin, and an increase in free plasma levels of 
platelet contents, such as beta-thromboglobulin and 
serotonin. I developed therefore a highly reproducible 
(intra and interassay co-efficients of variation 2.2% and 
7.1% respectively), sensitive method (limit of detection 
<5pmol/ml) using high pressure liquid chromatography with 
electrochemical detection to allow accurate measurement of 
platelet serotonin. Levels of platelet serotonin and 
plasma beta-thromboglobulin were not altered in 
hypertensive patients compared to age and sex matched 
normotensive controls. These findings do not support
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increased platelet aggregation in-vivo as an invariable 
feature of essential hypertension.
Serotonin's vasoconstrictor effects are claimed to be 
mediated through the type-2 subset of serotonergic 
receptors. In-vitro studies suggest that serotonin acts 
not only in its own right as a vasoconstrictor but that it 
also potentiates the effects of other vasoconstrictors 
such as noradrenaline and angiotensin II. This effect can 
be shown in isolated blood vessels from normal and 
hypertensive animals, and appears to be mediated through 
the serotonergic type-2 binding site. The introduction of 
antagonists at this site capable of reducing blood 
pressure has lead to renewed interest in the possible role 
of serotonin in raising blood pressure.
Ketanserin was the first agent available for the 
investigation of the putative role of the serotonergic 
type-2 receptor in blood pressure control in man. It is a 
competitive serotonergic type-2 antagonist and an 
effective antihypertensive agent. I set out therefore to 
examine the claimed mechanism of action of this drug. 
Although initially disputed, ketanserin also has alpha-1 
adrenoreceptor antagonist activity when given in doses 
used to treat hypertension in man; this may contribute to 
its antihypertensive effects. In a double blind randomised 
placebo controlled study of 8 healthy subjects ketanserin 
40mg twice daily for 3 days reduced significantly mean 
arterial pressure but did not attenuate the pressor 
response to infused angiotensin II. This confirmed that 
the attenuation of response to alpha-1 agonists caused by
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ketanserin was related4 to an alpha-1 adrenoreceptor 
effect, and indicated, in contrast to in-vitro findings, 
that serotonin does not potentiate the vasoconstrictor 
effects of angiotensin II in-vivo. It follows that the 
short-term reduction of blood pressure caused by 
ketanserin in these subjects was not likely to be related 
to inhibition of angiotensin II-induced vasoconstriction.
Ketanserin reduces blood pressure by vasodilatation but 
unexpectedly does not seem to cause an appropriate reflex 
tachycardia even after acute administration. The drug 
reduced mean arterial pressure and heart rate by 
5.7jHl.8mmHg (mean+standard error; p<0.05) and 3.5_+1.5 
beats/minute (p<0.05) respectively compared to placebo, at 
1 hour after dosing on day 4. This reduction in heart rate 
was accompanied by a tendency (not statistically 
significant) for cardiac vagal outflow, assessed by the 
heart rate responses to standing, deep breathing and the 
Valsalva maneouvre, to be reduced rather than increased 
after ketanserin compared to placebo. Thus the reduction 
in heart rate caused by ketanserin is unlikely to be 
caused by increased cardiac parasympathetic outflow.
Ketanserin 40mg twice daily for 3 days caused 
prolongation of the electrocardiographic QT and QTC 
intervals by 26-40 milliseconds compared to placebo. This 
finding is consistent with Class III antiarrhythmic 
activity. It is likely that this effect is mediated 
through the serotonergic type-2 rather than the alpha-1 
adrenoreceptor, as- the highly selective serotonergic 
type-2 antagonist ritanserin, given in a dose of lOmg
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twice daily for 4 weeks to patients with essential 
hypertension, also caused prolongation of the QTC 
interval, by 39jfll milliseconds (p<0.05 compared to 
placebo). Although a minor prolongation this is an 
important observation as in some situations, for example 
hypokalaemia, patients may be predisposed to ventricular 
arrythmias.
A considerable body of evidence has accrued, mainly from 
in-vitro studies, to indicate a role for serotonin in the 
regulation of plasma renin, aldosterone and cortisol. 
Reduced activity of the renin-angiotensin system or 
adrenal cortex could contribute to the antihypertensive 
effects of ketanserin. However, 3 days of ketanserin 40mg 
twice daily did not affect basal plasma renin, 
aldosterone, angiotensin II, and cortisol, or importantly 
the rise in plasma aldosterone and suppression of plasma 
renin caused by infused angiotensin II in normotensive 
subjects. These findings do not support a major role for 
the serotonergic type-2 receptor in the control of plasma 
renin, aldosterone or cortisol in healthy man.
To try and dissect out further the role of serotonin in 
blood pressure control, studies were undertaken using 
ritanserin, a new highly selective serotonergic type-2 
antagonist. This drug differs from ketanserin in that it 
is virtually devoid of alpha-1 adrenoreceptor binding 
affinity in. vitro. When given in a dose of lOmg orally, 
ritanserin has been shown to have central effects, 
significantly altering sleep patterns in man. Ten patients 
with untreated essential hypertension were given single
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oral doses of ritanserin 10 and 20mg, ketanserin 40mg and 
placebo in a double blind randomised crossover study. 
Ketanserin caused a significant reduction in sitting mean 
arterial pressure (p<0.05 compared to placebo), while
ritanserin had no significant effects on sitting or 
standing blood pressure in either dose, compared to 
placebo. This did not support the concept that serotonin 
antagonism plays an independent role in acute blood 
pressure reduction caused by ketanserin. To look for an 
effect of more chronic therapy, ritanserin lOmg twice 
daily was given for 4 weeks in a double blind randomised 
placebo controlled parallel group study of patients with 
untreated essential hypertension. Ten patients received 
ritanserin and 8 placebo. Chronic ritanserin treatment
inhibited serotonin — induced platelet aggregation (p<0.05 
compared to placebo), an effect mediated through the 
serotonergic type-2 receptor, but did not significantly 
lower blood pressure in patients with essential 
hypertension. Ritanserin had no significant effect on 
forearm blood flow or venous tone, measured by
mercury-in-strain-gauge plethysmography. These findings do 
not support a major independent role for the serotonergic 
type-2 receptor in the maintenance of raised arterial 
pressure in essential hypertension or in the regulation of 
tone of forearm resistance vessels or veins in these 
patients. Furthermore, it is unlikely that enhanced 
serotonin— induced platelet aggregation in patients with 
untreated essential hypertension is a direct contributory 
factor to raised arterial pressure in these patients.
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Serotonin has'been claimed to be a possible mediator of 
brochoconstriction. A logical extension to the main thrust 
of this work was then to examine the effects of 
serotonergic antagonists in patients with asthma. In a 
double blind randomised placebo controlled crossover study 
of 8 adult atopic asthmatics, ketanserin 40mg orally had 
no significant acute effects compared to placebo on 
resting bronchomotor tone or in preventing exercise 
induced asthma. These findings do not support a major 
contributory role of the serotonergic type-2 receptor in 
the regulation of resting bronchomotor tone or in exercise 
induced bronchoconstriction in adult atopic asthma, but 
suggest that ketanserin is likely to be safe for use as an 
alternative antihypertensive agent in patients with this 
condition.
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Chapter 1; Introduction
1.1 Discovery of serotonin
In 1918, Janeway et al reported that serum contained a 
factor which caused vasoconstriction. The vasoconstriction 
was dependent on blood clotting, as carefully prepared 
plasma did not have this effect. The substance responsible 
for this vasoconstrictor activity was isolated and
identified by two separate groups of workers, and
initially given the name of serotonin (Rapport et al,
1948) or enteramine (Erspamer and Asero, 1952).
1.2 Biosynthesis and metabolism of serotonin
Serotonin (5-hydroxytryptamine) biosynthesis (figure 1) 
requires the essential aromatic amino-acid tryptophan 
(Culley et al., 1963). The rate limiting step is the
hydroxylation of tryptophan by the enzyme tryptophan 
hydroxylase to 5-hydroxytryptophan (Tong & Kaufman, 1975). 
This reaction is highly dependent on the presence of 
oxygen and the co-factor tetrahydrobiopterin (Baumann, 
1985). Synthesis of serotonin can only take place in 
tissues which contain tryptophan hydroxylase. The 
ubiquitous enzyme aromatic L-amino-acid decarboxylase then 
catalyses the step from 5-hydroxytryptophan to serotonin 
(Bouchard & Roberge, 1979). The main mode of metabolism of 
serotonin (figure 1) is by monoamine oxidase A, producing 
the unstable intermediate compound
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Tryptophan
i CH9—  CH—  COOH
I
n h2
Tryptophan hydroxylase
5-hydroxytryptophan iC H o — CH— COOH
L-aromatic amino acid decarboxylase
5-hydroxytryptamlne
(serotonin)
iC H 2—  c h 2—  n h2
Monoamine oxidase
5-hydroxy 1ndo1eacetaldehyde
rC H 2 — CHO
Aldehyde dehydrogenase
HO
5-hydroxylndoleacetlc acid JCH2 — COOH
Figure 1
Serotonin biosynthesis and major pathway of metabolism.
5-hydroxyindoleacetaldehyde (Youdim & Ashkenazi, 1982). 
This aldehyde undergoes oxidation, catalysed by aldehyde 
dehydrogenase (Erwin & Deitrich, 1966), resulting in the 
major final metabolite 5-hydroxyindole acetic acid, which 
is excreted in the urine (Tyce et al., 1983). The aldehyde 
can also be reduced by aldehyde reductase forming 5 
hydroxytryptophol (Tyce et al., 1968), although this
pathway is usually of less importance than oxidation.
1.3 Serotonin receptor sites
The first classification of serotoninergic receptors was 
by Gaddum and Picarelli (1957). They discovered that 
serotonin-induced contractions in isolated ileal segments 
were antagonised by morphine and dibenzyline 
(phenoxybenzamine). These two drugs appeared to act at 
different sites, designated by their first letters as M 
and D binding sites, associated with cholinergic nerves 
and smooth muscle cells respectively. Although this 
classification remains valid it did not prove to be of 
major use in understanding the cardiovascular effects of 
serotonin (Fozard 1984) .
In 1979 Peroutka and Snyder published the results of 
receptor binding studies in rat brain which were to 
provide the basis of much of our current understanding of 
the effects of serotonin in cardiovascular regulation. 
They demonstrated two separate serotonin binding sites 
which preferentially bound tritium labelled serotonin and 
spiroperidol, and designated them 5HT-1 and 5HT-2
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respectively. The serotonergic type-2 binding site is 
thought to be equivalent to Gaddum and Picarelli's D 
receptor (Fozard, 1984).
Peripherally, serotonin is thought to act through 5HT-1 
receptor sites to cause vasodilatation and at 5HT-2 sites 
to cause vasoconstriction (1.5.2). Radioligand binding 
studies suggest that several different subtypes of the 
5HT-1 site exist (Pedigo, Yamamura & Nelson, 1981; 
Middlemiss & Fozard, 1983; Pazos, Hoyer & Palacios, 1985). 
Gaddum and Picarelli's M receptor has now been 
redesignated 5HT-3 (Gothert & Schliker, 1987). There is 
also evidence that several different subtypes of the 5HT-3 
binding site exist. A subtype, 5HT-3A, has been identified 
on substance P containing neurones in guinea pig ileum 
(Buchheit et al., 198 5). Pain caused by applying serotonin 
to blistered skin is not inhibited by methysergide (a 
5HT-1 and -2 antagonist) but is prevented by the compound 
ICS 205-930, acting at a site named 5HT-3B (Richardson et 
al. , 1985). The Bezold-Jarisch reflex, by which serotonin
causes reflex vagal bradycardia by a direct action on the 
coronary chemoreceptor, appears to be mediated through yet 
another subtype, designated 5HT-3C (Richardson et al., 
1985). These subtypes of 5HT-1 and -3 binding sites have 
not yet been shown to have a definite role in the 
regulation of cardiovascular function in man.
Many of the ligands which have been used to identify 
serotonin binding sites are structurally very different 
from serotonin itself. Furthermore, agents such as 
ketanserin, trazodone, and spiperone have widely differing
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affinities for supposed serotonergic type-2 receptors in 
different tissues (Leff & Martin, 1986). In marked 
contrast, tryptamine analogues, compounds which are 
structurally very similar to serotonin, have very 
consistent affinities for serotonin binding sites in 
different tissues (Leff, Martin & Morse, 1986). Thus, it 
is possible that serotonin binding sites identified by 
serotonin antagonists which are structurally dissimilar 
from serotonin do not correspond with true serotonin- 
receptor subtypes.
1.4 Serotonin in blood platelets and plasma
1.4.1 Gut enterochromaffin cells; the major source of 
blood serotonin.
It is likely that most of the serotonin present in 
peripheral blood comes from enterochromaffin cells in the 
gut (Pletscher, 1968). In mammals, the largest store of 
serotonin in the body is in gut enterochromaffin cells 
(Erspamer, 1954) , from where it is released by 
parasympathetic or sympathetic nerve stimulation, and 
increased intraluminal intestinal pressure and acidity 
(Forsberg & Miller, 1983). Serotonin may play a role in 
the regulation of gut peristalsis (Ruckebusche, 1984) and 
secretory function (Cho & Ogle, 1986; Jaffe, Ferrara & 
Sherlock, 1986). Some of the serotonin released from 
enterochromaffin cells finds its way into portal blood and 
then passes through the liver, where it is substantially
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inactivated by hepatic monoamine oxidase A (Thomas & Vane, 
1967). Serotonin which escapes metabolism by the liver is 
transported to the lungs, where most of the free amine 
that remains is removed by pulmonary endothelial cells. 
These cells have an avid uptake mechanism for serotonin 
(Lee & Fanburg, 1986) which they then metabolise through 
the monoamine oxidase A pathway (Gillis & Pitt, 1982) .
1.4.2 Blood platelets and serotonin:
Almost all the serotonin in blood is stored in platelets 
(Tranzer, Da Prada & Pletscher, 1966). Platelets cannot 
synthesise serotonin as they do not contain tryptophan 
hydroxylase (Morrissey, Walker & Lovenberg, 1977). Hence, 
platelet stores of serotonin are entirely dependent on 
uptake of serotonin from plasma. Platelets actively take 
up serotonin from plasma when the concentration of free 
serotonin is < 5jjM (Hardisty & Stacey, 1955) . This mode of 
uptake is inhibited by tricyclic antidepressants such as 
amitryptyline and imipramine (Peters & Grahame-Smith, 
198 0) . When the concentration of free serotonin is > lOpiM, 
the predominant mode of uptake changes to a passive 
mechanism (Malmgren et al., 1981). However, as maximal 
free serotonin levels in-vivo are in the low nanomolar
range (Molyneux & Clark, 1985) the passive mechanism is 
unlikely to play any physiological role. After uptake
through the external platelet membrane, serotonin is
stored in the dense granules as high molecular weight 
complexes with 5'di- and tri-phosphonucleotides and
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divalent cations (Pletscher, 1968). Storage in the dense 
granules is inhibited by reserpine (Da Prada & Pletscher,
1969) .
Serotonin and other platelet contents are released from 
platelets when platelet aggregation occurs. Aggregation 
occurs in a stepwise manner. Initially there is a 
reversible change in platelet shape from a disc to a spiny 
sphere, then platelet clumping occurs, and finally there 
is release of platelet contents (Holmsen, 1977). The 
contents of the dense granules, including serotonin, 
adenosine diphosphate, adenosine triphosphate, calcium and 
inorganic pyrophosphate, are released before the contents 
of the alpha granules, which include beta-thromboglobulin, 
platelet factor 4, acid hydrolases and fibrinogen 
(Holmsen, 1977; De Clerck, 1986). Adenosine diphosphate 
and serotonin can cause further platelet aggregation, 
initiating a positive feedback loop (Holmsen, 1977). 
Serotonin induces complete aggregation of cat platelets 
with platelet content release. This effect is inhibited by 
5HT-2 antagonists (De Clerck, Van Nueten & Reneman, 1984). 
In man, serotonin is a weak stimulant for platelet 
aggregation in platelet rich plasma (Holmsen & Karpatkin,
1983). I n  healthy subjects serotonin usually causes 
reversible platelet shape change in platelet rich plasma 
without proceeding to full platelet aggregation and 
content release. This shape change is .inhibited by 
serotonergic type-2 antagonists (De Clerck, David & 
Janssen, 1982). Serotonin also potentiates the effects of 
threshold concentrations of powerful stimulants to
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platelet aggregation, such as collagen and adenosine
diphosphate. This potentiation is again inhibited by
serotonergic type-2 antagonists (De Clerck et al., 1984).
Serotonin induced platelet aggregation appears therefore
to be largely mediated through the serotonergic type-2 
receptor.
Vasoactive substances released during platelet
aggregation can cause smooth muscle contraction in
isolated blood vessels. This effect is inhibited by
serotonergic type-2 antagonists (Vanhoutte & Cohen, 198 3). 
This suggests that serotonin released from aggregating
platelets can affect vascular tone.
1.4.3 Free plasma serotonin:
Problems of ex-vivo platelet aggregation and serotonin 
release make the estimation of free plasma serotonin
difficult and prone to artefact. With scrupulous
collection and preparation of samples, levels are 
virtually undetectable, < lng/ml (Molyneux & Clarke,
1985). There are several mechanisms for removing serotonin 
from plasma, including metabolism by the liver (Thomas & 
Vane, 1967) and lungs (Gillis & Pitt, 1982), and uptake by 
platelets (Peters & Grahame-Smith, 1980). Furthermore
there is a high affinity serotonin binding protein,
serotonectin, a glycoprotein which circulates in plasma 
both in the free state and bound to leucocyte and platelet 
membrane surfaces (Gershon & Tamir, 1984). Albumin has low 
affinity for serotonin, but can bind appreciable amounts,
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because of the large amount of this protein in plasma 
compared to serotonectin (Pignatti & Cavalli-Sforza, 
1975). Protein binding effectively reduces the amount of' 
serotonin circulating free in plasma.
1.4.4 Blood serotonin and the carcinoid syndrome.
Patients with the carcinoid syndrome, caused by a tumour 
of enterochromaffin cells, secrete large quantities of 
serotonin into their blood. However this syndrome is not a 
good model for studying the effects of serotonin excess on 
blood pressure, as other vasoactive hormones, such as 
Substance P, are also secreted (Emson et al., 1984).
1.5 Peripheral cardiovascular effects of serotonin
1.5.1 Effects of serotonin on different parts of the 
vasculature.
Serotonin causes contractions in in-vitro preparations 
of most large arteries, including rat caudal artery 
(Cohen, Fuller & Wiley, 1981) and rabbit femoral artery 
(Van Nueten et al., 1982), and in large veins (Victorzon,
Tapparelli & Muller-Schweinitzer, 1986). Concentrations of
—  6  *“ 710 to 10 M are required to elicit these effects. There 
is a close correlation between the affinity of antagonists 
for the serotonergic type-2 binding site and their ability 
to antagonise serotonin induced vasoconstriction in these 
preparations (Van Nueten et al., 1982). This suggests that
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serotonin-induced vasoconstriction is mediated through the 
type-2 binding site. Serotonin also amplifies the effect 
of other vasoconstrictors including noradrenaline, 
adrenaline, angiotensin II, prostaglandin F2 alpha and 
arginine vasopressin (Kubu & Su, 1983; Van Nueten et al., 
1982). These amplifying effects are also inhibited by 
antagonists drugs in correlation with their serotonergic 
type-2 binding affinity. However, serotonin induced 
vasoconstriction is not always mediated through the 
serotonergic type-2 binding site. Serotonin induced 
contraction of isolated rabbit basilar artery and dog 
saphenous vein is not affected by the serotonergic type-2 
antagonist ketanserin (Bradley, Humphrey & Williams,
1986). As the serotonergic type-1 agonist
5-carboxamidotryptamine causes vasoconstriction in these 
preparations, it has been concluded that the receptor 
mediating serotonin induced vasoconstriction in these 
cases is likely to be similar to the serotonergic type-1 
binding site (Bradley, Humphrey & Williams, 1986). The 
serotonergic type-2 antagonists ketanserin, trazodone and 
spiperone have variable effects on serotonin induced 
vasoconstriction in different tissues, not corresponding 
to their serotonergic type-2 receptor binding affinity 
(Leff & Martin, 1986). There are two main possible 
explanations for these findings. The binding sites for 
serotonin may differ between animal species. However, 
using tryptamine analogues (compounds structurally similar 
to serotonin) no differences could be found in serotonin 
receptors mediating vasoconstriction in blood vessels from
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different animal species (Leff, Martin & Morse, 1986).
This suggests that serotonergic binding sites identified 
by ligands such as ketanserin, trazodone or spiperone 
(compounds which are structurally dissimilar from 
serotonin) do not represent true serotonin receptor sites.
In small arteries and arterioles, serotonin causes
vasodilatation. This effect appears to be mediated through 
the serotonergic type-1 binding site as it is blocked by 
methysergide, a non-specific serotonergic type-1 and -2 
antagonist, but not by the serotonergic type-2 antagonist 
ketanserin (Feniuk, Humphrey & Watts, 1983, Marwood &
Stokes, 1983). The 5HT-1 agonist 5-carboxamidotryptamine 
also relaxes arterioles (Saxena & Verdouw, 1985).
Serotonin-induced vasodilatation of isolated contracted 
coronary arteries appears to be mediated through the 5HT-1 
receptor. Interestingly, this vasodilatation does not
occur in vessels stripped of endothelium (Cohen & 
Vanhoutte, 1985). The vasodilatation caused by serotonin 
in this preparation may be due to release of a
vasorelaxant factor from endothelial cells, such as 
endothelium derived relaxant factor.
1.5.2 Peripheral cardiovascular effects of serotonin in 
intact animals and man.
Serotonin does not readily cross the blood brain barrier 
(Lexchin, Cude-Simpson & Stancer, 1979), therefore
intravenous or intraperitoneal administration of serotonin 
can be used to investigate its action in the periphery. It
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is an unpleasant drug to administer intravenously (Page & 
McCubbin, 1953), causing nausea, dizziness, tingling and 
transient hyperventilation. Hence very few studies have 
examined the effects of intravenous serotonin in man.
Serotonin has complex actions on the cardiovascular 
system when administered intravenously to intact animals. 
An intravenous bolus of serotonin initially causes a 
reduction in blood pressure. This is due to a marked 
bradycardia caused by a direct action of serotonin on 
vagal afferents in the coronary vasculature initiating the 
Bezold Jarisch reflex, thought to be mediated through the 
M receptor (Kalkman, Engel & Hoyer, 198 4? Saxena & Lawang, 
1985; Saxena, Mylecharane & Heiligers, 1985). The binding 
site mediating this reflex also has been designated 5HT-3c 
(Richardson et al., 1985). After the initial depressor 
response there is a rise in blood pressure, caused by 
serotonin — induced vasoconstriction and a positive 
inotropic effect on the heart. This rise in blood pressure 
is thought to be mediated through the serotonergic type-2 
receptor as it is inhibited by serotonergic type-2 
antagonists (Kalkman et al., 1984? Saxena, Mylecharane & 
Heiligers, 1985). Lastly there is a prolonged period of 
hypotension due to serotonin induced peripheral 
vasodilatation thought to be mediated through the 
serotonergic type-1 receptor, as it is inhibited by drugs 
with serotonergic type-1 antagonistic activity such as 
methysergide but not by the serotonergic type-2 antagonist 
ketanserin (Marwood & Stokes, 1983? Kalkman et al., 1985? 
Saxena & Lawang, 1985). Similar triphasic responses have
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been reported in the rat, the dog and man (Page & 
McCubbin, 1953? Marwood & Stokes, 1984).
1.5.3 Interactions between serotonin and the
sympathetic nervous system in the periphery.
Serotonin may play a role in the regulation of 
noradrenaline release from sympathetic nerve endings. Low 
concentrations of serotonin decrease the release of 
noradrenaline (Langer, 1981; Shepherd & Vanhoutte 1981). 
Serotonin released from aggregating platelets has been 
shown to inhibit adrenergic neurotransmission in isolated 
arteries and veins (Lorenz & Vanhoutte, 1985). This effect 
is probably mediated through a presynaptic serotonergic 
type-1 like receptor (Lorenz & Vanhoutte, 1985). Although
. _5
high concentrations of serotonin (10 M) cause 
noradrenaline release (McGrath, 1977), it is unlikely that 
this mechanism plays any physiological role as free plasma 
serotonin levels are well below this range (1.3.3).
The effects of infused serotonin in the intact animal 
also depend on sympathetic nervous activity. Intravenous 
serotonin has a strong depressor effect in dogs made 
hypertensive by increasing sympathetic nervous outflow by 
sectioning buffer nerves. However, when sympathetic 
nervous activity is blocked serotonin causes a marked rise 
in blood pressure (Page & McCubbin, 1953). Similarly, 
Phillips, Mylecharane & Shaw, (1985) have shown that 
serotonin causes vasodilatation in the femoral bed of the 
dog in the presence of increased sympathetic tone. This
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effect of serotonin is thought to be mediated through a 
presynaptic inhibitory serotonergic receptor. In contrast, 
serotonin potentiates the vasoconstrictor response to 
intra-arterial noradrenaline in the forearm in man (Scroop 
& Walsh, 1968). Furthermore, serotonin augments the 
vasoconstrictor effects of noradrenaline in isolated blood 
vessels (Manzini, Maggi & Meli, 1986), an effect thought 
to be mediated through the serotonergic type-2 receptor 
(1.5.1). It has even been suggested that there may be 
structural overlap between serotonergic type-2 and alpha-1 
adrenoreceptors in the periphery (Marwood & Stokes, 198 4).
t
In conclusion there is evidence that the action of 
*■
serotonin at,' postsynaptic serotonergic type-2 receptors, 
augmenting noradrenergic vasoconstriction, may be opposed 
by its effects at presynaptic serotonergic type-1 
receptors where serotonin seems to inhibit noradrenaline 
release.
1.5.4 Effects of serotonin on the heart.
Serotonin is present in myocardial cells, which can 
sythethise and metabolise the amine (Sole, Schum & Van 
Loon, 1979). Serotonin may therefore have a local effect 
on myocardial function. Serotonin has a positive inotropic 
effect on cardiac muscle due to a local increase in 
noradrenaline concentration (Buccino et al., 1967; Reid,
1970). This action may be important when ventricular 
function is impaired (Sole et al., 1979). The receptor 
mediating the chronotropic effects of serotonin is
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controversial. In isolated kitten atrial cells, serotonin 
has a positive chronotropic effect which does not appear 
to be mediated through serotonergic type-1 or -2 receptors 
(Kaumann, 1983). In contrast the tachycardia response to 
infused serotonin in the rat appears to be mediated 
through a serotonergic type-2 like receptor (Saxena & 
Lawang, 1985), and in the cat through a serotonin 
type-l-like receptor (Saxena, Mylecharane & Heiligers,
1985). It is not clear whether these conflicting findings 
represent genuine differences between species, or are 
simply due to the use of different serotonergic
antagonists. These drugs may have variable effects as they
may not act at true serotonin receptor sites, as 
previously discussed (1.3).
1.6 Serotonergic neurones and the central regulation of 
heart rate
Serotonergic neurones may play a role in the central 
regulation of heart rate by modulating sympathetic and 
parasympathetic outflow. In the cat, the reduction in
heart rate caused by the serotonin precursor 
5-hydroxytryptophan appears to be due to a centrally
mediated decrease in sympathetic nervous activity (Baum & 
Shropshire, 1975). In the dog (Bhargava & Tangri, 1959), 
the cat (Baum & Shropshire, 1975) and the rat (Lambert et 
al., 197 8) intracerebroventricular serotonin causes a fall 
in heart rate associated with reduced sympathetic nervous 
activity. Therefore, increased levels of brain serotonin
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appear to reduce heart rate at least partly by lowering 
sympathetic nervous activity.
Serotonergic neurones may also influence parasympathetic 
control of heart rate. In the rat, intracerebroventricular 
serotonin reduces heart rate by increasing parasympathetic 
outflow as well as reducing sympathetic outflow (Dalton,
1986). The precursor 5-hydroxytryptophan, given to 
increase cerebral serotonin levels, attenuates reflex 
vagal bradycardia in the rat (Lin & Chern, 1979) . 
Baroreceptor mediated reflex vagal bradycardia in the cat 
is also inhibited by intracerebroventricular
5-hydroxytryptophan (Tadepalli, 1980). This effect appears 
to be dependent on central conversion of 
5-hydroxytryptophan to serotonin, as it is prevented by 
peripheral decarboxylase inhibition (Tadepalli, 198 0). 
Conversely, depletion of serotonin in the rat brain with 
intracerebroventricular para-chlorophenyalanine or
5,7-dihydroxytryptamine enhances reflex vagal bradycardia 
caused by peripheral infusion of adrenaline (Lin & Chern, 
1979) .
Thus, there is substantial evidence from animal studies 
that serotonergic neurones play a role in the regulation 
of heart rate by altering sympathetic and parasympathetic 
cardiac nervous outflow. It is not clear at which receptor 
site or sites serotonin mediates these effects.
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1.7 Serotonergic neurones and the central regulation of 
blood pressure
1.7.1 Effects of alteration of serotonergic neuronal 
activity on blood pressure.
The serotonin precursors tryptophan and
5-hydroxytryptophan, administered centrally or
peripherally, are used to increase cerebral serotonin 
levels. Tryptophan usually does not alter blood pressure, 
except in very high doses in rats (Sved, Fernstrom & 
Wurtman, 1979) or after pretreatment with a monoamine 
oxidase inhibiter in cats (Florez & Armijo, 1974) . High 
doses of tryptophan are not required to achieve maximal 
increases in brain serotonin levels, therefore the 
alteration of blood pressure seen by Sved et al. (1979) is 
probably due to a direct effect of tryptophan itself. 
Monoamine oxidase inhibitors can themselves alter blood 
pressure, also they affect the degradation of 
noradrenaline, a substance unequivocally implicated in 
blood pressure control (Kuhn, Wolf & Lovenberg, 1980) .
Administration of the serotonin precursor 
5-hydroxytryptophan usually causes a reduction in blood 
pressure. In the decerebrate and intact cat 
5-hydroxytryptophan reduces blood pressure (Baum & 
Shropshire, 1975; Tadepalli, Mills & Schanberg, 1977; 
Florez & Armijo, 1974; Freed, Echizen & Bhaskaran, 1985) . 
Intravenous and intracerebroventricular
5-hydroxytryptophan decrease blood pressure in dogs
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(McCubbin, Kameko & Page, 196 0; Rabinowitz & Lown, 1978). 
This effect is associated with reduced sympathetic nervous 
activity (McCubbin et al., 1960). However, other 
investigators found that 5-hydroxytryptophan causes an 
increase in blood pressure in dogs (Dunkley et al., 1972). 
In all these studies, effects of 5-hydroxytryptophan on 
blood pressure are prevented by decarboxylase inhibition, 
suggesting that these effects are dependent upon 
conversion to serotonin. Thus, the data on the effects of 
5-hydroxytryptophan on blood pressure are conflicting. A 
possible explanation for this comes from a recent study 
which suggests that the effects of centrally administered 
5-hydroxytryptophan may be dose dependent. In the rat, 
large doses of 5-hydroxytryptophan cause a reduction in 
blood pressure, whereas small doses produce a rise in 
blood pressure (Dalton et al., 1986).
Conflicting data have also arisen from studies of the 
effects of electrical stimulation of serotonergic neurones 
in the medullary raphe; blood pressure has been found to 
increase or decrease in different animal species (Coote & 
McLeod, 1974; Koss & Wang, 1972; Neumayer, Hare & Franz, 
197 4). Furthermore, activation of serotonergic neurones in 
different anatomical areas can cause opposite effects on 
blood pressure in the one animal species (Adair et al., 
1977).
Para-chlorophenylalanine (PCPA) is an irreversable£
•
inhibitor of tryptophan hydroxylase. It can therefore be 
used to inhibit serotonergic neuronal activity. However 
this substance has had variable effects on blood pressure.
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In the rat, intraperitoneal and intracerebroventricular 
PCPA increase blood pressure (Ito & Schanberg, 1972), 
whereas oral PCPA decreases blood pressure (Jarrott et 
al., 1975). PCPA appears to have no effect on blood 
pressure in cats (Helke et al., 1976; Helke, Quest &
Gillis, 1978) or rabbits (Wing & Chalmers, 1974).
The neurotoxins 5,6- and 5,7-dihydroxytryptamine are 
taken up into serotonergic and noradrenergic neurones. 
Pretreatment with desimipramine inhibits noradrenaline 
uptake and increases the specificity of these neurotoxins 
for serotonergic neurones. Using these methods
intracerebroventricular 5,7-dyhydroxytryptamine reduces 
blood pressure in the spontaneously hypertensive rat 
(Gothert & Klupp, 1978). Injection of
5,7-dihydroxytryptamine into the dorsal raphe inhibits the 
pressor response to electrical stimulation of this area in 
the Sprague Dawley rat (Robinson, Austin & Gibbens, 1985).
The great variability of effects of activation or 
inhibition of the serotonergic nervous system is probably 
due to several factors. The various mechanisms used in 
these experiments lack specificity. There are definite
differences between species. Effects of these studies 
depend also on the activity of other counter-regulatory 
mechanisms for blood pressure control. As in the 
periphery, different serotonergic receptor subtypes may 
have opposing effects on blood pressure (1.5.1). It is not
possible to draw firm conclusions on the role of
serotonergic neurones in the central regulation of blood 
pressure in man from these studies.
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1.7.2 Effects of alterations of blood pressure on 
serotonergic neuronal activity.
During drug induced hypertension serotonergic neuronal 
acivityin the dorsal raphe and nucleus tractus solitarius 
is increased. This effect is blocked by sino-aortic 
denervation, and is therefore thought to be mediated 
through the baroreceptors (Freed et al., 1985). This
provides indirect evidence that changes in serotonergic 
neuronal activity may be involved in baroreceptor mediated 
regulation of blood pressure.
1.7.3 Interaction between serotonergic and
noradrenergic neurones in the central regulation of blood 
pressure.
It is likely that there is an interaction between 
serotonergic neurones and sympathetic control of blood 
pressure. Serotonergic neuronal tracts have a close 
anatomical association with noradrenergic neuronal 
pathways which are involved in blood pressure control. 
Several studies in cats and dogs suggest that increased 
levels of brain serotonin cause a reduction in sympathetic 
nervous outflow (Baum & Shropshire 1975; Tadepalli et al., 
1977; Antonaccio & Taylor, 1977; Coote & McLeod, 1974; 
Koss & Wang, 1972; Neumayer et al., 1974).
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1.8 Serotonergic neurones and behaviour
Serotonergic neurones may play a role in the regulation 
of neuropsychological function. In man, the serotonergic 
agonists lysergic acid diethylamide (LSD) and 
M-chlorophenylpiperazine cause anxiety, activation and 
euphoria (Mueller, Murphy & Sunderland, 1985). 
Serotonergic type-2 antagonists such as ritanserin inhibit 
LSD induced behavioural changes in animal models (Colpaert 
et al., 1985) and improve symptoms in patients with 
anxiety disorders (Ceulemans et al., 1985). In animals, 
serotonin, serotonin precursors and serotonergic agonists 
cause behavioural excitation; these effects appear to be 
mediated through the serotonergic type-2 receptor (Leysen,
1984). In view of all these findings, there is great 
interest in the potential use of serotonergic type-2 
antagonists as anxiolytics.
Chronic treatment with known effective antidepressant 
drugs generally down-regulates serotonergic type-2 
receptor sites, although the situation is complex as 
serotonergic neuronal transmission is usually increased 
due to inhibition of serotonin uptake (Willner, 1985) . The 
precise role of serotonergic neurones in the pathogenesis 
of depression remains controversial.
Drugs that act at serotonergic type-1 receptor subtypes 
affect behaviour in mice and rats (Goodwin & Green, 1985). 
However serotonergic type-1-like receptors have not yet 
been shown to have a definite role in the control of 
behaviour in man.
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1.9 Effects of serotonin on the renin-angiotensin
system and adrenocortical function
It has been claimed that serotonin plays a role in the 
regulation of plasma renin, aldosterone and cortisol. 
Serotonin and its precursor tryptophan increase plasma 
renin in rats (Meyer & Hertting, 1974) and man (Modlinger, 
Schonmuller & Arora, 1979) respectively. Stimulation of
serotonergic neurones with p-chloroamphetamine in rats
causes a rise of plasma renin (Van De Kar & 
Richardson-Morton, 198 6). This effect does not appear to 
be due to alterations in sympathoadrenal activity (Van De 
Kar & Richardson-Morton, 1986). Serotonin uptake blockers 
inhibit fenfluramine induced rises in plasma renin in the
rat (Van De Kar, Richardson-Morton & Urban, 1985). In man, 
non-selective serotonergic type-1 and -2 blockade with 
cyproheptidine inhibits the rise in renin caused by sodium 
depletion (Epstein & Hamilton, 1977). It is thought that 
all these effects are mediated centrally through 
serotonergic neurones.
Serotonin causes increased production of aldosterone and 
corticosterone in isolated rat zona glomerulosa cells. 
This effect appears to be mediated through the
serotonergic type-2 receptor as it is inhibited by
ketanserin, a serotonergic type-2 antagonist with alpha-1 
adrenoreceptor blocking activity, but not by the alpha-1 
adrenoreceptor antagonist prazosin (Williams, Shaikh & 
Edwards, 1984). The increased production of aldosterone 
and cortisol from zona glomerulosa cells caused by
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angiotensin II is inhibited by ketanserin, suggesting that 
adrenal serotonergic type-2 receptors may modify 
angiotensin II stimulated aldosterone production (Rocco et 
al., 1985). Serotonin induced aldosterone production in 
isolated rat zona glomerulosa cells appears to be linked 
through the serotonergic type-2 receptor to increased 
adenylate cyclase activity (Matsuoka et al., 1985). Thus 
there is good evidence from these in-vitro studies that 
serotonin acts in the periphery at the serotonergic type-2 
receptor in the adrenal zona glomerula to enhance 
steroidogenesis.
Serotonergic neurones may be involved in the central 
regulation of steroidogenesis. The increase in serum
corticosterone levels in rats caused by the non-specific 
serotonergic agonist quipazine is inhibited by ketanserin 
(Fuller & Snoddy, 1984). This is thought to be a central 
serotonergic type-2 effect, as enhanced steroidogenesis 
caused by quipazine is not blocked by peripheral 
serotonergic antagonists such as xylamidine (Fuller & 
Snoddy, 1983). Serotonergic agonists increase
corticotrophin releasing factor release from in vitro
preparations of rat hypothalamus (Holmes et al., 1982). In 
the intact rat, serotonergic agonists increase serum 
coricotrophin releasing factor (Gibbs & Vale, 198 3) and 
adrenocorticotrophic hormone (Bruni, Hawkins & Yen, 1982). 
In man, the serotonergic type-2 antagonist ketanserin 
attenuates the rise in adrenocorticotrophic hormone caused 
by hypoglycaemia (Prescott et al., 1984). The serotonin 
precursor tryptophan increases plasma aldosterone and
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cortisol in healthy man (Modlinger et al., 1979). 
Similarly, M-chlorophenylpiperazine, a serotonin agonist, 
increases plasma cortisol in healthy subjects (Mueller et 
al., 1985). The serotonin precursor 5-hydroxytryptophan 
increases plasma aldosterone in healthy man, but this 
effect is not inhibited by either the serotonergic type-2 
antagonist ketanserin or the non-selective serotonergic 
type-1 and -2 antagonist methysergide (Shenker, Gross & 
Grekin, 1985a). Thus it is not clear which receptor type 
mediates the rise in aldosterone caused by 
5-hydroxytryptophan. However, inhibition of peripheral 
decarboxylase activity with carboxydopa potentiates the 
effects of 5-hydroxytryptophan, suggesting that 
5-hydroxytryptophan induced aldosterone production is 
mediated through central conversion to serotonin, as 
5-hydroxytryptophan itself does not increase aldosterone 
production in isolated zona glomerulosa cells (Shenker, 
Gross & Grekin, 1985b). The serotonergic type-1 and -2 
antagonist cyproheptidine reduces plasma aldosterone in 
patients with idiopathic hyperaldosteronism (Gross et al., 
1981). This effect also is probably mediated through a 
central pathway, as peripheral decarboxlase inhibition 
potentiates the effects of cyproheptidine (Gross et al., 
1981) .
Thus, there is evidence to suggest that serotonin is 
involved in both the central and the peripheral regulation 
of aldosterone and cortisol production.
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1.10 Effects of serotonin on bronchial smooth muscle
In the cat and dog exogenously administered serotonin 
has a direct action on bronchial smooth muscle, causing 
constriction of both central and peripheral airways 
(Colebatch, Olsen & Nadel, 1966). The direct effect of 
serotonin on respiratory smooth muscle appears to be 
mediated through the serotonergic type-2 receptor (Cohen 
et al., 1985; Saxena & Lawang, 1985). Serotonin may have 
also an effect on the efferent vagal pathway, potentiating 
vagal bronchoconstriction, as central bronchoconstriction 
caused by stimulation of the vagus nerve in the dog is 
potentiated by inhaled serotonin (Sheller et al., 1982). 
However not all investigators have confirmed this finding; 
parasympathetic mediated constriction in isolated guinea 
pig trachea is not affected by serotonin (McCaig, 1986). 
Serotonin-induced bronchoconstriction in the cat is partly 
mediated by inhibition of the non-adrenergic 
non-cholinergic neural system (Bai, Macklem & Martin, 
198 6). Despite the in-vitro and animal data, the role of 
serotonin in the regulation of airway calibre in man 
remains unclear.
If serotonin is an important mediator of 
bronchoconstriction in man, it is likely that the main 
source would be from enhanced platelet aggregation and 
content release. Although platelet aggregation has been 
claimed to be increased in both allergen (Knauer et al., 
1981) and exercise induced asthma in man (Johnson et al., 
1984), not all studies have confirmed this (Durham et al.,
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1984) . An association between enhanced platelet 
aggregation and exercise or allergen induced 
bronchoconstriction in man has not been firmly 
established.
1.11 Non-specific serotonergic type-1 and -2
antagonists
Of the non-specific serotonergic type-1 and -2
antagonists available, the effects on the cardiovascular 
system of cyproheptidine and methysergide have been the 
most thoroughly investigated. Cyproheptidine is also a 
potent histamine type-1 receptor antagonist (Stone et al., 
1961). It has no detectable effects on blood pressure 
(Stone et al., 1961; Marwood & Stokes, 1983). Methysergide 
has partial agonist activity at serotonergic type receptor 
sites (Saxena, Bolt & Dhasmana, 1987). It acts centrally, 
reducing blood pressure by lowering sympathetic outflow 
(Antonaccio & Taylor, 1977). It is not clear whether this 
central effect is mediated through 5HT-1 or -2 receptors.
Methysergide has no peripheral effects on the
cardiovascular system (Antonaccio & Taylor, 1977). However 
these findings do not exclude a role for serotonin in the 
regulation of blood pressure in the periphery, as 
serotonergic type-1 and -2 antagonism may have opposing 
effects on vascular tone (1.5.1).
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1.12 The serotonergic type-2 antagonist ketanserin
1.12.1 Receptor binding affinity of ketanserin.
Ketanserin is the first clinically available 
serotonergic type-2 antagonist which is virtually devoid 
of serotonergic type-1 binding affinity (Leysen et al,
1981) . In most tissues it is a competitive serotonergic 
type-2 antagonist (Van Nueten et al., 1981; Marwood &
Stokes, 1983). Importantly, ketanserin has no partial 
agonist effects (Leysen et al., 1981). However, ketanserin 
also has appreciable alpha-1 adrenoreceptor binding 
affinity, approximately one fifth of its affinity for the 
serotonergic type-2 receptor (Leysen et al., 1981). The 
major mode of metabolism of ketanserin is by reduction of 
the ketone to alcohol (figure 2). The resulting 
metabolite, ketanserinol, has one thousand times less 
affinity than ketanserin for the 5HT-2 receptor (Frenken & 
Kaumann, 1984).
1.12.2 Mechanism of the antihypertensive action of 
ketanserin.
Ketanserin is an effective antihypertensive agent. It 
reduces blood pressure in both acute (Wenting et al., 
1982; Wenting et al., 1984; Zoccali et al., 1983;
Zabludowski et al., 1984) and chronic dosage (De Cree et 
al., 1981; Fagard et al., 1984; Woittiez et al., 1986). 
However, the mechanism of reduction of blood pressure
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Figure 2
Structural formulae of ketanserin and its major 
metabolite ketanserinol.
caused by ketanserin remains controversial.
Ketanserin inhibits serotonin induced platelet 
aggregation in acute (De Clerck & Xhonneux, 1985) and 
chronic dosage in man (Vermylen et al., 1986). Serotonin 
induced platelet aggregation is thought to be mediated 
through the serotonergic type-2 binding site (1.4.2). 
Thus, in keeping with its pharmacological profile, 
ketanserin seems to be an effective serotonergic type-2 
antagonist when given in doses known to lower blood 
pressure in essential hypertension.
It is possible that ketanserin reduces blood pressure by 
acting through the serotonergic type-2 receptor to inhibit 
serotonin induced vasoconstriction in the periphery. 
Ketanserin has been shown to inhibit serotonin induced 
vasoconstriction in isolated blood vessels (Van Nueten et 
al., 1982). Serotonin also amplifies the effect of other 
vasoconstrictor agents such as noradrenaline and 
angiotensin II (Van Nueten et al., 1981; Van Nueten et 
al., 1982). This amplification is inhibited by 
serotonergic antagonists in close correlation with their 
serotonergic type-2 binding affinity (Van Nueten et al.,
1982). In is possible that ketanserin could act on these 
amplification mechanisms in-vivo to reduce arterial blood 
pressure.
Ketanserin may also have a central effect on 
serotonergic neurones involved in the regulation of blood 
pressure. Ketanserin is not lipid soluble and therefore 
crosses the blood-brain barrier poorly (Leysen et al., 
1981), however the blood brain barrier is deficient in
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certain areas, some of which lie close to parts concerned 
with cerebrovascular regulation. Undoubtably,
radiolabelled ketanserin does cross the blood-brain 
barrier in rats (Laduron, Jannsen & Leysen, 1982). 
Furthermore, ketanserin has been shown to have central
effects in-vivo in animals and man. Neuropsychological 
effects of serotonin agonists in rats are prevented by 
ketanserin (Niemegeers et al., 1983). In man, ketanserin 
can cause side effects of drowsiness and headache
(Staessen et al., 1985). Therefore, ketanserin should not 
be considered to act solely in the periphery.
Another possible mechanism for the reduction in blood 
pressure caused by ketanserin is by decreasing activity of 
the renin-angiotensin-aldosterone system. Ketanserin may 
act directly on serotonergic type-2 receptors on zona 
glomerulosa cells in the adrenal cortex to reduce 
aldosterone and corticosterone synthesis (Williams et al., 
1984; Rocco et al., 1985), or have a central effect on 
serotonergic type-2 receptors possibly involved in the 
regulation of plasma renin (Epstein & Hamilton, 1977),
aldosterone (Shenker et al., 1985b) and cortisol
(Modlinger et al., 1979; Mueller et al., 1985).
Although there has been considerable interest raised at 
the possibility that ketanserin reduces blood pressure by 
its effects as a serotonergic antagonist, ketanserin could 
be acting through the alpha-1 adrenoreceptor to reduce 
blood pressure. Alpha-1 adrenoreptor antagonists such as 
prazosin have a direct effect on vasculai smooth muscle 
causing vasodilatation (Stanaszek et . al.,\1983). Central
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alpha-1 adrenoreceptor antagonism may also reduce blood 
pressure by lowering sympathetic nervous outflow (McCall & 
Humphrey, 1982; McCall & Schuette, 1984).
The possibility that ketanserin reduces blood pressure 
by peripheral alpha-1 antagonism has been studied in-vivo 
in man by examining the pressor response to intravenous 
infusion or bolus injection of alpha-1 agonists such as 
phenylephrine and methoxamine. Acute intravenous 
administration of ketanserin can lower blood pressure in 
hypertensive patients without attenuating the pressor 
response to phenylephrine (Wenting et al. , 1982;
Zabludowski et al., 1984). These results suggest that
acutely ketanserin reduces blood pressure by mechanisms 
other than peripheral alpha-1 antagonism. In contrast, 
Reimann & Frohlich (1983) have shown that an intravenous 
infusion of ketanserin attenuated the pressor response to 
methoxamine. Three days of ketanserin 40mg twice daily 
administered to healthy subjects attenuated the pressor 
response to infused phenylephrine (Zabludowski, Ball & 
Robertson, 1985). Four weeks of ketanserin 40mg twice 
daily given to hypertensive patients attenuated the 
pressor response to methoxamine (Fagard et al., 1984). 
These results suggest that intravenous infusion or chronic 
oral administration of ketanserin causes alpha-1 
antagonism, and that the reduction of blood pressure 
caused by the drug in these circumstances may be at least 
partly due to this effect.
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1.12.3 Effects of ketanserin on heart rate.
Ketanserin reduces blood pressure by peripheral 
vasodilatation (Wenting et al., 1982; Wenting et al.,
1984: Fagard et al., 1984). Drugs which cause
vasodilatation usually stimulate a baroreceptor mediated 
increase in heart rate, due to increased cardiac 
sympathetic outflow and reduced cardiac vagal activity 
(Man In'T Veld et al., 1980). However, the acute reduction 
in blood pressure caused by intravenous ketanserin 
administration is accompanied by only a small rise in 
heart rate (Wenting et al., 1982; De Cree et al., 1981; 
Zoccali et al., 1983). Similarly, chronic oral ketanserin 
has been reported to reduce blood pressure either without 
increasing heart rate (De Cree et al., 1981; Woittiez et 
al. , 1986), or even with a small reduction in heart rate
(Fagard et al., 1984). This lack of reflex tachycardia 
suggests that ketanserin may modify baroreceptor arc 
activity, although the precise mechanism of this action is 
unclear.
1.13 The serotonergic type-2 antagonist ritanserin
Ritanserin (figure 3) is a new, highly selective 
serotonergic antagonist (Leysen et al., 1985). It is a 
non-competitive serotonergic type-2 antagonist. 
Importantly, like ketanserin, it has no partial agonist 
activity at this site. Ritanserin is virtually devoid of 
receptor binding affinity at serotonergic type-1 and
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Structural formula of ritanserin
alpha-1 receptor sites; it binds to histamine type-1 
receptors with one twenty-fifth of its affinity at the 
serotonergic type-2 receptor. Ritanserin is a very long 
acting agent. In the rat, serotonergic type-2 receptor 
sites are occupied for over 24 hours after a single dose 
(Leysen et al., 1985). It is more lipophilic than 
ketanserin, and therefore should cross the blood brain 
barrier more readily. Ritanserin inhibits head twitch 
behaviour in mice (Goodwin & Green 1985) and has 
anxiolytic effects in rats (Colpaert et al., 1985). In man 
a single oral dose of ritanserin lOmg has detectable 
central effects 12 hours after dosing, causing alterations 
in sleep pattern (Idzikwski & Mills, 1986). In a placebo 
controlled study, ritanserin lOmg daily for 2 weeks 
improved symptoms in patients with anxiety disorders 
(Ceulemans et al., 1985).
The main advantage of ritanserin over ketanserin as a 
research tool is its lack of alpha-1 adrenoreceptor 
binding affinity (Leysen et al., 1981; Leysen et al.,
1985). This makes ritanserin a more appropriate agent to 
investigate the role of the serotonergic type-2 receptor 
in the regulation of blood pressure and heart rate.
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1.14 Background and objectives of the research
1.14.1 Serotonin and platelet function in essential 
hypertension.
Serotonin is a vasoactive amine that may play a role in 
the development and maintenance of raised arterial 
pressure. Nearly all the serotonin circulating in blood is 
stored in platelets. Platelet contents, including 
serotonin and beta-thromboglobulin, are released during 
platelet aggregation (Holmsen, 1977). Serotonin released 
from platelets may cause vasoconstriction and raised 
arterial pressure. Serotonin is itself a weak stimulant of 
platelet aggregation (De Clerck, 198 6) and may cause 
therefore a further increase in platelet aggregation and 
platelet content release.
I have studied serotonin induced platelet aggregation, 
spontaneous platelet aggregation, platelet serotonin 
levels and plasma beta-thromboglobulin in patients with 
untreated essential hypertension compared to age and sex 
matched normotensive controls.
1.14.2 Assay of platelet serotonin levels by high 
pressure liquid chromatography with electrochemical 
detection.
In view of its high sensitivity, specificity, safety and 
relatively low cost compared to other techniques 
(Kissinger, Bruntlett & Shoup, 1981? Sasa et al., 1985)
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high pressure liquid chromatography with electrochemical 
detection is potentially a useful method for serotonin 
assay. I have investigated the use of this method in the 
assay of serotonin in human platelet rich plasma and whole 
blood.
1.14.3 Mechanism of action of the serotonergic type-2 
antagonist ketanserin.
The serotonergic type-2 antagonist ketanserin is an 
effective antihypertensive agent. However its effects may 
not be wholly due to serotonergic antagonism. Short-term 
oral ketanserin has been shown to reduce the pressor 
response to the alpha-1 adrenoreceptor agonists 
phenylephrine (Zabludowski et al., 1985) and methoxamine 
(Fagard et al., 1984), suggesting that the drug acts at 
least partly as an alpha-1 antagonist. However, 
alternative explanations for these findings have been 
suggested. The reduction in blood pressure caused by 
ketanserin is due primarily to peripheral vasodilatation, 
which could in itself reduce the vascular response to any 
pressor agent. Also there may be an important interplay 
between serotonergic type-2 and alpha-1 adrenoreceptor 
sites, in that in vitro, serotonin can be shown to amplify 
the vasoconstriction caused by noradrenaline. This effect 
is also seen with other vasoconstrictors such as 
angiotensin II (Van Nueten et al., 1981). This 
amplification is inhibited by serotonin antagonists in 
close correlation with their serotonergic type-2 binding
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affinity, suggesting that it is mediated through the 5HT-2 
receptor (Janssen, 1985). Therefore, I have studied the 
effects of ketanserin on the pressor response to infused 
angiotensin II, a vasoconstrictor largely devoid of
alpha-1 adrenergic activity, in healthy subjects.
Ketanserin inhibits the increase in production of 
aldosterone caused by serotonin and angiotensin II in 
isolated rat zona glomerulosa cells (Rocco et al., 1985? 
Williams et al., 1984). Serotonergic neurones may also
play a role in the central regulation of aldosterone 
(Shenker et al., 1985b), cortisol (Prescott et al., 1984) 
and renin (Epstein & Hamilton, 1977). I have examined the 
effects of ketanserin on the renin-angiotensin-aldosterone 
system and plasma cortisol before and after graded 
intravenous infusion of angiotensin II in healthy 
subjects.
The peripheral vasodilatation and reduction in blood
pressure, caused either by acute (Zabludowski et al.,
1984) or chronic (Fagard et al., 1984) ketanserin 
administration is not associated with the expected reflex 
increase in heart rate. It has been claimed that this
effect may be due to changes in cardiac autonomic outflow. 
I have studied the effects of ketanserin on cardiac 
parasympathetic outflow, measured by the heart rate 
responses to change of posture from lying to standing, 
deep breathing and Valsalva manoeuvre.
In vitro, ketanserin causes prolongation of the action 
potential and effective refractory period (Saman, 
Thandroyen & Opie, 1985), effects consistent with class
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Ill antiarhythmic activity. I have examined the effects of 
ketanserin on the QT interval, representing action 
potential duration, in healthy subjects.
1.14.4 Effects of ritanserin in essential hypertension:
Ritanserin is a new serotonergic type-2 antagonist which 
differs from ketanserin in that it is virtually devoid of 
alpha-1 adrenoreceptor binding affinity (Leysen et al.,
1985). This makes it a particularly useful agent to 
investigate the role of the serotonergic type-2 receptor 
in hypertension. Ritanserin is more lipophilic than 
ketanserin and should penetrate the blood brain barrier 
more readily (Leysen et al., 1985). Central serotonergic
antagonism may cause changes in psychological function. 
Serotonin-induced platelet aggregation is mediated through 
the serotonergic type-2 receptor, making this a useful 
marker to demonstrate drug compliance and adequate dosing.
I have studied? (a) the effects of acute ritanserin 
administration on blood pressure, heart rate and 
psychological function, and (b) the effects of chronic 
oral ritanserin on serotonin induced platelet 
aggregation, blood pressure, heart rate, forearm blood 
flow and venous compliance, QT interval, and psychological 
function, in patients with essential hypertension.
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1.14.5 Effects of ketanserin on resting bronchomotor 
tone and exercise-induced bronchospasm in adult atopic 
asthma:
Serotonin, acting through the type-2 receptor, may cause 
contraction of respiratory smooth muscle (Colebatch et 
al., 1966; Cohen et al., 1985). It has been suggested that 
serotonin released from platelets may play a role in the 
pathogenesis of asthma. I have studied the effects of 
acute administration of the serotonergic type-2 antagonist 
ketanserin on resting bronchomotor tone and exercise- 
induced bronchoconstriction in adult patients with atopic 
asthma.
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Chapter 2? Methods
2.1 Measurement of serotonin in platelet rich plasma 
and whole blood by high pressure liquid chromatography 
with electrochemical detection
2.1.1 Materials.
Serotonin, 5-hydroxyindoleacetic acid and prostaglandin 
were purchased from Sigma Laboratories. Methanol (HPLC 
grade) was purchased from Rathburn Chemicals. All other 
routine laboratory chemicals (Analar grade) were purchased 
from Sigma laboratories. All water used was doubly glass 
distilled.
2.1.2 Methods of measurement.
Serotonin levels were measured by high pressure (3000 
P.S.I.) liquid chromatography (HPLC) with electrochemical 
detection (oxidation potential +0.7V). The following 
equipment was used: a glassy carbon electrochemical
detector (Bioanalytical Systems), a Gilson model 302 pump 
with a model 802 manometric module, a Gilson 231 automated 
sample injector, and a Shimadzu C-R3A Chromatopac 
integrator. The HPLC column used was a Spherisorb 5 ODS2, 
length 30cm and diameter 2mm (HPLC technology). The flow 
rate was 0.2ml/minute. The automated injector was set to 
sample 50pL. The electrochemical detector was set at 1 
nanoamp/volt. All chromatography was performed at room
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temperature.
The mobile phase consisted of a citrate / acetate*
buffer, pH 5.2, containing 0.25g/l octyl sulphate and 
17.5% methanol, giving retention times for serotonin and 
5-hydroxyindoleacetic acid of 13.9 minutes (n=19, 
coefficient of variation 2.2%) and 0.4 minutes (n=19, 
coefficient of variation 5.9%) respectively.
Standard solutions of serotonin were prepared 
immediately before each assay. For assay of serotonin in 
platelet rich plasma and whole blood, a standard solution 
of 200 nanogrammes serotonin / m l  (0.494nmol/ml) was
prepared by dissolving lOmg of serotonin creatinine 
sulphate (molecular weight 405) in 100ml 0.1M hydrochloric 
acid, and further diluting 200pL of this solution to 100ml 
with 0.1M hydrochloric acid. Standard solutions remained 
stable at room temperature for up to 5 hours (figure 4). 
Standard solutions of serotonin were run in duplicate 
prior to and after every 6 platelet rich plasma or whole
blood samples. The peak height for serotonin, as measured
by electrochemical detection, was found to be directly 
proportional to known concentrations of serotonin in 0.1 N 
hydrochloric acid over the range l-50ng/50jiL 
(20-1000ng/ml; figure 5), which embraces the range 
required for assay of serotonin in platelet rich plasma. 
The limit of detection of serotonin by these methods was < 
5 pmol/ml.
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Figure 4
Serial measurements of a standard solution of 
serotonin ( O . W n m o l / m l  in 0.1M hydrochloric 
acid) at room temperature using high pressure 
liquid chromatography with electrochemical 
detection. Initial peak height (at time 0 
hours) = 1 0 0 % .
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Figure 5
Serotonin peak height, measured by high pressure 
liquid chromatography with electrochemical 
detection, verses serotonin concentration in 
0.1M hydrochloric acid.
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Figure 6
Chromatogram of serotonin ( O . W n m o l / m l )  and 
5-hydroxyindoleacetic acid ( 1 .235nmol/l) in 0.1M 
hydrochloric acid, measured by high pressure liquid 
chromatography with electrochemical detection.
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Figure 7
Chromatogram of serotonin in platelet rich plasma, 
measured by high pressure liquid chromatography with 
electrochemical detection.
2.1.3 Collection of blood.
Venous blood for assay of serotonin was collected from 
the ante-cubital fossa or other prominant arm veins using 
a 19 gauge Butterfly cannula, without venous stasis. 
During development of the assay blood was donated by 
healthy male volunteers from the medical and laboatory 
staff. Samples were transferred immediately to the 
appropriate collection media and placed on ice. All 
samples which were not analysed immediately were prepared 
and stored at -70°C within 30 minutes of collection.
2.1.4 Serotonin in platelet rich plasma.
Samples for assay of serotonin in platelet rich plasma 
were prepared as follows; 5mls whole blood was added to 
200uL containing 50ng prostaglandin , sodium
metabisulphite 25mM and ethylenediamine tetra-acetic acid 
15%, and spun at 160G for 10 minutes to obtain platelet 
rich plasma (PRP). An aliquot of PRP was used for 
determination of platelet count using a Coulter Counter, 
and the remainder was stored at -70°C. At the time of 
assay samples were thawed and 0.5ml distilled water was 
added to 0.5ml PRP and left on ice for 5 minutes to ensure 
platelet lysis. Samples were deproteinised by adding 50uL 
sodium hydroxide (1M) and 50jiL zinc sulphate 20% with 
centrifugation at 10,000G in a cold-room at 4°C for 5 
minutes. Further sample purification was achieved by 
taking 0.5ml of the supernatent, adding 100|iL perchloric
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acid (4M) and repeat centrifugation at 10,000G at 4°C for
5 minutes. The resulting supernatant was then assayed for
serotonin. Each sample was assayed in duplicate.
These preparation steps resulted in the dilution of
platelet rich plasma by a factor of 2.76. The serotonin
9
content of PRP, expressed per 10 platelets can be 
calculated as follows, using the dilution factor, the peak 
heights of serotonin from the standard solution of 
serotonin and platelet rich plasma, and the platelet count 
in that platelet rich plasma:
standard 
PRP peak. 2.76. [5HT](nmol/ml)
Platelet serotonin =
9
(nmol/I0 platelets) , , , , , , n ,■ standard . number platelets
peak height in PRP (10^/ml)
With the retention time for serotonin of 13-15 minutes 
there was good discrimination between serotonin and other 
peaks in all patients. However, the 5-hydroxyindoleacetic 
acid peak at 0.4 minutes could not be reliably separated 
from other interfering peaks in platelet rich plasma 
(figures 6 and 7).
Using these methods the inter-assay co-efficient of 
variation for 6 aliquots of platelet rich plasma prepared 
in parallel was 7.1%. The intra-assay co-efficient of 
variation was 2.2% (n=10). There was no detectable
reduction of serotonin peak height in platelet rich plasma 
after 5 hours at room temperature (n=6, change = 0.(H9.2%, 
mean^standard deviation) . The recovery of lOOOng serotonin
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in 50pL 0.1 N hydrochloric acid spiked into 0.5ml platelet 
rich plasma was 102+10 % (n=6, mean+standard deviation).
2.1.5 Serotonin in whole blood.
Samples for analysis of serotonin content of whole blood 
were collected as follows: 2mls whole blood were added to 
200jiL containing 15% ethylenediamine tetra-acetic acid and 
25mM sodium metabisulphide. Samples were frozen on dry 
ice, then thawed at room temperature. An alternative 
method of collection of whole blood into 200jiL 
ethylenediamine tetra-acetic acid 15% and ascorbic acid 
3%, as used by Geeraerts, Schimpfessel & Crockaert, 
(1974) in a fluorometric assay, was found to cause a broad 
interfering peak on electrochemical detection. Therefore, 
this method of sample collection was not pursued further.
The methods of sample preparation of Kellum & Jaffe, 
(1976) and Korczyn et al., (1985), used prior to 
radio-immunoassay and fluorometric assays respectively, 
were investigated for applicability to high pressure 
liquid chromatography with electrochemical detection.
To ensure complete platelet lysis, 2mls of ice cold 
distilled water were added to each 2ml sample of whole 
blood (collected as above), and samples left on ice for 
lOminutes. To this was added 200jjL sodium hydroxide (1M) 
and 200pL zinc sulphate 20%. This step caused a thick 
slurry which was extremely difficult to mix. This problem 
could not be resolved even with increased sample dilution 
with distilled water compared to published methods (Kellum
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& Jaffe, 1976: Korczyn et al., 1985). After prolonged
sample mixing, centrifugation was performed at 1500g at
4°C for lOminutes, using a Beckman TJ4 centrifuge. Each
lml of supernatant was mixed with 200uL of perchloric acid
(4M), then centrifuged at 10,000g for 5minutes. This added
step removed a further substantial precipitate. The
resulting supernatant was assayed for serotonin.
The recovery of 2,500 and 10,000ng serotonin in 100
microlitres 0.IN hydrochloric acid, added to 2mls whole
blood and prepared as above was 9 and 27% respectively. In
one subject, the serotonin content of whole blood
9expressed per 10 platelets was only 23% of that found m
9
the same subject m  platelet rich plasma per 10 
platelets. No residual serotonin could be extracted with 
perchloric acid (4M) from either of the precipitates 
obtained after the two centrifugation steps described 
above.
In view of the difficulties with the serotonin assay in 
whole blood it was abandoned in favour of assay of 
serotonin in platelet rich plasma (2.1.4).
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2.2 Serotonin and platelet aggregation in patients with
essential hypertension compared to age and sex matched 
normotensive controls
2.2.1 Patients and subjects.
Twenty three patients (12 males) with untreated 
essential hypertension, defined as a supine blood pressure 
of > 160/90mmHg, were compared with 20 normotensive
subjects (12 males), with supine blood pressure < 
160/90mmHg. All women were post-menopausal. The study 
protocol was approved by the Ethical Supervisory Committee 
of the Western Infirmary, Glasgow. Informed consent was 
obtained. The mean age of patients with hypertension was
60.7 (range 47-70) years compared to 59.9 (51-70) in the 
normotensive group.
Hypertensive patients were recruited from a local 
general practice and from general medical outpatient 
clinics. Two of these patients had a history of stable 
angina pectoris, 1 intermittent claudication, and 3 
chronic obstructive airways disease. Fundoscopy revealed 
no patients with fundal haemorrhages or exudates. 
Urinalysis (Multistix) was negative for blood and protein 
in all patients. One patient had electrocardiographic 
evidence of left ventricular hypertrophy (S . in V2 .+ R in 
Vg > 35mm) and strain (downsloping ST depression > 1mm in 
the lateral leads). All other electrocardiographs were 
normal. Hypertensive patients all had a cardiothoracic 
ratio of < 50% on postero-anterior chest X-ray.
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Normotensive subjects were recruited from the same general 
practice and a general surgical outpatient clinic. They 
were healthy or had minor surgical problems such as 
inguinal hernia or ingrown toe-nails. The only drug 
allowed in either group was paracetamol. Particular care 
was taken to exclude those with a recent history of 
ingestion of aspirin, non-steroidal anti-inflammatory 
drugs, antihypertensive drugs, or any other agents known 
to have haemodynamic or antiplatelet effects.
2.2.2 Methods.
Patients attended on two occasions one week apart. At 
the first visit, a full medical history (including smoking 
habit and usual weekly alcohol intake) and examination 
were performed. Supine blood pressure (mean of 2 
recordings, right arm) and heart rate were measured after 
15 minutes lying, and erect blood pressure and heart rate 
after 2 minutes standing. Venous blood was taken for urea 
and electrolytes, blood sugar, liver function tests, and 
full blood count. A standard 12-lead electrocardiograph 
was recorded. In hypertensive patients, a chest X-ray was 
performed. At the second visit, body weight was recorded, 
then repeat measurements of blood pressure and heart rate 
were made as above. A size 19 gauge Butterfly cannula was 
then inserted into a vein in the left ante-cubital fossa 
for blood (without stasis) for plasma
beta-thromboglobulin, serotonin induced and spontaneous 
platelet aggregation, whole blood viscosity and platelet
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serotonin. Samples were taken in a standard order as 
above.
2.2.3 Methods of measurement.
Blood pressure was measured using a Hawksley Random Zero 
Sphygmomanometer (diastolic phase V). Pulse rate was 
measured by manual palpation at the wrist over 60 seconds.
Serotonin-induced platelet aggregation and spontaneous 
platelet aggregation in whole blood were quantified as 
described by Saniabadi et al., (1983). Venous blood was 
anticoagulated with 3.8% trisodium citrate in a proportion 
of 9 to 1, giving a final citrate concentration of 12.9mM. 
One ml aliquots of this mixture were then transferred to 
plastic vials, flushed with 5% carbon dioxide in air, and 
sealed. Ten microlitres was withdrawn from an aliquot and 
added to 9.1mls diluent (Laboratory Impex Limited, London) 
and mixed by gentle inversion. The red cell count was 
determined with the Clay Adams haematology analyser 
(HA-5), allowing determination of whole blood single 
platelet count by the Ultra flow 100 whole blood platelet 
counter (Clay Adams). The aliquots were then incubated at 
37°C in a Gallenkamp shaking water bath at 130-140 shakes 
per minute. Spontaneous platelet aggregation was 
quantified by measuring the reduction in platelet count 
caused by incubation in the shaking water bath. 
Serotonin-induced platelet aggregation was quantified by 
measuring the reduction in single platelet count caused by 
adding serotonin (ljiM) to whole blood and incubation at
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37°C in the shaking water bath for 15 minutes. A blank 
test was also performed with the solvent used for 
serotonin. The time taken from the collection of blood to 
the completion of the assay was less than 3 hours in all 
subjects.
For measurement of whole blood viscosity, venous blood 
was anticoagulated with ethylenediamine tetra-acetic acid
(1.5g/L). Whole blood viscosity was measured at high
—1 -1(94s ) and low (0.94s ) shear rates using a Contraves
LS30 rotational viscometer. Haematocrit was determined
using a Hawksley microcentrifuge at 13,000g for 5 minutes,
allowing correction of whole blood viscosity for this
variable. The shear rate is defined as the gradient in
velocity between adjacent fluid layers in laminar flow
(arterial blood flow in-vivo is laminar); the velocity
-1difference (m.s ) divided by distance between layers (m)
-1gives the S.I. units, s . Shear stress is the force which 
causes shearing (relative movement of layers) in a flowing 
liquid (mPa). The viscosity of fluid in laminar flow is 
equal to the ratio of shear stress to shear rate (Lowe, 
1986) .
Plasma beta-thromboglobulin was measured by 
radioimmunoassay (Radiochemical Centre, Amersham). Venous 
blood was collected into proprietary test tubes containing 
ethylenediamine tetra-acetic acid, theophylline and 
prostaglandin , and placed in ice-cold water before 
centrifugation at 3000g at 4°C for 30 minutes. The middle 
third of the platelet poor plasma was then removed and 
stored at -70°C until assay.
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Platelet serotonin was measured as described in section 
2.1.4 .
Data for platelet agregation studies, plasma 
beta-thromboglobulin, whole blood viscosity and platelet 
serotonin were incomplete due to technical problems.
2.1.4 Statistical analysis.
Statistical analysis of the differences between the 
hypertensive and normotensive groups was by unpaired 
Student (t) test (2-tailed). For each subject, mean supine 
and erect blood pressures and heart rates from the 2 
visits were calculated for analysis.
To analyse the relationship between serotonin-induced 
platelet aggregation and other variables, linear 
regression analyses were performed, using the percentage 
of platelets remaining after the addition of serotonin as 
the dependent variable and choosing the independent 
variables from age, body weight, supine blood pressure, 
plasma beta-thromboglobulin, whole blood viscosity and red 
blood cell count. Multiple regression analysis of the 
percentage of platelets remaining after the addition of 
serotonin as the dependent variable against the 
independent variables as above was then performed; in this 
analysis, whole blood viscosity corrected for haematocrit 
at high and low shear rates were used as they correlated 
better than uncorrected viscosities with the percentage of 
platelets remaining after the addition of serotonin. Only 
23 patients (12 hypertensive, 11 normotensive) had
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recorded data for all variables, and consequently only 
these patients have been included in the multiple 
regression analysis. To analyse the relationship between 
platelet serotonin content and plasma
beta-thromboglobulin, a linear regression model was fitted 
using the platelet serotonin content as the dependent 
variable and plasma beta-thromboglobulin as the 
independent variable. Regression analyses were performed 
using the BMPD statistical package.
Results are expressed as the meanjH standard error of the 
mean. Results were considered statistically significant at 
p<0.05.
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2.3 The effects of short-term ketanserin treatment on
blood pressure, heart rate, the renin angiotensin system, 
adrenocortical function, QT interval and vagal function 
and the response to infused angiotensin II in healthy 
subjects
2.3.1 Subjects.
Eight normotensive male volunteers, mean age 25 (range 
20-31) years, weight 75 (64—88) Kg, were investigated. All 
were healthy, as determined by history, physical 
examination and routine laboratory screening. The study 
protocol was approved by the Ethical Supervisory Committee 
of the Western Infirmary, Glasgow. Informed consent was 
obtained.
2.3.2 Methods.
In a double blind randomised crossover study design, 
ketanserin 40mg and matching placebo were each given 
orally twice daily for three days, with a minimum of three 
days between phases. Supine (5 minutes lying) and erect 
blood pressure (2 minutes standing) and pulse rate were 
measured before (9am) and one hour after (10am) the first 
doses of ketanserin 40mg and placebo. On the fourth day 
subjects attended the ward at 8am for supervised 
administration of ketanserin or placebo and insertion of 
an intravenous cannula. Having lain supine for 45 minutes, 
3 baseline measurements of blood pressure and heart rate
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were made over a 15 minute period prior to a graded 
intravenous infusion of angiotensin II (Hypertensin, Ciba) 
(2,4,8,16 and 32 ng/Kg/minute, 5 minutes at each rate); 
blood pressure and heart rate were recorded at the end of 
each 5 minute period. Venesection was performed before and 
at the end of each infusion. Plasma concentrations of 
drug, renin, angiotensin II, aldosterone and cortisol were 
measured. Fifteen minutes after the infusion, when blood 
pressure had returned to baseline, supine and erect 
pressure and heart rate responses to the lying to 
standing, Valsalva and deep breathing manoeuvres were 
recorded (Ewing & Clarke, 1982). The timing of these 
observations was chosen to correspond as closely as 
possible with the likely time of peak plasma ketanserin 
concentrations (Hedner, Pettersson & Persson, 1986; 
Waller, Tucker & Ramsay, 1987).
The above observations and angiotensin II infusion were 
repeated at 3pm on day 4, 7 hours after drug or placebo,
when drug concentrations were expected to be approaching 
trough levels (Hedner, Pettersson & Persson, 1986; Waller, 
Tucker & Ramsay, 1987).
2.3.3 Method of measurement of blood pressure.
Blood pressure was measured with a standard mercury 
sphygmomanometer (diastolic phase V). Mean arterial 
pressure was calculated as diastolic blood pressure + 
[(systolic - diastolic pressure)/3].
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2.3.4 Methods of measurement of cardiac parasympathetic 
outflow.
Heart rate responses to change of posture from lying to 
standing, deep breathing, and the Valsalva manoeuvre were 
recorded as described by Ewing and Clarke (1982). These 
tests of autonomic function were performed in standard 
order as above. Blood pressure and heart rate were allowed 
to return to basal levels, with a minimum of 5 minutes 
rest between tests. Changes in RR' interval were recorded 
using a single channel electrocardiograph with a paper 
speed of 25mm/sec.
Changing posture from lying to standing initially causes 
an increase in blood pressure due to increased peripheral 
resistance, caused by compression of arteries and 
arterioles by contraction of muscles in the legs and 
abdomen. This increase in blood pressure lasts only a few 
seconds (Borst et al., 1984). Subsequently, blood pressure 
decreases, probably due to reduced cardiac output caused 
by venous pooling and reduced venous return to the heart, 
and stimulation of arterial baroreceptors due to the 
initial increase in blood pressure (Borst et al., 1984). 
This reduction in blood pressure is minimised by 
baroreceptor mediated increased sympathetic nervous 
outflow, causing peripheral vasoconstriction, and by an 
increase in heart rate, which is maximal around the 15th 
beat after standing. This increase in heart rate is 
largely abolished by atropine, suggesting that it is 
caused mainly by a reflex reduction in cardiac vagal
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outflow (Ewing et al., 1978; Ewing et al., 1980). These 
reflex responses act to increase blood pressure back above 
supine levels. There is then a rebound reduction in heart 
rate, maximal around the 30th beat after standing, which 
is abolished by atropine suggesting that it is mediated 
through increased cardiac vagal outflow (Ewing et al.,
1978; Ewing et al., 1980). The ratio of the longest to the 
shortest RR1 interval, around the 30th and 15th beats 
respectively after standing, gives an index of cardiac 
parasympathetic outflow (Ewing et al., 1978; Ewing &
Clarke, 1982). Changes in this ratio reflect alterations
in cardiac vagal tone.
Deep breathing causes marked changes in heart rate 
(sinus arrhythmia) in healthy subjects. Inspiration causes 
activation of the stretch receptors in the lungs, causing 
reduced vagal outflow and an increase in heart rate. The 
opposite occurs during expiration. The beat to beat 
variation in heart rate caused by breathing is abolished 
by atropine but unaffected by propranolol, suggesting that 
it is largely under vagal control (Wheeler et al., 1973). 
Deep breathing, with maximal inspiration and expiration 
each lasting 5 seconds, was performed for 30 seconds in 
the sitting position (Ewing & Clarke, 1982); the mean 
ratio of the longest RR' interval during expiration to the 
shortest RR' interval during inspiration was calculated. 
Changes in this ratio reflect alterations in cardiac 
parasympathetic outflow.
The Valsalva manoeuvre was performed at an intra-oral 
pressure of 40mmHg (measured by blowing into a standard
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mercury sphygmomanometer) for 15 seconds while seated 
(Ewing & Clarke, 1982). This test was performed 3 times, 
each from tidal inspiration. Subjects were instructed to 
avoid gasping after releasing intra-oral pressure. The 
Valsalva manoeuvre causes a transient increase in 
intrathoracic pressure. The sudden increase in 
intrathoracic and intra-abdominal pressure caused by 
straining compresses blood out into peripheral arteries, 
causing an initial increase in arterial pressure (Eckberg, 
1980). In response, there is a baroreceptor mediated 
reduction in heart rate due to increased cardiac 
parasympathetic outflow (phase I), and reduced 
vasoconstrictor sympathetic nervous outflow to resistance 
vessels. In phase II there is a reduction in venous 
return,, with pooling of blood in the limbs, causing 
reduced left ventricular stroke volume and cardiac output, 
leading to reduced arterial pressure. In response to this 
there is a baroreceptor mediated increase in heart rate 
caused by reduced parasympathetic nervous outflow, and an 
increase in peripheral resistance due to augmented 
sympathetic vasoconstrictor tone. In phase 111, 
immediately after the release of straining there is a 
further reduction in blood pressure due to the sudden 
reduction in intrathoracic pressure and consequent 
dilatation of intrathoracic vessels. This causes a further 
increase in heart rate mediated by reduced vagal outflow, 
and increased sympathetic nervous outflow to resistance 
vessels. In phase IV, left ventricular stroke volume and 
cardiac output rapidly return to normal, but arterial
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resistance vessels remain constricted, causing a rise in 
arterial pressure above baseline levels. This in turn 
causes a baroreceptor mediated reduction of sympathetic 
vasoconstrictor outflow to resistance vessels, and a fall 
in heart rate due to increased parasympathetic tone 
(Eckberg, 1980). Thus the heart rate changes during 
Valsalva are mediated by alterations in cardiac vagal 
outflow. The mean ratio of the longest RR1 interval during 
phase II (while straining) to the shortest RR' interval 
during phase IV (after straining) gives an index of 
cardiac parasympathetic tone (Ewing & Clarke, 198 2).
2.3.5 Methods of measurement of the QT interval.
QT and QTc intervals were calculated as the mean from 
four consecutive cardiac cycles, taken from a single 
channel electrocardiograph with a paper speed of 25mm/sec. 
The QTc was calculated by Bazett's formula (QT divided by 
the square root of the preceeding RR' interval; Bazett, 
1920). For each subject, the most appropriate standard 
limb lead, with a clearly defined Q and upright T wave, 
was selected and maintained for all further recordings. 
All QT intervals were measured from the beginning of the Q 
wave to the end of the T wave.
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2.3.6 Methods of measurement of plasma renin, 
angiotensin II, aldosterone, cortisol, ketanserin and 
ketanserinol.
Plasma active renin (Millar et al., 1980), angiotensin 
. cII (Dusterdieck & M Elwee, 1971), aldosterone and cortisol 
(Nicholls et al., 1980) were measured by 
radio-immumoassay; plasma ketanserin and ketanserinol by 
high pressure liquid chromatography with fluorescence 
detection (Davies, 1983). Interassay coefficients of 
variation were less than 15% for all methods.
2.3.7 Statistical analysis.
Data were analysed by Student's paired (t) test 
(2-tailed). All comparisons are of ketanserin verses 
placebo. For analysis of the blood pressure responses to 
infused angiotensin II regression lines of blood pressure 
change against infusion rate were calculated by the method 
of least squares after drug and placebo for each subject. 
All results are expressed as the mean+standard error of 
the mean. Results were considered statistically 
significant at p<0.05.
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2.4 Effects of single oral doses of ritanserin and
ketanserin on blood pressure, heart rate and psychological 
function in patients with untreated essential hypertension
2.4.1 Patients.
Ten patients (8 males), mean age 62 (range 40-79) years, 
weight 73 (40-103) kg, with untreated essential
hypertension, defined as a blood pressure of greater than 
160/95mmHg measured in the sitting position on at least 2 
occasions, were studied. The study protocol was approved 
by the Ethical Supervisory Committee of the Western 
Infirmary, Glasgow. Informed consent was obtained from all 
patients.
2.4.2 Methods.
In a double blind randomised four-way crossover study, 
ritanserin lOmg, ritanserin 20mg, ketanserin 40mg and 
placebo were each given as a single dose orally, with a 
minimum of 1 week between phases. Patients attended at 
9am. Two baseline measurements of sitting and standing 
blood pressure and heart rate were made, after 30mins 
sitting in quiet surroundings. The drug or placebo was 
then administered, and repeat measurements of blood 
pressure and heart rate made at 30, 60 and 90 mins, and 2, 
4, 6 and 8hrs later. Psychological function testing (6
patients only) was performed prior to, and at 1, 2, 4, 6 
and 8 hrs after, drug and placebo administration.
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2.4.3 Methods of measurement of blood pressure, heart 
rate and psychological function.
Blood pressure (phase V diastolic) was measured using a 
Hawksley Random Zero Sphygmomanometer. Mean arterial 
pressure was calculated as diastolic blood pressure + 
[(systolic - diastolic pressure)/3]. At each time point 3 
measurements of blood pressure and pulse rate after 5 mins 
sitting, and 2 measurements immediately on standing, were
i
taken. Pulse rate was measured by manual palpation at the 
wrist over 60 seconds.
Psychological function testing was performed using a 
standard visual anologue scale of 18 subjective feelings 
(Herbert, Johns & Dore, 197 6; appendix 1) which allows 
calculation of scores for tranquillity and alertness, and\ 
the Multiple Affect Adjective Check List (Zuckerman & 
Lubin, 1965; appendix 2), which gives scores for anxiety, 
depression and hostility.
2.4.4 Statistical analysis.
Analyses of blood pressure and pulse rate were done by 
calculating the area under the curve after each treatment 
for each patient, and tests of psychological function by 
calculating mean changes from baseline after drug and 
placebo. Blood pressure and pulse rate changes after drug 
administration were then compared with changes after 
placebo using the Student's paired (t) test (2-tailed); 
psychological function test changes were compared
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similarly but using the Wilcoxon signed rank test. The 
tranquillity and alertness scores (Herbert, Johns & Dore, 
197 6) are expressed as percentages of the maximal possible 
scores. All results are expressed as mean^standard error 
of the mean. Differences were considered statistically 
significant at p<0.05.
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2.5 Effects of chronic oral ritanserin on blood
pressure , heart rate, forearm blood flow and venous
compliance, QRS and QT intervals, serotonin-induced
platelet aggregation and psychological function in
patients with untreated essential hypertension
2.5.1 Patients.
Nineteen patients (11 males) with untreated essential 
hypertension were studied. All women were post-menopausal. 
Age and weight ranged from 42-71 (mean 60) years and 
55.4-100.9 (74.2) Kg respectively. The study protocol was
approved by the Ethical Supervisory Committee of the 
Western Infirmary, Glasgow. Informed consent was obtained 
from all patients. The study was discontinued prematurely 
(the study protocol was for 3 0 patients) when reports of 
possible adverse effects on the electrocardiograph of 
healthy volunteers were received from another centre. 
These changes proved subsequently to be machine artifact.
2.5.2 Methods.
After 4 weeks single-blind placebo run-in (weeks -4 to 
0), patients received either ritanserin lOmg twice daily 
(10 patients) or matching placebo (9 patients) for a 
further 4 weeks (weeks 0 to 4) in a randomised 
double-blind parallel group study. One patient was removed 
from the study after developing a supra-ventricular 
tachycardia following randomisation to placebo. Analysis
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has been restricted to the 18 patients who completed the 
study.
Investigations were performed in a standard order, with 
measurements repeated at the same time of day within 
individuals. At weeks -4, -2, 0, 2 and 4 body weight was 
recorded prior to measurement of supine blood pressure 
(twice) and pulse rate after 15 minutes lying, and erect 
blood pressure (once) and pulse rate 2 minutes after 
standing. Blood pressure was measured in the right arm by 
Hawksley Random Zero Sphygmomanometer (diastolic phase V). 
Pulse rate was measured by manual palpation at the wrist 
over 60 seconds.
At weeks 0 and 4 a Butterfly cannula (19 gauge) was then 
inserted into the left antecubital fossa and blood taken 
for platelet aggregation studies, platelet serotonin 
levels, urea and electrolytes and full blood count. An 
electrocardiograph was recorded and tests of psychological 
function then administered. Finally, forearm blood flow 
and venous compliance were measured in the right arm.
Measurements of blood pressure, pulse rate, body weight, 
urea and electrolytes and full blood count were made on, 
and tests of psychological function administered to, all 
18 patients. The electrocardiograph was recorded, and 
platelet aggregation studies measured in 14 patients (7 on 
ritanserin). Spontaneous and serotonin-induced platelet 
aggregation were measured as previously described (2.2.3).
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Figure 8
Forearm blood flow at rest and after 3 minutes of 
arterial occlusion, measured by mercury-in-strain 
guage venous occlusion plethysmography.
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Figure 9
Forearm venous compliance, quantified by measuring the 
increase in forearm volume at venous occlusion, pressures 
of 30, itO, 50 and 60mmHg, by mercury-in-strain guage 
venous occlusion plethysmography.
2.5.3 Measurement of forearm blood flow and venous 
compliance by mercury-in-strain gauge venous occlusion 
plethysmography.
Forearm blood flow and venous compliance were measured 
by mercury-in-strain gauge venous occlusion
plethysmography using the Janssen Periflow. This is a 
simple, safe non-invasive technique. If we assume that the 
forearm is approximately cylindrical in shape: 
c = 2Tfr or r = c/2 TT"
V = Ltfr2 = LTT (c/2TT') 2 = Lc 2/4tT
(Where c is the circumferance, r the radius, V the 
volume and L the length of a cylinder).
Therefore the volume of the forearm is proportional to 
the square of the circumference.
As the amount of mercury in the strain guage is 
constant, any increase (n) in length of the mercury column 
causes a proportional decrease (n) in cross-sectional 
area.
R = SL/a 
v = la = nla/n
(where R is the resistance of the column, S the specific 
resistance of mercury, 1 the length and a the cross 
sectional area of the mercury column)
Therefore, R = Sn 1/a, and any change in resistance of 
the mercury column is proportional to the square of the 
change in length of the column. The length of the mercury 
column is equal to the circumferance of the forearm. Thus, 
changes in both the resistance of the mercury column and
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the volume of the forearm are proportional to the square 
of the change in forearm circumferance. It follows that 
changes in volume of the forearm are directly proportional 
to changes in resistance of the mercury strain gauge. 
These assumptions have been shown to be valid by studies 
of blood flow measured by mercury-in-strain gauge venous 
occlusion plethysmography during isolated limb perfusion 
(Englund, Hallbrook & Ling, 1972).
Co-ordination of measurements of change in forearm 
volume with the R wave on an electrocardiograph 
(representing the begining of ventricular systole) allows 
accurate semi-continuous measurement of limb arterial flow 
(Barendsen, Venema & Van Den Berg, 1971). An appropriate 
delay for the passage of the pulse wave from the heart to 
the measured area can be set on the Periflow: for the
forearm 60 milliseconds was chosen. Forearm blood flow was 
measured as follows: forearm venous return was occluded 
with a cuff pressure of 40mmHg for 3 heart beats (RR1 
intervals). The increase in forearm volume was measured 
over the second and third heartbeats. The initial 
heartbeat was ignored to minimise artifact caused by the 
rapid inflation of the cuff. The cuff pressure was then 
released for 2 heart beats to allow forearm volume to 
return towards normal. After determination of resting 
blood flow (RF, figure 8), post-ischaemic flow (PF) was 
measured after 3 minutes of arterial occlusion (d'Inverno, 
1980, figure 8) at a cuff pressure of 40mmHg greater than 
systolic blood pressure. Blood flow was expressed as 
ml/lOOml/min. Basal vascular resistance and minimal
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vascular resistance were calculated as mean arterial 
pressure divided by rest flow and post-ischaemic flow 
respectively (Strano et al., 1985).
Venous compliance was quantified by measuring the % 
increase in forearm diameter at continuous venous 
occlusion pressures of 30, 40, 50 and 60mmHg. The slope of
change in limb volume against change in pressure gives an
index of venous compliance (d'Inverno, personal
communication, figure 9).
All measurements were made in a draught-free room, the 
daily temperature of which was 20-22°C and relative 
humidity 40-6 0%. Patients lay supine for 15 minutes rest 
before recordings began. The right arm was supported along 
its length with the elbow held in extension and the hand 
raised 20cm above the bed. An occluding cuff was placed
just proximal to the elbow, and a mercury strain gauge 
around the widest part of the forearm. A light blanket 
covered the arm to avoid fluctuations in temperature of 
the mercury strain gauge which would alter its electrical 
resistance.
2.5.4 Methods of measurement of QRS and QT intervals.
Electrocardiographic QT, QTC (Bazett, 1920) and QRS 
interval durations were calculated as the mean from 5 
consecutive cardiac cycles, taken. from a 6-channel
(standard limb leads I-aVL) electrocardiograph with a
paper speed of lOOmm/sec. The most appropriate limb lead,
with a clearly defined Q wave and upright T wave, was
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chosen for all measurements for each subject. QRS and QT 
intervals were measured from the begining of the Q to the 
end of the S and T waves respectively. QTc was calculated 
as the QT interval divided by the square root of the 
preceeding RR' interval.
2.5.5 Psychological function.
Subjective feelings were measured by 6 standard 10cm 
visual analogue scales (Herbert, Johns & Dore, 1976). 
Co-ordination and concentration were assessed using the 
Digit Substitution Test (Oswald et al., 1978), in which 
standard symbols are substituted for digits (0-9); the 
score was counted as the number of correct substitutions 
in 3 minutes.
2.5.6 Statistical analysis.
Statistical analysis of platelet aggregation, QT, QTc 
and psychological function was by Wilcoxon rank sum test 
for non-parametric data. All other data were analysed by 
Student's unpaired (t) test (2-tailed). For analysis of 
venous compliance, regression lines of change in forearm 
volume against venous occlusion pressure were calculated 
by the method of least squares for each subject. All 
results are expressed as the meanj^standard error of the 
mean. The 95% confidence limits (2-tailed) were calculated 
as described by Gardner & Altman (1986). Results were 
considered statistically significant at p<0.05.
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2.6 Effects of the serotonergic type-2 antagonist 
ketanserin on resting bronchomotor tone and exercise 
induced bronchoconstriction in adult atopic asthma
2.6.1 Patients.
Eight atopic asthmatic patients aged 17-40yrs (table 1) 
were studied. Six had positive prick skin tests to one or 
more common allergens and all had eosinophilia in blood 
and/or sputum. The study protocol was approved by the
Ethical Supervisory Committee of the Western Infirmary, 
Glasgow, and each subject gave fully informed consent.
Patients taking inhaled bronchodilators discontinued 
them for at least 8h before each test; subjects on inhaled 
corticosteroids continued these during the study. No 
patients were taking sodium cromoglycate or oral steroids.
2.6.2 Methods.
In a double blind randomised balanced crossover trial 
the effects of a single oral dose of ketanserin (40mg)
were compared with that of a matching placebo, with a
minimum of 4 days between phases.
Measurements of FEV^ FVC, V5Q c^) and V25(p) were made 
at the same time of day in each patient in the sitting 
position, in a draught-free room, the daily temperature of 
which was 20-22^C and relative humidity 40-60%. Baseline 
recordings of pulmonary function and of sitting blood 
pressure and heart rate were made before and 45mins after
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Patient Age
(Years)
Sex Height
(cm)
Baseline 
FEV1(L)
FEV1 
% predicted
Current
treatment
1 22 F 168 1.78 52 F ,Bt
2 40 F 155 2.73 108 F/I,B
3 25 F 165 2.43 74 S,B
4 30 M 179 2.65 63 S
5 17 M 172 4.50 119 S
6 28 M 175 2.88 72 S,B
7 24 M 178 4.15 96 S
8 25 M 170 4.63 117 none
* = Mean of study days 
M = male, F = female
B = beclomethosone dipropionate inhaler 
Bt = betamethasone valerate inhaler 
F = fenoterol inhaler
F/I = fenoterol and ipratropium bromide inhaler 
S = salbutamol inhaler
Table 1:
Characteristics of adult atopic asthmatics studied.
both drug and placebo. Subjects then exercised on the 
treadmill for 8mins at 6kph at 10^. Blood pressure and 
heart rate were recorded at the end of exercise. Pulmonary 
function was assessed at the end of exercise and every 
5mins for 20min after exercise.
Venous blood was taken at 45 and 75mins (20mins after 
exercise) after drug and placebo for measurements of 
plasma ketanserin and its metabolite ketanserinol.
2.6.3 Methods of measurement.
Pulmonary function tests were performed using a Morgan
12L Spiroflow with a flow volume differentiator and
modified Rikadenki X-Y plotter (RW 201-T); measurements of
forced expiratory volume in 1 second (FEV^), forced vital
capacity (FVC) and maximal flow rates at 50% .(Vgg^j) and
25% (V2s(p)) of forced vital capacity (figure 10) were
made in triplicate (90secs apart), with the maximal values
• •
of FEV^ and FVC, and the mean values of V5Q(C) an<^  V25 (p)
being used for analysis. Initially a forced expiration was
0
made from tidal breathing for measurement of V25 (p) • T^^ -s
expiration was held for 1-2 seconds before a maximal
inspiration, which was also held for 1-2 seconds before a
full forced expiration, allowing measurement of FEV^ and 
•
V50(c) * Maximal inspiratory volume was assumed to be equal 
in each series of 3 measurements for the purpose of 
calculating maximal expiratory flow rates (Boushey & 
Dawson, 1982).
Arterial blood pressure (diastolic phase V) was measured
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Expiration
Complete
curve
(C)
Maximum
inspiration
Flow
Partial 
curve 
(P)
50 
(at 50%) 
FVC)
(at 25% FVC)
I
Artefact at 1 second 
on complete curve
Maximum
expiration
Inspiration
Volume
Figure 10
Respiratory flow volume loop, showing forced vital capacity, forced 
expiratory volume in 1 second, expiratory flow rate at 50% of forced 
vital capacity and expiratory flow rate at 25% of forced vital capacity.
in the right arm with the patient seated, using a standard 
mercury sphygmomanometer. Mean arterial pressure was 
calculated as the diastolic + [(systolic - diastolic)/3]. 
Baseline measurements of blood pressure and heart rate 
were performed after 5 minutes sitting.
Plasma ketanserin and ketanserinol were measured by high 
pressure liquid chromatography with fluorescence detection 
(Davies, 1983).
2.6.4 Statistical analysis.
Analysis of changes in resting bronchomotor tone, blood 
pressure and heart rate after ketanserin compared to 
placebo were by Student's paired (t) test (2-tailed). 
Post-exercise pulmonary function values were expresssed as 
a percentage of the immediate pre-exercise values. 
Statistical analysis of pulmonary function tests after 
.exercise was by repeated measures of analysis of variance, 
using the GENSTAT statistical package. The 95% confidence 
limits (2-tailed; Gardner & Altman, 1986) of the effect of 
ketanserin compared to placebo on resting bronchomotor 
tone and maximal percentage reduction in pulmonary 
function after exercise were also calculated. All results 
are expressed as the mean+standard error of the mean. 
Differences were considered statistically significant at 
PC0.05.
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Chapter 3; Results
3.1 Serotonin and platelet aggregation in patients with 
essential hypertension compared to age and sex matched 
normotensive controls
3.1.1 Blood pressure and heart rate.
Mean supine and erect blood pressures in the 
hypertensive group were 176.70.6 / 98.60.1 and 162.60.1 
/ 99.60.7 mmHg respectively, compared to 135.5+2.2, /
77.00.3 and 122.10.5 / 78.30.5 in the normotensive
group. Mean supine heart rate was higher in the 
hypertensive group at 78.20.7 beats / minute compared to
70.00.1 in the control group (p<0.005). There was a 
similar tendency for erect heart rate to be increased in 
the hypertensive group, at 85.90.9 compared to 81.60.0, 
although this difference did not achieve statistical 
significance (p=0.17). Four (17%) of the hypertensives and 
3 (15%) of the normotensives had a known family history of 
a first degree relative with hypertension.
3.1.2 Body weight, smoking habit, and alcohol.
Mean body weight was significantly higher (p<0.01) in 
the hypertensive patients (73.60.7Kg) than the 
normotensives (66.50.3) . Seventeen (74%) of the 
hypertensive patients were non or ex-smokers, compared to 
15 (75%) in the normotensive group. Six (26%) of the
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hypertensives were non-drinkers, 6 (26%) drank less than 1 
unit (lOg) of alcohol per week, and the 11 (48%) regular 
drinkers consumed 5.5_+1.7 units per week. Of the 
normotensives, 8 (40%) were non-drinkers, 4 (20%) drank
less than 1 unit per week and 8 (40%) drank 8.10.5 units 
per week.
3.1.3 Platelet aggregation.
There was no significant difference between the 
hypertensive and normotensive groups in initial platelet 
count measured prior to the aggregation studies (table 2). 
The percentage of platelets remaining after 
serotonin-induced platelet aggregation in whole blood was 
less in the hypertensives, 50.00.8%, than the control 
group, 56.90.4% (p<0.05, figure 11). Thus serotonin-
induced platelet aggregation was enhanced in the 
hypertensives compared to the normotensive group. 
Serotonin-induced platelet aggregation did not appear to 
be selectively increased in those patients with known 
ischaemic heart disease, peripheral vascular disease or 
chronic obstructive airways disease (figure 11). When the 
data from the hypertensive and normotensive groups were 
combined (table 3) there was a statistically significant 
linear correlation (p<0.001) between the percentage of 
platelets remaining after the addition of serotonin to 
whole blood and systolic (table 4, figure 12) but not 
diastolic blood pressure (table 4, figure 13) . The 
percentage of platelets remaining after the addition of
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serotonin to whole blood was also significantly correlated 
with patient age (table 4, figure 14) and sex (table 4, 
figure 15). There was no significant difference in 
spontaneous platelet aggregation between the hypertensive 
and normotensive groups (table 2, figure 16). The 
percentage of platelets remaining after the addition of 
serotonin to whole blood could not be adequately described 
by the nine independent variables considered (table 5; 
age, sex, weight, supine systolic and diastolic blood 
pressure, red blood cell count, plasma
beta-thromboglobulin and whole blood viscosity at low and 
high shear rates corrected for haematocrit)? even with all 
nine variables in the model this only accounted for 43.2% 
of the variability.
3.1.4 Platelet . serotonin and plasma
beta-thromboglobulin.
Platelet serotonin and plasma beta-thromboglobulin 
levels did not differ significantly between the 
hypertensive and normotensive groups, although there was a 
tendency for beta-thromboglobulin to be reduced in the 
hypertensive group (table 2, figures 17 and 18). There was 
no significant linear correlation between platelet 
serotonin and plasma beta-thromboglobulin levels (figure 
19) .
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3.1.5 Full blood count, urea and electrolytes, blood 
sugar and liver function tests.
Red blood cell count, haemoglobin and haematocrit were 
all slightly higher in the hypertensive than the control 
group, although these differences did not reach 
statistical significance (table 3). Mean cell volume did 
not differ between the two groups (table 3). There were no 
significant differences in serum sodium, potassium, urea, 
creatinine, gamma glutamyl transferase or blood sugar 
between the hypertensive and normotensive groups (table 
6) .
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Hypertensive Normotensive
Platelet count (10^/L) 205+10 (n=23) 206+15 (n=20)
Platelets remaining 
after serotonin-induced 
aggregation (%)
50.0+3.8 (n= 22) 56.9^2.4 (n=20)
Platelets remaining 
after spontaneous 
aggregation (%)
49.5+4.6 (n=23) 47.2+4.8 (n=20)
Platelet serotonin 
(nmol/10 platelets) 3.7+0.4 (n=20) 3.7+0.4 (n=19)
Beta-thromboglobulin
(ng/mL) 41.5+4.4 (n=20) 54.3+12.4 (n=17)
(* = p<0.05, unpaired Student (t) test, 2-tailed)
Table 2:
Platelet count, percentage of platelets remaining after 
serotonin-induced and spontaneous aggregation, platelet 
serotonin content, and plasma beta-thromboglobulin, in
patients with untreated essential hypertension compared to
an age and sex matched normotensive control group.
Hypertensive Normotensive
Red blood cell count 
(1012/L) 4.7 6+0.09 (n=23) 4.58+0.09 (n=20)
Haemoglobin (g/dL) 14.8+0.3 (n=23) 14.1+0.2 (n=20)
Haematocrit (%) 43.6+0.9 (n=23) 41.9+0.7
oCMIIc
Mean cell volume (fL) 91.7+1.0 (n=23) 91.6+0.7 (n=20)
94s”’1 5.01+0.17 (n=18) 5.10+0.12 (n=10)
94s"1(c) 4.96+0.13 (n=18) 5.37+0.19 (n=10)
0.94s"1 20.2+1.1 (n=18) 18.3+0.7 (n=10)
0.94s"1(c) 19.7^0.6 (n=18) 19.8^0.6 (n=10)
-194s = whole blood viscosity at high shear corrected (c) and
uncorrected for haematocrit
0.94s 1 = whole blood viscosity at low shear corrected (c) and
uncorrected for haematocrit
Table 3:
Red blood cell count, haemoglobin, mean cell volume, 
haematocrit and whole blood viscosity at high and low shear 
rates in patients with untreated essential hypertension 
compared to an age and sex matched normotensive control 
group.
Linear regression analysis of the percentage of platelets 
remaining after serotonin-induced aggregation verses each
independent variable.
Independent Number Regression
variable patients coefficient t-statistic p % fit
Sex 42 -12.35 -3.32 0.002 21.6
Age (years) 42 -0.90 -2.82 0.007 16.6
Body weight (Kg) 42 0.12 0.91 0.37 2.1
Supine SBP (mmHg) 42 -0.26 -3.60 <0.001 24.5
Supine DBP (mmHg) 42 -0.26 -1.49 0.15 5.2
)3tG (ng/mL) 37 0.08 1.43 0.16 5.5
94s f- 27 2.13 0.54 0.60 1.1 .
94s 1 (c) 27 -2.3 8 -0.58 0.34 1.3
0.94s j- 27 -0.09 -0.14 0.89 <0.1
0.94s“|lc) 27 -1.43 -1.48 0.15 8.1
RBC(10 /L) 42 4.69 0.92 0.37 2.1
Sex (male=l, female=2)
SBP = systolic blood pressure
DBP = diastolic blood pressure
J3tG__^  = beta-thromboglobulin
94s = whole blood viscosity at high shear corrected (c) and
uncorrjcted for haematocrit
0.94s = whole blood viscosity at low shear corrected (c) and
uncorrected for haematocrit 
RBC = red blood cell count
Table 4:
Linear regression analysis of serotonin-induced platelet 
aggregation in whole blood (dependent variable) against sex, 
age, body weight, supine systolic and diastolic blood pressure, 
plasma beta-thromboglobulin, whole blood viscosity at high and 
low shear rates and red blood cell count (independent 
variables).
Multiple regression analysis of the percentage of platelets 
remaining after serotonin-induced aggregation verses all 9 
independent variables (23 patients).
Independent Regression
variable coefficient t-statistic P
Sex -11.31 -1.53 0.15
Age (years) 0.22 0.34 0.74
Body weight (Kg) -0.14 -0.68 0.51
Supine SBP (mmHg) -0.06 -0.33 0.75
Supine DBP (mmHg) -0.10 -0.25 0.81
btG (ng/ml) 0.06 0.68 0.51
94s 1 (c) -1.00 -0.16 0.87
0.94 1(c)19 
RBC {10 /1)
-1.80 -1.28 0.22
-2.39 -0.27 0.79
Sex (male=l, female=2)
SBP = systolic blood pressure
DBP = diastolic blood pressure
btG_^ = beta-thromboglobulin
94s (c) = whole blood viscosity high shear corrected for 
haematjcrit
0.94s (c) = whole blood viscosity low shear corrected for 
haematocrit
RBC = red blood cell count
Table 5:
Multiple regression analysis of serotonin-induced platelet 
aggregation in whole blood (dependent variable) against sex, 
age, body weight, supine systolic and diastolic blood pressure, 
plasma beta-thromboglobulin, whole blood viscosity at high and 
low shear rates (corrected for haematocrit) and red blood cell 
count (independent variables).
Hypertensive 
(n=23)
Sodium (mmol/L) 141.7^0.5
Potassium (mmol/L) 4.16_+0.07
Urea (mmol/L) 4.7^0.2
Creatinine {jj mol/L) 85.8+^4.5
XGT (U/L) 29.5+5.1
Blood sugar (mmol/L) 5.3+0.2
(tfGT = gamma glutamyl transferase)
Table 6:
Normotensive
(n=20)
142.3+0.4 
4.05+0.05 
5.1+0.3 
81.9+3.3 
27.1+6.0 
5.1+0.2
Serum urea and electrolytes, gamma glutamyl transferase and 
blood sugar in patients with untreated essential hypertension 
compared to age and sex matched normotensive subjects.
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Percentage'of single platelets remaining 
after the addition of serotonin (1juM) to whole 
blood, in patients with untreated essential 
hypertension compared to age and sex matched 
normotensive subjects.
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Percentage of single platelets remaining after 
the addition of serotonin (1/jM) to whole blood 
verses supine systolic blood pressure.
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Percentage of single platelets remaining-after 
the addition of serotonin. (ljuM) to whole blood 
verses supine diastolic blood pressure.
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Percentage of single platelets remaining after 
the addition of serotonin (1/iM) to whole blood 
verses age in years.
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Percentage of single platelets remaining 
after the addition of serotonin (1/jM) to 
whole blood, verses patient sex.
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Percentage of single platelets 
remaining after spontaneous platelet 
aggregation in whole blood (15 minutes 
incubation at 130-140 shakes/minutes 
at 37°C), in patients with untreated 
essential hypertension compared to 
age and sex matched normotensive 
subjects.
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Plasma beta-thromboglobulin in patients 
with untreated essential hypertension 
compared to age and sex matched normotensive 
subjects.
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Platelet serotonin content in patients 
with untreated essential hypertension 
compared to age and sex matched 
normotensive subjects.
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Linear regression analysis of platelet serotonin 
content (dependent variable) against plasma beta- 
thromboglobulin (independent variable).
3.2 The effects of short-term ketanserin treatment on
blood pressure, heart rate, the renin-angiotensin system, 
adrenocortical function, QT interval and vagal function 
and the response to infusion of angiotensin II in healthy 
subjects
3.2.1 Blood pressure and heart rate.
a) First dose:
One subject experienced symptomatic postural hypotension 
after the first dose of ketanserin 40mg. His standing 
blood pressure and heart rate fell from 124/72 mmHg and 
100 beats/min, before the drug, to 82/48 mmHg and 72
beats/min respectively 1 hour after drug administration;
*
supine blood pressure and heart rate were 132/60 mmHg and 
88 beats/min prior to ketanserin compared to 123/50 mmHg 
and 88 beats/min 1 hour after drug administration. 
However, mean changes in blood pressure 1 hour after the 
first dose of ketanserin were small; although standing 
systolic blood pressure was reduced by ketanserin compared 
to placebo (p<0.05), there were no significant changes in 
systolic, diastolic, mean arterial pressure or heart rate 
either supine or erect after ketanserin compared to 
placebo (table 7).
b) Chronic oral dosing.
Three days of ketanserin caused only minor but 
significant effects on blood pressure; mean supine 
arterial blood pressure was significantly lower (p<0.02) 
at 45-60 minutes after ketanserin on the morning of day 4
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(80.2j^ 2.2 mmHg) compared to placebo (85.9+^1.5); there were 
no detectable differences around 7 hours after dosing. 
There were no significant changes in erect blood pressure 
after 3 days of ketanserin, either around 1 or 7 hours 
after dosing, compared to placebo (table 8).
On the morning of day 4 (1 hour after dosing) supine 
heart rate was reduced after ketanserin by 3.5+1.5 
beats/min when compared to placebo (p<0.05); there were no 
significant differences 7 hours after dosing (table 8).
c) Angiotensin II infusion.
Ketanserin did not attenuate the rise in blood pressure 
in response to the graded intravenous infusions of 
angiotensin II at 1 and 7 hours after dosing on day 4 
(figures 20 and 21). The maximal reductions in heart rate 
caused by the infusion of angiotensin II were 6.9jh3.6 and 
9.8jf3.3 beats/minute at 1 and 7 hours respectively after 
ketanserin compared to 6.5^4.0 and 11.9jf3.2 after placebo; 
there were no significant differences between drug and 
placebo.
3.2.2 Autonomic function tests.
The deep breathing, Valsalva and 30 : 15 lying to
standing ratios were all reduced 90 mins after ketanserin 
on day 4, consistent with a decrease in cardiac 
parasympathetic outflow; however, individually these 
changes did not achieve statistical significance (p=0.16, 
p=0.09 and p=0.06 respectively). At 7 hours post drug on 
day 4 there were no detectable differences in the above
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ratios between the ketanserin and placebo phases (table 
9) .
3.2.3 The QT interval.
Both the uncorrected QT and QTc intervals were prolonged 
after ketanserin therapy, by 26-40 milliseconds. This 
effect was apparent at both 1 and 7 hours after drug 
administration on day 4 (table 10, figures 22 and 23).
3.2.4 Plasma renin, aldosterone, angiotensin II and 
cortisol.
No significant differences were observed in supine 
resting plasma renin, aldosterone, angiotensin II or 
cortisol after 3 days of ketanserin, compared to placebo 
(table 11). The morning angiotensin II infusion caused 
similar rises in plasma aldosterone after both ketanserin 
(4.1+^ 1.4 ng/lOOml) and placebo (4.8 + 1.0- ng/lOOml) . The 
suppression of plasma active renin by angiotensin II 
infusion was also not significantly affected by 
ketanserin, with a reduction of 5.1 + 1.3 jiU/ml, compared to 
4.1+1.0 after placebo.
3.2.5 Plasma ketanserin and ketanserinol levels.
Plasma ketanserin levels were 118+^ 38, 106^32 and 54h^5 
nmol/1, at 45 mins, 90mins (before and after the morning 
angiotensin II infusion) and 7 hours respectively after
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drug administration on day 4; plasma ketanserinol levels 
were 219_+41, 222^35 and 205_+19 nmol/1.
3.2.6 Adverse drug reactions:
One subject developed syptomatic first dose hypotension 
as detailed above (3.2.1). Two subjects complained of 
nasal stuffiness while taking ketanserin.
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Time
Placebo 
0 1 hour
Ketans
0
erin 
1 hour
Supine SBP 121.1+3.3 118.9+3.3 125.4+2.5 121.0+2.7
Supine DBP 68.3+2.9 70.1+3.8 63.7+3.6 62.3^3.0
Supine map 85.9+2.0 86.3+3.0 84.1+4.7 81.7+1.9
Supine HR 70.9+3.6 68.6+3.2 69.7+4.0 68.6+4.7
Erect SBP 110.4+1.6 114.3+1.7 115.9+2.1 104.7+4.1*
Erect DBP 77.4+1.8 7 6.0+3.3 72.4+3.4' 69.9+4.1
Erect map 87.9+1.5 88.7+2.0 86.9+2.4 81.0_+4.0
Erect HR 85.6+3.7 85.7+3.5 83.1+5.9 85.7+6.1
(* p<0 .05, paired Student (t) test, 2-tailed)
SBP = systolic blood pressure (mmHg)
DBP = diastolic blood pressure (mmHg) 
map = mean arterial pressure (mmHg)
HR = heart rate (beats/minute)
Table 7:
Effects of ketanserin 40mg orally, compared to placebo, on 
supine and erect blood pressure and heart rate, before and 1 
hour after dosing, in 8 healthy subjects.
Day 4
1 hour after dosing 7 hours after dosing
Ketanserin Placebo Ketanserin Placebo
Supine SBP 118.1+3.5 118.6+3.5 120.3+3.1 120.3+3.1
Supine DBP 61.3+2.9 6 7.7+3.0 60.0+3.6 61.3+2.7
Supine map 80.2+2.2* 85.9+1.5 8 0.0+2.0 80.4+1.6
Supine HR 59.5+2.8* 63.0+3.2 63.0+2.9 66.6+3.0
Erect SBP 111.4+2.1 110.4+3.1 113.3+3.4 111.5+2.2
Erect DBP 70.9+2.6 75.6+2.1 70.9+3.1 72.1+2.1
Erect map 8 4.4+1.8 87.3+2.3 84.9+2.7 85.4+1.9
Erect HR 83.8+4.0 80.6+4.2 84.6+2.7 87.5+3.7
(* p<0 .05, paired Student (t) test, 2-tailed)
SBP = systolic blood pressure (mmHg)
DBP = diastolic blood pressure (mmHg) 
map = mean arterial pressure (mmHg)
HR = heart rate (beats/minute)
Table 8:
Supine and erect blood pressure and heart rate, at 1 and 7 
hours after dosing after 3 days ketanserin 40mg twice daily, 
compared to matching placebo, in 8 healthy subjects.
Day 4
1 hour after dosing 7 hours after dosing
Ketanserin Placebo Ketanserin Placebo
1.44+0.10 1.31+0.08 1.30+0.06
1.63+0.06 1.55_+0.0 8 1.62+0.08
1.64+0.08 1.55+0.07 1.56+0.06
Table 9:
Ratios of maximal to minimal RR1 intervals during lying to 
standing, Valsalva and deep breathing manoevres after 3 days 
ketanserin 40mg twice daily compared to matching placebo, 1 and 
7 hours after dosing, in 8 healthy subjects.
Lying to
standing 1.25+^0.09
ratio
Valsalva 1.52+0.04
ratio
Deep breathing 1.5 0j+0.09 
ratio
Day 4
1 hour after dosing 7 hours after dosing
Ketanserin Placebo Ketanserin Placebo
QT (msec)
QTC (msec)
(* p<0.05, ** p<0.01, paired Student (t) test, 2-tailed)
Table 10:
Electrocardiographic QT and QTc intervals, at 1 and 7 hours 
after dosing after 3 days ketanserin 40mg twice daily, compared 
to matching placebo, in 8 healthy subjects.
434+17* 408+8 432+9** 392+11
444+12* 416+10 446+9** 416+7
Day 4 (1 hour after dosing)
Ketanserin Placebo
Renin (pU/mL) 18.4+^ 3. 3 18.0_+2.8
Aldosterone (ng/lOOmL) 4.5+^ 0.7 3.0_+0.5
Angiotensin II (pg/mL) 5.5+^ 1.4 4. 9^1.2
Cortisol (pg/lOOmL) 13.5j+1.3 15.3+^1.3
Potassium (mmol/L) 4.0+0.1 4.0+0.1
Table 11:
Plasma renin, aldosterone, angiotensin II and cortisol and 
serum potassium after 3 days ketanserin 40mg twice daily 
(1 hour after dosing) compared to matching placebo, in 8 
healthy subjects.
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Figure 20
Change in mean arterial pressure due to incremental 
infusion of angiotensin II after 3 days ketanserin 
40mg twice daily compared to matching placebo, 1 
hour after dosing, in 8 healthy subjects.
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Anr.a.p. = change in mean arterial pressure 
Figure 21
Change in mean arterial pressure due to incremental 
infusion of angiotensin II after 3 days ketanserin 
AOmg twice daily compared to matching placebo,.7 
hours after dosing, in 8 healthy subjects.
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b) 7 hours after dosing
Figure 22
Electrocardiographic QT interval after 3 days ketanserin 
40mg twice daily compared to matching placebo, 1 and 7 
hours after dosing, in 8 healthy subjects.
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Figure 23
Electrocardiographic QT q  interval after 3 days ketanserin 
40mg twice daily compared to matching placebo, 1 and 7 hours 
after dosing, in 8 healthy subjects.
3.3 Effects of single oral doses of ritanserin and
ketanserin in patients with untreated essential
hypertension
3.3.1 Blood pressure and heart rate.
Ketanserin 40mg caused a significant (P<0.03) reduction 
of the area under the curve for sitting mean arterial 
pressure over the 8 hours after drug administration 
compared to placebo (figure 24). There was a mean 
reduction of sitting mean arterial pressure of 15.4^3.2 
(baseline = 119. 4jf2. 4mmHg) after ketansrin, compared to 
8.5^2.2 (baseline = 118.2jf2.1) after placebo. Ritanserin 
had no significant effects on sitting mean arterial 
pressure when compared to placebo; there were average 
reductions of 9.CH2.6 (baseline = 117.CK3.3) and 10.8^1.8 
(baseline = 119.8^0.9) after 10 and 20mg ritanserin
respectively (figure 24). There was a trend for ketanserin 
to reduce erect mean arterial pressure, by 10.8^3.1 
(baseline = 120.0jh2.8) compared to a reduction of 6.6_+3.1 
(baseline = 119.8^2.1) after placebo, but there was no 
statistically significant difference in area under the 
curve (figure 25). Ritanserin 10 and 20mg had no 
significant, effects on erect mean arterial pressure 
compared to placebo (figure 25) .
There were no significant changes in area under the 
curve for sitting (figure 26) or standing heart rate 
(figure 27) after ritanserin or ketanserin compared to 
placebo. Average pulse rate over the 8 hours after placebo
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was reduced by 1.6_+0.9 beats / min (baseline 78.8^1.6) 
sitting and 2.4jf1.0 (baseline 82.4^1.1) standing, compared 
to reductions of 3.6^2.6 (baseline 81.6^2.2) and 2.8^2.2 
(baseline 82.2^1.8) after ritanserin lOmg, 2.2+0,8 
(baseline 77.5+^ 2.5) and 2.1+_1.8 (baseline 80.0+^2.9) after 
ritanserin 20mg, and 3.1+1.4 (baseline 80.3j^l.2) and 
0.3_+1.0 (baseline 18.1+1.2) after ketanserin 40mg.
3.3.2 Psychological function tests.
There were no significant changes in tranquillity or 
alertness scores (Herbert, Johns & Dore, 1976) or 
hostility, anxiety or depression scores (Zuckerman & 
Lubin, 1965) after ritanserin 10 or 20mg or ketanserin 
40mg compared to placebo (tables 12 and 13).
3.3.3 Adverse drug reactions.
No adverse drug reactions or side effects were noted 
after ritanserin or ketanserin in this study.
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Placebo Ritanserin
lOmg
Ritanserin
20mg
Ketanserin
40mg
Baseline
Hostility 4.2+1.0 5.2+1.3 5. 0 + 1.2 4.3+1.0
A
Hostility 0.7+0.2 -0.7+0.5 0.1+0.5 0.6 + 0.3
Baseline
Anxiety 4.3+1.5 5. 3 + 2. 4 5.0+1.5 4.2+1.9
A
Anxiety 0. 3 + 0. 8 —0.6+0.8 0.1+0.9 0.3+0.7
Baseline
Depression 8.2+2.1 10.3+2.8 10.0+2.3 10.2+2.5
A
Depression 1.8+0.9 -0.3+0.4 0. 3 + 0. 6 0.3+1.0
^  = mean change from baseline
Table 12:
Baseline and mean change from baseline of hostility, 
anxiety and depression scores during 8 hours after single oral 
doses of placebo, ritanserin lOmg, ritanserin 20mg and 
ketanserin 40mg in 6 patients with untreated essential 
hypertension.
Placebo Ritanserin
lOmg
Ritanserin
20mg
Ketanserin
40mg
Baseline
Alertness
A
81.0+5.4 79.4+9.2 8 4.6+6.8 87.2+6.3
Alertness 2.7+2.9 1.2+5.7 2. 3 + 5.1 1.9+2.4
Baseline
Tranquillity
A
77.9+5.5 76.8+9.6 83.2+6.2 84.1+6.8
Tranquillity 0.0+0.9 -3.4+4.9 -0.4+0.5 1.6+2.2
Baseline is % of maximal possible score 
= mean % change from baseline
Table 13:
Baseline and mean change from baseline of alertness 
and tranquillity scores during 8 hours after single oral 
doses of placebo, ritanserin lOmg, ritanserin 20mg and 
ketanserin 40mg in 6 patients with untreated essential 
hypertension.
a  ritanserin lOmg 
a ritanserin 20mg 
o ketanserin 40mg 
•  placebo
120 -
co
Time (hours)
Figure 24
Sitting mean arterial pressure before and after single oral doses 
of ritanserin 10mg, ritanserin 20mg, ketanserin 40mg and placebo 
in 10 patients with untreated essential hypertension.
Si
tt
in
g 
he
ar
t 
ra
te
 
(m
in
a  ritanserin 10mg 
a ritanserin 20mg 
o ketanserin 40mg 
•  placebo
rrc
7 0 -
0 2 86
Time (hours)
Figure 25
Sitting heart rate before and after single oral doses of 
ritanserin 10mg, ritanserin 20mg, ketanserin 40mg and placebo 
in 10 patients with untreated essential hypertension.
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Figure 26
Standing mean arterial pressure before and after single oral 
doses of ritanserin 10mg, ritanserin 20mg, ketanserin 40mg and 
placebo in 10 patients with untreated essential hypertension.
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Figure 27
Standing heart rate before and after single oral doses of 
ritanserin 10mg, ritanserin 20mg/ ketanserin 40mg and placebo in 
10 patients with untreated essential hypertension,
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3.4 Effects of chronic oral ritanserin in patients with
untreated essential hypertension
3.4.1 Serotonin-induced and spontaneous platelet 
aggregation.
Ritanserin significantly inhibited serotonin-induced 
platelet aggregation compared to placebo (p<0.05, figure 
28); the % reduction in platelet numbers caused by 
serotonin decreased from 50.4_+5.8 to 21.7^7.0% over 4 
weeks (week 0-4) active treatment, compared to 49.0_+7.0% 
at week 0 and 58.7jf3.9% at week 4 in the placebo control 
group. Ritanserin had no significant effects on total 
platelet numbers, spontaneous platelet aggregation or 
platelet serotonin content (table 14).
3.4.2 Blood pressure and heart rate.
Ritanserin had no significant effects on supine or erect 
blood pressure or heart rate compared to placebo (table 
15, figures 29 and 30). Supine systolic and diastolic 
blood pressures rose by 1.2 + 4.1 and decreased by 0. 6h^0.9 
mmHg respectively over 4 weeks treatment with ritanserin 
(weeks 0-4), compared to reductions of 7.3jf7.8 and 3.L+4.0 
mmHg over the corresponding period in the placebo control 
group; erect systolic and diastolic pressures decreased by 
0.3_+3.7 and 3.30.0 mmHg in the ritanserin group compared 
to 7.9j^ 8.3 and 6.8M.6 mmHg in the control group. Supine 
and erect heart rate decreased by 2.0jf2.5 and 1.0^3.8
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beats/min respectively over 4 weeks of ritanserin 
treatment, compared to reductions of 5.0_+2.2 and 5.0_+3.0 
beats/min over the corresponding period in the control 
group. The 95% confidence limits (2-tailed) for the 
effects of ritanserin compared to placebo at 2 and 4 weeks 
are shown in table 16.
3.4.3 Forearm blood flow and venous compliance.
There were no significant changes in forearm blood flow 
at rest, of peak flow after 3 minutes of arterial 
occlusion or of basal or minimal forearm vascular 
resistance in the ritanserin treated patients compared to 
the placebo control group (table 17, figures 31 and 32). 
Forearm venous compliance also did not change 
significantly after drug compared to placebo (table 17, 
figure 33).
3.4.4 Electrocardiographic QRS and QT intervals.
Ritanserin caused prolongation of the QTc interval by 
41+11 milliseconds compared to 4.4^4.0 after placebo 
(p<0.05, table 18, figure 34). There was a similar 
tendency for the drug to prolong the uncorrected QT 
interval (figure 35), although this did not acheive 
statistical significance. Ritanserin had no detectable 
effects on QRS duration (table 18).
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3.4.5 Urea and electrolytes, haematocrit and body 
weight.
There were no significant changes in plasma sodium, 
potassium, urea or creatinine during treatment with 
ritanserin (table 19). Weight remained steady during drug 
treatment, with no detectable alterations of haematocrit 
(table 19).
3.4.6 Tests of psychological function.
There were no significant changes caused by ritanserin 
(compared to placebo) in the digit subtraction 
substitution test score (table 20) or in subjective 
feelings measured by visual analogue scales (table 21).
3.4.7 Adverse drug reactions.
One patient complained of drowsiness and lethargy while 
taking ritanserin. No other adverse drug reactions or side 
effects were noted.
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Ritanserin (n=7) Placebo (n=7)
Week 0 4 0 4
202+17 217+27 203+21 214+16
94.4+4.5 79.0+5.3 86.2+3.2 88.2+12.0
49.6+5.8 78.3+7.0*51.0+7.0 41.3+3.9
47.4+8.9 56.1+6.9 55.3+9.6 41.3+8.9
(* p<0.05, Wilcoxon rank sum test, change after ritanserin 
compared to change after placebo)
Table 14:
Platelet count and platelet aggregation (quantified by the 
reduction in single platelet count in whole blood) in patients 
with essential hypertension, before and after 4 weeks of 
ritanserin lOmg twice daily compared to a parallel placebo 
control group.
Platelet count 
(10 /L)
Platelets 
remaining after 
blank test (%)
Platelets 
remaining after 
serotonin-induced 
aggregation (%)
Platelets 
remaining after 
spontaneous 
aggregation (%)
Ritanserin lOmg 
daily (n=10
twice
)
Matching placebo 
(n= 8)
Week 0 2 4 0 2 4
sSBP 166.7+3.5 165.5+7.9 167.9+9.7 167.3+5.9 160.4+4.2 160.0+5.2
sDBP 97.1+3.8 96.2+2.9 96.5+3.7 90.0+2.5 88.3+2.9 86.9+3.9
sHR 80.6+4.4 78.6+3.9 78.6+3.9 72.5+2.0 68.1+2.6 67.5+2.8
eSBP 158.8+8.5 161.4+8.3 158.5+9.3 153.5+7.4 148.3+4.6 145.6+5.3
eDBP 103.6+3.4 102.6+3.3 100.3+3.6 93.5+4.7 91.9+3.2 86.8+5.0
eHR 90.2+5.0 88.8+4.4 89.2+4.3 81.5+2.4 78.0+3.5 76.5+3.1
s = supine, e = erect
SBP = systolic blood pressure (mmHg)
DBP = diastolic blood pressure (mmHg)
HR = heart rate (beats/minute)
Table 15:
Supine and erect blood pressure and heart rate in patients 
with essential hypertension before and after 2 and 4 weeks
of ritanserin lOmg twice daily compared to a parallel
placebo control group.
Mean changes in blood pressure and heart rate 
(95% confidence limits) after ritanserin lOmg (n=10) 
twice daily compared to placebo (n=8).
Week 2 Week4
Supine SBP 5.6 (“7.8, 19.0) 8.5 (“9.3, 26.3)
Supine DBP 3.6 (“6.3, 13.5) 2.5 (“6.3, 11.3)
Supine HR -2.4 (“7.7, 2.9) 3.0 (“4.0, 10.0)
Erect SBP 7.9 (“6.3, 22.1) 7.6 (-10.5 , 25.7)
Erect DBP 0.6 (“9.7, 8.5) 3.5 (“7.6, 14.6)
Erect HR 2.9 (“3.7, 9.5) 4.0 (“6.3, 14.3)
SBP = systolic blood pressure (mmHg) 
DBP = diastolic blood pressure (mmHg) 
HR = heart rate (beats/min)
Table 16:
Mean changes and 95% confidence limits (2-tailed) of 
supine and erect blood pressure and heart rate in patients 
with essential hypertension, after 2 and 4 weeks of 
ritanserin lOmg twice daily compared to a parallel 
placebo control group.
Ritanserin (n=7)
Week 0 4
Placebo (n=7)
0 4
RF 11.5+2.7 12.2+1.4 8. 3 + 1.2 9.4+1.7
PF 59.1+10.2 62.1+5.5 48.6+6.5 41.6+3.4
BVR 13.2+2.5 10.4+1.0 16.7+3.4 14.1+2.1
MVR . 2. 5J+0.5 2.1 + 0.3 2 . 6 + 0. 3 2 . 8jhO . 2
Intercept -0.16+0.43 -0.13+0.51 -0.26+0.37 -0.35+0.51
Slope 0.107+0.016 0.119+0.012 0.107+0.009 0.110+0.005
RF = forearm resting blood flow (ml/lOOml/min)
PF = maximal forearm post-ischaemic flow (ml/lOOml/min)
BVR = basal vascular resistance = mean arterial pressure / RF 
MVR = minimal vascular resistance = mean arterial pressure / PF
The intercept (a) and slope (b) describe the regression line of 
venous occlusion pressure in mmHg (x) against % increase in 
forearm volume (y), where y=a+bx
Table 17:
Forearm blood flow at rest, maximal post-ischaemic flow, 
basal and minimal vascular resistance and venous compliance in 
patients with essential hypertension, before and after 4 weeks 
of ritanserin lOmg twice daily compared to a parallel placebo 
control group.
Ritanserin (n=7)
Week 0 4
Placebo (n=7)
0 4
QT (msec) 385+10 422+15 388+10 392+10
QTc (msec) 
QRS (msec)
439+12 478+12* 402+5 410 + 5
93 + 3 92 + 2 89 + 2 89 + 3
(* p<0.05, Wilcoxon rank sum test; change after ritanserin 
compared to change after placebo)
Table 18:
Electrocardiographic QT, QTc and QRS interval durations in 
patients with essential hypertension, before and after 4 weeks 
of ritanserin lOmg twice daily compared to a parallel placebo 
control group.
Ritanserin (n=10)
Week 0 4
Placebo (n=8)
0 4
Na+ (mmol/L) 141.6+0.5 141.1+0.6 141.0+0.8 142.4+0.9
K+ (mmol/L) 3.97+0.10 4.06+0.09 4.10+0.13 4.05+0.10
U (mmol/L) 4.8+0.3 4.9^0.2 4.9+0.4 5.2+0.4
Cr (pmol/L) 86.5+5.6 82.9+6.8 75.1+5.5 78.6+6.4
Hct (%) 43.8+1.5 43.1+1.5 41.5+0.8 40.8+1.2
Weight (Kg) 74.8+5.5 75.2+5.4 73.6+5.8 73.4+5.9
N^+ = sodium 
K = potassium 
U = urea 
Cr = creatinine 
Hct = haematocrit
Table 19:
Serum sodium, potassium, urea, creatinine, and haematocrit 
and body weight in patients with essential hypertension, before 
and after 4 weeks of ritanserin lOmg twice daily compared to a 
parallel placebo control group.
Ritanserin (n=10) Placebo (n=8)
Week 0 4 0 4
DST score 48.4+4.4 51.2+5.5 48.4+6.1 54.3+5.2
DST = digit substitution test
score = number of correct digit substitutions in 3 minutes
Table 20:
Digit substitution test score in patients with essential 
hypertension before and after 4 weeks of ritanserin lOmg 
twice daily compared to a parallel placebo control group.
Ritanserin (n=10) Placebo (n=8)
Week 0 4 0 4
Alert-Drowsy 34.2+5.5 28.6+4.1 34.8+10.7 34.4+11.3
Well co-ordinated- 
Clumsy 22.6+4.1 21.8+5.0 27.6+11.6 35.9+10.9
Tense-Relaxed 52.8+11.6 59.4+7.7 60.8+12.0 49.1+12.1
Incompetent-
Proficient 69.7+6.6 73.7+6.7 64.1+8.0 82.8+4.9
Happy-Sad 28.9+7.5 31.0+6.7 20.5+8.5 17.8+6.6
Withdrawn- 80.8+8.2 76.0+6.6 76.9+6.0 79.1+4.5
Sociable
Distance (mm) along line (100mm) between 2 words as shown, 
on visual analogue scales.
Table 21:
Subjective feelings, measured by self-administered visual 
analogue scales, in patients with essential hypertension before 
and after 4 weeks of ritanserin lOmg twice daily compared to a 
parallel placebo control group.
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Figure 28
Serotonin - induced platelet aggregation, quantified as 
the reduction in single platelet count in whole blood 
caused by the addition of serotonin (1/jM), in patients 
with essential hypertension before and after 4 weeks of 
ritanserin 10mg twice daily (n = 7) compared to a parallel 
placebo control group (n = 7).
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Figure 29
Supine systolic and diastolic blood pressure 
in patients with essential hypertension treated 
with ritanserin 10mg twice daily for 4 weeks 
( n = 1 0 ) ,  compared to a parallel placebo control 
group (n = 8),
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Figure 30
Standing systolic and diastolic blood pressure 
in patients with essential hypertension treated 
with ritanserin 10mg twice daily for 4 weeks, 
compared to a parallel placebo control group 
(n = 8).
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Figure 31
Forearm blood flow at rest in patients with 
essential hypertension before and after 4 weeks 
of ritanserin 10mg twice daily ( n = 7 )  compared 
to a parallel placebo control group (n = 7).
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Figure 32
Post-ischaemic forearm blood flow In patients with 
essential hypertension before and after 4 weeks of 
ritanserin 10mg t w i c e . d a i l y ( n = 7) compared to a 
parallel placebo control group (n = 7).
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Figure 33
Forearm venous compliance, measured by percentage increase 
in forearm volume at increasing venous occlusion 
pressures, in patients with essential hypertension before 
and after 4 weeks of ritanserin 10mg twice daily in = 7) 
compared to a parallel placebo control group ( n = 7 ) .
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Figure 34
Change in electrocardiographic QTC interval 
in patients with essential hypertension after 
4 weeks of ritanserin 10mg twice daily In = 7 )  
compared to a parallel placebo control group 
(n = 7).
Placebo Ritanserin
Figure 35
Change in electrocardiographic QT 
interval in patients with essential 
hypertension after 4 weeks of 
ritanserin 10mg twice daily (n = 7) 
compared to a parallel placebo 
control group (n = 7).
3.5 Effects of ketanserin in adult atopic asthma
3.5.1 Resting bronchomotor tone and exercise-induced 
bronchoconstriction.
• •
FEV^, V50(c) or V25(p) Pre" an<3 45 m:*-n post-treatment,
were not significantly different after administration of
either ketanserin or placebo (tables 22 and 23).
Ketanserin had no significant effects on the fall in 
■ • •
FVC, FEV^, V50 c^j or V25 (p) after exercise (figures 36,
37, 38 and 39), although there was a tendency for the fall
in FEV^ and FVC after exercise to be reduced by drug
treatment. The mean maximal absolute and percentage (%)
fall in FEV^ caused by exercise was 0.48^0.Q9L (16.8_+3.7%)
after ketanserin compared to 0.55^0.08L (19.2^4.2%) after
0
placebo; the mean maximal fall in V25(p) was 
0.58jf0. 14L/sec •'(32-.5_+5.7%) after drug compared to 
0.49 + 0. 11 (28. 2j+1. 3%) after placebo. The 95% confidence
limits of the effects of ketanserin on maximal percentage 
reduction in pulmonary function after exercise compared to 
placebo are shown in table 23.
3.5.2 Blood pressure and heart rate.
There were no significant changes in resting mean 
arterial blood pressure (m.a.p.) after either ketanserin 
or placebo; exercise caused a rise in m.a.p. of 8.3j^l.l 
mmHg after drug compared to 10.5jf1.4 after placebo (not 
significant). Exercise caused a similar rise in heart
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rate, 46.CH4.7 beats/min after ketanserin compared to 
4 6. 3j^ 4. 7 after placebo.
3.5.3 Plasma ketanserin and ketanserinol levels.
Plasma ketanserin and ketanserinol levels were 25.4+11.4 
and 16.1jf5.2 ng/ml respectively at 45 mins, and 36.5_+9.6 
and 23.2^6.1 ng/ml respectively 75 mins after drug.
3.5.4 Adverse drug reactions.
One patient complained of drowsiness after ketanserin. 
No other adverse drug effects were seen.
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Ketanserin Placebo
Time 0 45mins 0 45minj
FEV1 (L) 3.27+0.37 3.24+0.33 3.16+0.39 3.23+0.40
FVC (L) ,4.53+0.50 4.44+0.40 4.59+0.48 4.63+0.45
V50(c) (L/sec) 3.33+0.58 3.41+0.56 3.28+0.60 3.45+0.70
V25(p) (L/sec) 1.59+0.23 1.95+0.35 1.63+0.29 1.74+0.31
Table 22:
Effect of a single oral dose of ketanserin (40mg) compared 
to placebo on resting bronchomotor tone in 8 adult atopic 
asthmatic patients.
Mean % change in pulmonary function (95% confidence limits) 
after ketanserin 40mg compared to placebo
At rest After exercise
(0-45mins after dosing) (maximal change)
-2.8 (-11.8, 6.2) % 2.4 (-6.4, 11.2) %
-2.1 (-9.7, 5.5) % 3.7 (-5.5, 12.9) %
7.6 (-8.0, 23.2) % -4.2 (-22.5, 13.9) %
14.9 (-0.9, 30.7) % -4.3 (-19.2, 10.6) %
Table 23:
The 95% confidence limits (2-tailed) of the effects of 
ketanserin 40mg compared to placebo on resting bronchomotor 
tone and maximal bronchoconstriction after exercise in 8 adult 
atopic asthmatic patients.
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Figure 36
Percentage change in forced 
expiratory volume in 1 second, 
following exercise, 45 minutes 
after a single oral dose of 
ketanserin ^Omg compared to matching 
placebo in 8 adult atopic asthmatic 
subjects.
I
ketanseri ir i
placebo
n 1--- 1
10 15 200
O n ketanserin
1 0 -O'
o
placebo>LL
<
-20
0 5 10 15 20
Time after exercise (min)
Figure 37
Percentage change in forced vital 
capacity after exercise, 45' minutes 
after a single oral dose of ketanserin 
40mg compared to matching placebo in 8 
adult atopic asthmatic subjects.
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Figure 38
t
Percentage change in V5g (C) following 
exercise, 45 minutes after a single oral 
dose of ketanserin 40mg compared to 
matching placebo, in 8 adult atopic 
asthmatic subjects,
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Figure 39
Percentage change in V25 (P ) following 
exercise, 45 minutes after a single 
oral dose of ketanserin 40mg compared 
to matching placebo, in 8 adult atopic 
asthmatic subjects.
Chapter 4; Discussion
4.1 Measurement of platelet serotonin by high pressure 
liquid chromatography with electrochemical detection
4.1.1 High pressure liquid chromatography with 
electrochemical detection.
Measurement of hydroxyindoles such as serotonin by high 
pressure liquid chromatography with electrochemical 
detection is highly sensitive and specific. Furthermore it 
is a safe method, particularly in that it avoids the use 
of radio-isotopes. The equipment and reagents required are 
relatively inexpensive compared to other methods of 
serotonin assay (Sasa et al., 1978). When a potential of 
+0.5 to +1.0 volts is applied to a solution containing 
serotonin, the hydroxyl group of serotonin (figure 1) is 
oxidised (Tagari, Boullin & Davies, 1984), giving off a 
small current (measured in uamps). This current is 
directly proportional to the concentration of serotonin in 
the solute (Kissinger, Bruntlett & Schoup, 1981). However, 
in plasma and other body fluids, there are numerous other 
interfering substances which are also electroactive at 
these potentials. Therefore a separation step, such as 
high pressure liquid chromatography, is required to remove 
these substances prior to electrochemical detection. Under 
the assay conditions that I have described, the 
concentration of serotonin in known standard solutions was 
directly proportional to the serotonin peak height, across
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the likely 'range of serotonin levels in platelet rich 
plasma.
The retention time for serotonin on the column can be 
varied by adjusting the concentration of methanol in the 
mobile phase. Increasing the concentration of methanol 
allows serotonin to pass more quickly through the column, 
bringing the peak forwards. I have shown that, with a 
retention time of approximately 14 minutes, the serotonin 
peak in platelet rich plasma can be clearly distinguished 
with no interfering peaks. With this retention time up to 
6 samples can be assayed in duplicate before any 
significant reduction of serotonin peak height occurs, at 
around 5 hours. Using the automated sample injector, 12 
samples can be handled readily in an 8 hour working day.
With the above retention time for serotonin, the 
5-hydroxyindole acetic acid peak in platelet rich plasma 
arrives very early and cannot be clearly separated from 
other interfering peaks. Although the 5-hydroxyindole 
acetic acid peak could be delayed, by decreasing the 
amount of methanol in the mobile phase, allowing 
satisfactory separation from interfering peaks, 
prolongation of the retention time for serotonin would 
have lead to this being measured less accurately. 
Furthermore, very few samples could be assayed for both 
serotonin and 5-hydroxytryptamine in a single day, due to 
the lack of stability of serotonin. Therefore, attempts 
have not been made to analyse plasma 5-hydroxyindole 
acetic acid levels at the same time as serotonin.
The major drawback of serotonin assay in platelet rich
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plasma by high pressure liquid chromatography with 
electrochemical detection is the limited number of samples 
that can be processed in a single day. There are several 
other different basic methods by which serotonin can be 
measured. In early days bioassays were used (Erspamer, 
1954). Although these were sensitive, they were clumsy and 
lacked specificity and therefore fell into disfavour. 
There exist several different techniques for measurement 
of total hydroxyindoles by fluorescence, including native 
fluorescence in strong hydrochloric acid (Geeraerts, 
Schimpfessel & Crockaert, 1974), and derivatisation with 
ninhydrin (Nathenas, Dexter & Katzman, 1973) or 
o-phthalaldehyde (Shuttleworth & O'Brien, 1981). However, 
to measure serotonin rather than total 5-hydroxyindoles, a 
separation step such as high pressure liquid 
chromatography is required prior to fluorescence detection 
(Anderson, Young & Batter, 1981). Although the limit of 
detection for serotonin of fluorescence assays is at best 
around 2.5pmol/ml (Sasa et al. , 1978), compared to
detection limits of as low as 0.3pmol/ml using 
electrochemical detection (Artigas et al., 1985), high
pressure liquid chromatography with fluorescence detection 
is a useful alternative method for measurement of platelet 
serotonin content.
Radioimmunoassay techniques have also been used to 
measure serotonin (Kellum & Jaffe, 1979? Engbaek & Voldby, 
1982). This requires the raising of antisera to serotonin, 
and the use of radio-isotopes. Radio-immunoassay is 
certainly an acceptable technique for measuring serotonin,
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with claimed limits of detection of as low as 2pmol/ml 
(Engbaek & Voldby, 1982). Samples can be processed more 
rapidly by this technique than by high pressure liquid 
chromatography, however because of the materials used 
radio-immunoassay is significantly more expensive (Sasa et 
al., 1978) and is unlikely to have the precision of a 
chemical method involving high pressure liquid 
chromatography and oxidation at a given potential.
The limit of detection of 5pmol/ml that I found with 
high pressure liquid chromatography with electrochemical 
detection is perfectly satisfactory for measuring platelet 
serotonin, and is similar to that of Tagari, Boullin & 
Davies, (1984). Using more complicated sample preparation 
techniques, including the use of an internal standard and 
extraction into an organic solvent, Artigas et al., (1985) 
found a detection limit of 0.3pmol/ml for serotonin by 
high pressure liquid chromatography with electrochemical 
detection. Using a simple assay method without internal 
standards or an extraction procedure, Molyneux & Clarke 
(1985) reported a limit of detection of lpmol/ml. For 
measurement of tissue or free plasma serotonin clearly the 
most sensitive methods should be chosen, however such low 
detection limits hold no advantage for measurement of the 
large amounts of serotonin in platelet rich plasma. 
Consequently, simple and quick sample preparation 
techniques should be used.
page 122
4.1.2 Preparation of platelet rich plasma.
I have shown that serotonin levels in platelet rich 
plasma can be measured sensitively and accurately using a 
quick and simple sample preparation technique which avoids 
the need for time consuming extraction into organic 
solvents as previously described by other investigators 
(Sasa et al.,1978; Artigas et al., 1985). The two
deproteinisation steps used in the preparation of platelet 
rich plasma for serotonin analysis result in very clean 
samples which do not affect chromatographic efficiency. 
The excellent recovery of serotonin spiked into platelet 
rich plasma shows that this technique of sample 
preparation does not cause any significant loss of
serotonin during sample preparation.
Sodium metabisulphite was used as -an antioxidant 
(Molyneux & Clarke, 1985), as ascorbic acid, used in
various fluorescence methods for assay of total 
hydroxyindoles (Geeraerts et al., 1974), caused a broad 
interfering peak on electrochemical detection. Other 
authors have found low concentrations of ascorbic acid 
(lOuM) to be satisfactory as an antioxidant in assay of 
serotonin by high pressure liquid chromatogrphy 
(Baudouin-Legros et al., 1985). As well as ethylene
diamine tetra-acetic acid, prostaglandin was used for
collection of blood for platelet serotonin. It has been
claimed that further inhibition of platelet aggregation 
and content release can be acheived by using prostaglandin 
E^ (Kellum & Jaffe, 1979). It seems sensible to prevent
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platelet content release until the final stages of sample 
preparation, as intra-platelet serotonin may be less 
susceptable to degradation than when in the free state.
Samples of platelet rich plasma can also be prepared for 
serotonin assay by adding an extra centrifugation step to 
form a platelet pellet. This then requires re-suspension 
in a solvent before sample purification can proceed 
(Artigas et al., 1985). These added steps do not seem to 
have any major advantage over the simpler and quicker 
technique of platelet lysis and content release by 
freezing and thawing and the addition of de-ionised water, 
except to decrease the dilution of serotonin, which may be 
more important with less sensitive techniques than 
electrochemical detection.
In the assay of serotonin by high pressure liquid 
chromatography with electrochemical detection, some 
investigators have used an internal standard (Artigas et 
al., 1985). As the time of the serotonin peak on 
electrochemical detection is very reproducible, and the 
peak is well separated from any other interfering 
compounds, it seems that the use of an internal standard 
is not essential in serotonin assay in platelet rich 
plasma (Molyneux & Clarke, 1985). Avoiding the use of an 
internal standard keeps sample preparation as simple as 
possible.
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4.1.3 Assay of serotonin in whole blood
Published methods of analysis of whole blood serotonin 
levels were examined for possible applicablity to high 
pressure liquid chromatography with electrochemical 
detection. It was found that deproteinisation steps using 
sodium hydroxide and zinc sulphate (Geeraerts et al., 
1974; Kellum & Jaffe, 1979) caused a thick unmanageable 
slurry which was very difficult either to mix thoroughly 
or spin down. This problem was only partly ameliorated by 
increasing the dilution of whole blood with distilled 
water. More importantly, the recovery of spiked serotonin 
into frozen then thawed whole blood was very poor. 
Furthermore, disappointingly low levels of serotonin were 
detected in whole blood samples compared to levels in 
platelet rich plasma from the same subject. These findings 
are in direct contrast to those of Geerhardts et al., 
(1974) and Kellum & Jaffe, (1979), who found similar 
levels of serotonin in platelet rich plasma compared to 
whole blood from the same patients.
Attempts made to extract serotonin from the residual 
protein pellets after each of the two preparation steps 
yielded no detectable serotonin, therefore it is unlikely 
that the problem is failure of serotonin release during 
sample preparation. These findings suggest that serotonin 
is destroyed by a factor in frozen-thawed whole blood 
which is not present in platelet rich plasma. This factor 
may be haemoglobin, released from disrupted red cells 
after freezing and thawing. Oxidation of serotonin caused
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by haemoglobin is only partly inhibited by the addition of 
an anti-oxidant such as ascorbic acid or sodium 
metabisulphide (Blum & Ling, 1959).
Data from previous publications claiming good recovery 
of spiked serotonin from whole blood samples (Geeraerts et 
al., 1974; Kellum & Jaffe, 1979) may be explained by 
avoiding freezing and thawing with the inevitable 
haemolysis that this causes. However freezing and thawing 
is essential if samples are to be kept for any significant 
period of time and assayed in batches.
In view of these difficulties in sample preparation of 
whole blood for serotonin assay, and the poor recovery of 
spiked serotonin from frozen-thawed whole blood, assay of 
whole blood serotonin levels was abandoned in favour of 
platelet rich plasma. As nearly all the serotonin present 
in blood is stored in platelets, whole blood serotonin 
assay has no theoretical advantage over platelet rich 
plasma.
page 126
4.2 Serotonin and platelet aggregation in patients with
untreated essential hypertension compared to age and sex 
matched normotensive subjects
4.2.1 Characteristics of the hypertensive and 
normotensive control groups.
Supine heart rate was significantly higher in the 
hypertensive compared to the normotensive group. It is 
well recognised that heart rate is elevated in a 
proportion of patients with arterial hypertension (Julius, 
Esler & Randall, 1975).
The hypertensive patient group had a significantly 
greater mean body weight than the normotensive group. 
Otherwise the two groups were well matched for age, sex 
distribution, and had similar smoking and drinking habits. 
There were no significant differences between 
hypertensives and normotensives in renal function, based 
on serum urea and creatinine. Mean cell volume and serum 
gamma glutamyl transferase were similar in the 
hypertensive and normotensive groups, with no elevated 
values suggestive of concealed alcohol abuse.
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4.1.2 Serotonin-induced platelet aggregation.
a) Is enhanced serotonin-induced platelet aggregation 
associated with raised arterial blood pressure?
There is good evidence that serotonin-induced platelet 
aggregation is mediated through the serotonergic type-2 
receptor (1.4.2 ) and the phosphatidyl inositol messenger 
system (de Courcelles et al., 1985; de Courcelles et al., 
1987). I have shown that serotonin-induced platelet 
aggregation is significantly enhanced in patients with 
untreated essential hypertension compared to age and sex 
matched normotensive subjects. Although mean body weight 
was higher in the hypertensive than the normotensive 
group, there was no significant correlation between body 
weight and the percentage of platelets remaining after 
serotonin-induced platelet aggregation, suggesting that 
body weight did not contribute to the difference in 
serotonin-induced platelet aggregation between the two 
groups. There was a significant negative correlation 
between the percentage of single platelets remaining after 
serotonin-induced platelet aggregation and systolic blood 
pressure, suggesting that a direct linear relationship 
exists between systolic blood pressure and
serotonin-induced platelet aggregation. However, multiple 
regression analysis revealed no significant correlation 
between the percentage of single platelets remaining after 
serotonin-induced platelet aggregation and systolic blood 
pressure; thus, any independent relationship between
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serotonin-induced platelet aggregation and systolic blood 
pressure remains unproven. No significant relationship 
between serotonin-induced platelet aggregation and
diastolic pressure was demonstrated. It is not clear 
whether the enhanced serotonin-induced platelet 
aggregation seen in patients with untreated essential 
hypertension is due directly to raised arterial pressure, 
or conversely whether enhanced serotonin-induced platelet 
aggregation contributes to raised blood pressure; during 
platelet aggregation vasoconstrictor substances including 
serotonin are released (Holmsen, 1977). Thus, the
antihypertensive effects of the serotonergic type-2 
antagonist ketanserin could be due to inhibition of
serotonin-induced platelet aggregation, reducing release 
of intra-platelet vasoconstrictor. substances.
Alternatively, increased serotonin-induced platelet
aggregation in hypertension could be primarily due to
atheromatous complications rather than directly related to 
raised arterial pressure, although this hypothesis is not 
supported by the data from the small number of
hypertensive patients with known vascular disease in this 
study. Firm conclusions cannot be drawn for the cause or 
effect of enhanced serotonin-induced platelet aggregation 
in patients with essential hypertension. Nevertheless,
this association between enhanced serotonin-induced
platelet aggregation and hypertension has not been 
reported previously.
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b) Is serotonin-induced platelet aggregation related to
patient age or sex?
Increasing age and female sex were both associated with 
enhanced serotonin-induced platelet aggregation on linear 
regression analysis; however there were no significant 
relationships between these variables on multiple 
regression analysis. Thus, no clear independent 
relationships between serotonin-induced platelet 
aggregation and patient age or sex were demonstrated.
Other measures of in-vitro platelet aggregation may 
increase also with ageing. Enhanced adenosine 
diphosphate-induced platelet aggregation has been shown to 
be associated with increasing age on simple linear 
regression analysis (Vlachakis & Aledort, 1980; Yamanishi 
et al. , 1985). In Caucasians, plasma beta-thromboglobulin 
rises with increasing age (Dewar et al., 1979; Ludlum, 
1979), suggesting that platelet aggregation in-vivo is 
enhanced in older subjects. However, in a large study of 
Japanese men, there was no correlation of 
beta-thromboglobulin or platelet factor 4 with age 
(Yamanishi et al., 1985). Nevertheless, most of the
evidence suggests that platelet aggregation both in-vitro 
and in-vivo is enhanced with increasing age. Thus, the 
association between serotonin-induced platelet aggregation 
and age is only a part of the non-specific increase in 
platelet aggregability with ageing.
When differences in platelet aggregation between the 
sexes have been studied, it has been apparent that men
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have enhanced in-vivo platelet aggregation compared to 
women (Dewar et al., 1979). Furthermore, atheromatous 
vascular disease, to which men are at increased risk, 
enhances serotonin-induced platelet aggregation in 
platelet rich plasma (De Clerck, 1986). Thus, the finding 
that serotonin-induced platelet aggregation was increased 
in women was surprising and is difficult to explain. 
However, my study was not designed specifically to address 
this issue, therefore interpretation must be with caution; 
further confirmation of these findings is required before 
we can be certain that serotonin-induced platelet 
aggregation is enhanced in women.
c) Is serotonin-induced platelet aggregation related to 
blood viscosity?
Raised blood viscosity could contribute to raised 
arterial pressure in patients with arterial hypertension. 
It has been claimed that serotonin may modulate red cell 
filterability and blood viscosity. The serotonergic type-2 
antagonist ketanserin improves red cell filterability in 
patients with hypertension (Zannad et al., 1985), acute 
myocardial infarction and peripheral vascualr disease (De 
Cree et al., 1985a; De Cree et al., 1985b), inhibits 
serotonin-induced platelet aggregation (De Clerck & 
Xhonneux, 1985; Vermylen et al., 1986), and reduces 
arterial blood pressure. Improved red cell filterability 
after ketanserin is largely dependent on the presence of 
platelets (De Cree et al., 1985a). Thus, interest has been
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raised in 1 the possible relationship between
serotonin-induced platelet aggregation and blood
viscosity. I have found that whole blood viscosity at low
and high shear rates was not significantly correlated with
the reduction in single platelet count caused by
serotonin-induced platelet aggregation. However, only a
very small number of the patients studied had overt
vascular disease. It is possible that serotonin and
serotonin-induced platelet aggregation could play a role
in increasing blood viscosity and raising arterial
pressure in patients with atheromatous vascular disease,
or after acute ischaemic events such as myocardial
s
infarction (De Cree et al., 1985a; Dormandy, 1987) . This 
hypothesis remains however largely unproven.
d) Platelet aggregation in-vitro in whole blood compared 
to platelet rich plasma.
In platelet rich plasma from healthy subjects, serotonin 
is a weak aggregating agent, causing platelet shape change 
and reversable aggregation; however, serotonin also 
potentiates the aggregating effects of threshold 
concentrations of potent platelet aggregating agents such 
as thrombin and adenosine diphosphate (De Clerck et al., 
1984) . In the presence of sub-threshold concentrations of 
these aggregating agents, serotonin can cause irreversable 
platelet aggregation and content release (De Clerck et 
al., 1984). Platelets from patients with atheromatous 
vascular disease frequently show irreversable platelet
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aggregation and release of platelet contents in platelet
rich plasma in response to serotonin (De Cree et al., 
1985b). Thus, atheroma may cause enhanced
serotonin-induced platelet aggregation in platelet rich 
plasma. However, measurement of platelet aggregation in 
whole blood may have advantages over platelet rich plasma. 
Platelets vary in size and density, therefore
centrifugation for platelet rich plasma may select out 
platelets which do not fully represent platelets and 
platelet aggregability in-vivo (Haver & Gear, 1982). 
Furthermore, other cells in whole blood may influence 
platelet function. White blood cells can release
prostacyclin, which inhibits platelet aggregation 
(Blackwood et al., 1978). Red blood cells are thought to
augment platelet aggregation by releasing adenosine
diphosphate (Gaarder et al., 1982). Mechanical factors, 
with jostling of platelets by other blood cells, may also
influence platelet activity. Therefore, platelet
aggregation studies in whole blood may reflect in-vivo 
conditions more closely than studies of platelet rich 
plasma.
4.2.3 Spontaneous platelet aggregation.
There was no significant difference in spontaneous 
platelet aggregation in whole blood between the
hypertensive and normotensive patient groups. Adenosine 
diphosphate from red blood cells is thought to play an 
important role in spontaneous platelet aggregation in
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whole blood (Saniabadi et al., 1984). Indeed, spontaneous 
platelet aggregation is markedly attenuated in platelet 
rich plasma compared to whole blood (Saniabadi et al.,
1984) .
Other methods have been used to investigate adenosine 
diphosphate mediated platelet aggregation in hypertension. 
Although increased platelet aggregation in platelet rich 
plasma in response to adenosine diphosphate has been 
reported in small studies of hypertensive patients (Ikeda 
et al., 1985; Bodzenta-Lukasyk, Krupinski & Bielawiec, 
1987) other authors have found no difference compared to a 
normotensive control group (Mehta & Mehta, 1981; Yamanishi 
et al., 1982). By far the largest of these studies was by 
Yamanishi et al., 1982).
The threshold concentration of adenosine diphosphate 
required to cause platelet aggregation has been claimed to 
be reduced in hypertensives compared to normotensive 
controls (Coccheri & Fiorentini, 1971; Vlachakis & 
Aledort, 1980); however, in one of these studies the
control group is not age matched and a number of the
hypertensive patients are on treatment (Vlachakis & 
Aledort, 1980), and in the other no information is 
presented on age and sex matching of the control group 
(Coccheri & Fiorentini, 1971).
In an uncontrolled observational study, prazosin has 
been shown to reduce adenosine diphosphate-induced 
platelet aggregation in platelet rich plasma in
hypertensive patients (Ikeda et al, 1985). However, 
adequately controlled studies using antihypertensive
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agents with differing modes of action are required before 
we can be sure that reduction of blood pressure in 
patients with hypertension is associated with diminished 
adenosine diphosphate-induced platelet aggregation.
Thus, there is little evidence to suggest that raised 
arterial pressure is associated with enhanced adenosine 
diphosphate-induced platelet aggregation in hypertensive 
patients. Many studies reporting positive findings have 
been small (Ikeda et al., 1985; Bodzenta-Lukasyk et al.,
1985) or inadequately controlled (Coccheri & Fiorentini, 
1971; Vlachakis & Aledort, 1980; Ikeda et al., 1985). 
Furthermore, studies have failed to demonstrate a 
correlation between adenosine diphosphate-induced platelet 
aggregation and systolic or diastolic blood pressure.
Measurement of platelet aggregation in platelet rich 
plasma may be less physiological than spontaneous platelet 
aggregation in whole blood, as discussed above (4.2.2 ). 
The finding that spontaneous platelet aggregation in whole 
blood was not enhanced in patients with untreated 
essential hypertension compared to age and sex matched 
normotensive controls does not support an association 
between enhanced adenosine diphosphate-mediated platelet 
aggregation and raised arterial blood pressure.
4.2.4 Platelet serotonin.
Mean platelet serotonin content was not significantly 
different in hypertensives compared to age and sex matched 
normotensive controls. Levels were similar to those found
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by other groups (Baudouin Legros et al., 1985; Kamal, Le 
Quan Bui & Meyer, 1984; Puri et al., 1986). Platelet
serotonin levels have been claimed to be reduced in most 
studies of essential hypertension (Bhargava et al., 1979; 
Baudouin Legros et al., 1985; Kamal et al., 1984) and in 
some normotensive relatives of hypertensive patients 
(Kamal et al., 1984), although other investigators have 
found that platelet serotonin content was not different in 
hypertensives compared to a normotensive control group 
(Ahtee et al., 1974). It has been also claimed that 
platelets from hypertensives show reduced uptake of 
serotonin (Ahtee et al., 1974; Kamal, Le Quan Bui & Meyer,
1984) although Feltkamp, Meurer & Godehardt, (1984) found 
no difference in platelet serotonin uptake in 
hypertensives compared to normotensives. Bhargava et al., 
(1979) found reduced uptake of serotonin in platelets from 
hypertensive patients only when very high 
non-physiological concentrations of serotonin were used; 
at lower concentrations no differences could be 
demonstrated in platelets from hypertensive and 
normotensive subjects. Most of these studies are open to 
criticism. Many investigators either do not give important 
descriptive details of their control and hypertensive 
groups or use control groups which are unmatched for age 
and sex (Ahtee et al., 1974; Bhargava et al., 1979; Kamal 
et al., 1984; Baudouin-Legros et al., 1985).
Hypertensives may have enhanced platelet release 
reaction in response to various stimuli in vivo. It has 
been claimed that stimulation of the sympathetic nervous
page 136
system by isometric handgrip causes an increased release 
of serotonin from platelets in hypertensives compared to 
normotensive controls (Palermo et al., 1986). Enhanced 
platelet release reaction of serotonin might be expected 
to cause a detectable reduction in platelet serotonin 
content.
Plasma levels of free serotonin have been reported to be 
elevated in hypertensives (Biondi, Agostini & Marasini,
1986), in keeping with increased platelet turnover and 
serotonin release. However free plasma serotonin may not 
reflect in-vivo platelet aggregation. Even with scrupulous 
sample preparation, a small amount of serotonin will be 
released from platelets ex-vivo, resulting in 
artefactually high "free" plasma serotonin levels 
(Molyneux & Clarke, 1985). Thus it is unlikely that the 
so-called "free" plasma serotonin levels that Biondi et 
al., (1986) measure reflect the in-vivo situation.
In summary, although most studies have claimed reduced 
platelet serotonin levels, decreased platelet serotonin 
uptake, and possible increased platelet serotonin release 
in hypertension, these findings must be seriously 
questioned in view of the use of inadequate control groups 
and inherent difficulties with the methodology. It is not 
clear whether the vascular complications of hypertension, 
particularly atheroma, affect platelet release or uptake 
of serotonin. In my study, with carefully chosen controls 
and accurate measurement of platelet serotonin, there was 
no evidence to suggest that platelet serotonin is reduced 
in patients with essential hypertension.
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4.2.5 Plasma beta-thromboglobulin.
When care is taken in the collection and preparation of 
blood samples, plasma beta-thromboglobulin levels are 
thought to give an index of in-vivo platelet aggregation 
and platelet content release (Yamanishi et al., 1985). I 
found no difference in plasma beta-thromboglobulin between 
patients with untreated essential hypertension and a 
normotensive control group. Plasma beta thromboglobulin 
levels in venous blood have been reported to be increased 
in hypertensives compared to age and sex matched 
normotensives in some (Bodzenta-Lukasyk et al., 1987; 
Ikeda et al 1985; Mehta & Mehta, 1981; Kjeldsen et al., 
1983; Yamanishi et al., 1985) but not all studies 
(Petralito et al., 1982; Catalano et al., 1985). Even in 
those studies which have shown elevated venous 
beta-thromboglobulin levels in patients with essential 
hypertension, no significant correlation of
beta-thromboglobulin with systolic or diastolic blood 
pressure has been demonstrated.
Raised venous beta-thromboglobulin levels have been 
found in patients with peripheral vascular disease (Celia 
et al., 1979), and hypertensive retinopathy (Petralito et 
al., 1982), suggesting that underlying vascular disease, 
rather than the level of arterial blood pressure, may be 
the cause of raised venous plasma beta-thromboglobulin 
seen in some of the studies of essential hypertension.
In uncontrolled studies of antihypertensive agents, the 
alpha-1 adrenoreceptor antagonist prazosin (Ikeda et al.,
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1985) and the central sympathomimetic lofexidine (Mehta & 
Mehta, 1981) appeared to cause a fall in venous
beta-thromboglobulin levels in hypertensive patients. 
However, properly controlled studies of antihypertensive 
agents with varying modes of action are required before we 
can be sure that reducing blood pressure in patients with 
essential hypertension reduces plasma
beta-thromboglobulin.
51Platelet life span, determined by chromium 
radiolabelled autologous platelets, is reduced in patients 
with severe hypertension uncontrolled by thiazide
diuretics (Abrahamsen et al., 1968). Other authors have 
found reduced platelet life span, assessed by the return 
of platelet lipid peroxidation capacity after aspirin, in 
less severe untreated hypertension (Vlachakis & Aledort, 
1979). However, in neither of these studies was the
control group age and sex matched with the hypertensives.
There was no significant correlation between venous
beta-thromboglobulin and platelet serotonin content in 
normotensive and hypertensive patients. As
beta-thromboglobulin and serotonin are released during 
platelet aggregation (Holmsen, 1977) , it might be expected 
that plasma beta-thromboglobulin should be inversely 
related to platelet serotonin content. However, serotonin 
may be released by platelets without full platelet 
aggregation and release reaction (Ossim & Wylie, 1982; 
Ossim & Wylie, 1983). Serotonin, contained in the dense 
granules, may be released from platelets without release 
of beta-thromboglobulin from platelet alpha granules
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(Holmsen, 1977). Thus, it is perhaps not surprising that 
platelet serotonin levels were not significantly inversely 
correlated with plasma beta-thromboglobulin.
A direct association between enhanced platelet 
aggregation in-vivo, as measured by venous plasma 
beta-thromboglobulin levels, and raised arterial blood 
pressure remains as yet unproven. The result of my study, 
showing no significant difference in plasma 
beta-thromboglobulin between hypertensive patients and a 
carefully chosen age and sex matched control group, does 
not support enhanced platelet aggregation in-vivo as a 
feature of essential hypertension.
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4.3 The effects of short-term ketanserin on blood
pressure, heart rate, the renin-angiotensin system, 
adrenocortical function, QT interval and vagal function 
and the response to infusion of angiotensin II in healthy 
subjects
4.3.1 Blood pressure.
a) Is the reduction in blood pressure caused by 
ketanserin due to attenuation of angiotensin II-mediated 
vasoconstriction?
In isolated blood vessel preparations, serotonin 
amplifies the vasoconstriction produced by a number of 
agents, including noradrenaline and angiotensin II. This 
amplification is inhibited by ketanserin, and other 
serotonergic antagonists, in correlation with serotonergic 
type-2 antagonistic activity (Van Nueten et al., 1981? Van 
Nueten et al., 1982). It has therefore been deduced that 
serotonergic type-2 antagonism may reduce blood pressure 
by attenuating the effect of these non-serotonergic 
vasoconstrictors. However, I have shown that short term 
administration of the serotonergic type-2 antagonist 
ketanserin does not attenuate the pressor response to 
infused angiotensin II in healthy subjects. The timing of 
observations after short-term ketanserin administration, 
at around 1 and 7 hours after dosing, was chosen to 
represent the times of expected approximate peak and 
trough plasma ketanserin levels (Hedner et al., 1986;
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Waller, Tucker & Ramsay, 1987). Subsequently, other 
investigators have shown that chronic oral ketanserin does 
not attenuate the pressor response to angiotensin II in 
patients with essential hypertension (Donnelly et al., 
1987). Therefore, it is unlikely that ketanserin reduces 
blood pressure by inhibiting angiotensin II-mediated 
vasoconstriction, or that the serotonergic type-2 receptor 
amplifies angiotensin II mediated vasoconstriction 
in-vivo.
b) Is the reduction in blood pressure caused by 
ketanserin due to alpha-1 adrenoreceptor antagonism?
It has been shown that ketanserin, given in the same 
dose and for the same duration of time as my study, 
attenuates the pressor response to the alpha-1 agonist 
phenylephrine in healthy subjects (Zabludowski et al., 
198 5). Other investigators have shown a similar 
attenuation of pressor response to alpha-1 agonists with 
chronic oral ketanserin administration (Fagard et al., 
1984; Donnelly et al., 1987) or intravenous infusion of 
ketanserin (Reimann & Frohlich, 1983). These findings 
suggest that short term or chronic oral ketanserin causes 
alpha-1 antagonism, and that this effect may be at least 
partly responsible for the reduction in blood pressure 
caused by the drug. However, other explanations for these 
findings have been suggested. The reduction in blood 
pressure caused by ketanserin is due to peripheral 
vasodilatation (Fagard et al., 1984). This vasodilatation
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could non-specifically reduce the response to any 
vasoconstrictor agent. Also, there may be an important 
interplay or even structural overlap (Marwood & Stokes, 
198 4) between serotonergic type-2 and alpha-1 receptor 
sites. In vitro, serotonin amplifies vasoconstriction 
caused by noradrenaline (Van Nueten et al., 1981). This 
effect is inhibited by serotonin antagonists in close 
correlation with their serotonergic type-2 binding 
affinity, suggesting that it is mediated through the 
serotonergic type-2 receptor (Janssen, 1985).
In a study directly comparable with that of Zabludowski 
et al., (1985), I have now demonstrated that ketanserin 
does not attenuate the blood pressure response to infused 
angiotensin II, a vasoconstrictor agent largely devoid of 
alpha adrenergic activity. Although angiotensin II has a 
peripheral action augmenting vasoconstriction caused by 
the sympathetic nervous system (Zimmerman, 1980), the main 
mechanism by which it increases blood pressure is by a 
direct effect on specific angiotensin II receptors on 
vascular smooth muscle. Therefore, it is likely that the 
effect of ketanserin, attenuating the pressor response to 
alpha-1 agonists represents true alpha-1 adrenoreceptor 
blockade.
There is other supporting evidence for ketanserin 
causing alpha-1 blockade in vivo in man; pretreatment with 
the known competitive alpha-1 antagonist prazosin 
(compared with a dose of frusemide giving an equivalent 
blood pressure reduction) diminishes the antihypertensive 
effect of ketanserin (Wenting et al., 1984). In the
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spontaneously hypertensive rat serotonergic type-2 
antagonists reduce blood pressure in close correlation 
with their alpha-1 receptor binding affinity (Cohen et 
al., 1983).
However it is not possible to explain all of 
ketanserin's effects by alpha-1 blockade. Prazosin is a 
good example of a drug that reduces blood pressure by 
alpha-1 antagonism (Stanaszek et al., 1983). It causes 
marked attenuation of the pressor response to infused 
alpha-1 agonists. This effect can be detected even at low 
doses of infused alpha-1 agonist (Zabludowski et al.,
1984). In comparison ketanserin has only a small effect, 
attenuating the pressor response only at relatively high 
doses of infused alpha-1 agonist (Donnelly et al., 1987). 
Furthermore, acute intravenous administration of 
ketanserin causes a reduction in blood pressure without 
attenuating the blood pressure response to phenylephrine 
(Wenting et al 1982 and 1984, Zabludowski et al 1984). It 
has been shown also that ketanserin will reduce blood 
pressure in patients with autonomic insufficiency who are 
unresponsive to the alpha-1 antagonist phentolamine 
(Wenting et al, 1984). Although pretreatment with prazosin 
diminishes, it does not completely block the reduction in 
blood pressure caused by ketanserin (Wenting et al.,
1984). Therefore the antihypertensive effects of 
ketanserin cannot be explained entirely by alpha-1 
antagonism. However, it is likely that alpha-1 antagonism 
contributes to the reduction in blood pressure caused by 
ketanserin.
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c) Is the reduction in blood pressure caused by 
ketanserin due to serotnergic type-2 antagonism?
Both acute and chronic oral ketanserin attenuate 
serotonin-induced platelet aggregation in platelet rich 
plasma (De Clerck & Xhonneux, 1985; Vermylen et al.,
1986). As serotonin induced platelet aggregation is 
thought to be mediated through the type-2 receptor, 
ketanserin is appropriately designated a serotonergic 
type-2 antagonist, confirming receptor binding studies 
(Leysen et al., 1981). However it is not clear what role 
this serotonergic type-2 antagonism caused by ketanserin 
plays in mediating the antihypertensive effects of the 
drug.
d) Ketanserin and first dose hypotension.
One subject experienced marked postural hypotension 
after the first dose of ketanserin 40mg, associated with a 
reduction in heart rate. Similar first dose hypotension 
has been reported with the alpha-1 antagonist prazosin 
(Stanaszek et al., 1983). Reduced venous return caused by 
antagonism of alpha-1 adrenoreceptor mediated
venoconstriction may contribute to the first dose effects 
of prazosin (Schapel & Betts, 1981). Venodilatation could 
stimulate cardiopulmonary receptors, triggering increased 
vagal outflow, causing bradycardia and hypotension (Parati 
et al., 1987). In patients with essential hypertension a 
marked reduction in heart rate may accompany the fall in
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blood pressure caused by the first dose of prazosin 
(Kobrin et al., 1983). The acute reduction in blood 
pressure caused by prazosin correlates well with the 
activity of the sympathetic nervous system, measured by
plasma noradrenaline (Guthrie & Kotchen, 1983). It is 
notable that the subject who experienced first dose
postural hypotension after ketanserin had a high basal
heart rate, and that a marked reduction in standing heart 
rate accompanied the fall in erect blood pressure. The 
similarities between this "first dose" effect of 
ketanserin and those reported after prazosin suggest that 
this adverse effect of ketanserin was due to alpha-1
adrenoreceptor antagonism. However any drug causing 
vasodilatation may be capable of occasionally inducing 
severe hypotension and bradycardia in some individuals.
4.3.2 Heart rate and autonomic function.
a) Effect of ketanserin on heart rate.
The vasodilatation produced by ketanserin (Wenting et
al., 1982) should cause an increase in heart rate, due to
a combination of reduced parasympathetic tone and 
increased cardiac sympathetic outflow (Man In'T Veld et 
al., 1980). However, in our study ketanserin caused a 
slight decrease in supine heart rate at a time when mean 
blood pressure was significantly reduced. Other 
investigators have reported similar findings (Fagard et 
al., 1984; Zabludowski et al., 1984).
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b) Is the reduction in heart rate caused by ketanserin 
due to alterations of autonomic nervous outflow?
There are several possible explanations for the 
reduction in heart rate caused by ketanserin. Animal 
studies suggest that serotonin and serotonergic neurones 
may be involved in the central regulation of heart rate. 
Increased brain serotonin attenuates reflex vagal
bradycardia caused by intravenous pressor agents (Lin &
Chern, 1979; Tadepalli, 1980); diminished brain serotonin 
has the opposite effect (Lin & Chern, 1979). It is
conceivable therefore that central serotonergic type-2 
blockade caused by ketanserin could reduce heart rate by 
augmenting parasympathetic outflow; although ketanserin is 
not lipid soluble it has been shown to cross the
blood-brain barrier (1.13. 2). However, I found that there 
was a tendency for cardiac vagal activity, measured by the 
heart rate responses, to standing, deep breathing and the 
Valsalva maneouvre (Ewing and Clarke, 1982), to be
diminished at around the time of expected peak plasma drug 
levels (Hedner et al., 1986; Waller, Tucker & Ramsay,
1987), when heart rate and mean arterial pressure were 
significantly reduced. Although the changes in heart rate 
responses to lying to standing, deep breathing and the 
Valsalva ..maneouvre did not acheive statistical 
significance, it is possible that the tendency for 
parasympathetic tone to be reduced represents a normal 
reflex response of the autonomic nervous system to 
vasodilatation and reduced arterial pressure (Man In'T
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Veld et al.f 1980). The results from autonomic function 
testing certainly do not support increased parasympathetic 
activity as the mechanism for the reduction in heart rate 
caused by ketanserin.
Serotonergic antagonists, including methysergide, 
cyproheptadine (non-selective serotonergic type-1 and -2 
blockers) and ketanserin appear to have a central 
sympatholytic action in baroreceptor denervated cats? 
central alpha-1 adrenoreceptor blockade with prazosin has 
a similar effect (McCall & Schuette, 1984). It is possible 
that ketanserin could cause a fall in heart rate by 
reducing sympathetic outflow through central serotonergic 
type-2 or alpha-1 adrenoreceptor antagonism.
c) Is the reduction in heart rate caused by ketanserin 
due to a reduction in plasma angiotensin II?
Fagard et al., (1984) found reduced plasma angiotensin 
II levels after chronic oral ketanserin therapy. This also 
could cause a reduction in heart rate by influencing 
autonomic nervous system activity; there is evidence for 
angiotensin II causing an increase in heart rate by both 
reducing vagal activity (Lee, Ismay & Lumbers, 1980) and 
by activation of the sympathoadrenal system (Zimmerman, 
1981). However, at a time when heart rate was 
significantly reduced, I did not observe any reduction in 
plasma angiotensin II after ketanserin.
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d) Effects of ketanserin on the heart rate response to 
infused angiotensin II and the baroreceptor reflex.
Short term oral ketanserin did not affect the reduction 
in heart rate caused by the rise in blood pressure during 
the infusion of angiotensin II. The reduction in heart 
rate during angiotensin II infusion is less than that 
caused by equi-pressor doses of other vasoconstrictors 
such as alpha-1 antagonists. The reasons for this are
several. Angiotensin II may itself modify baroreceptor 
function (Marker, Miles & Scroop, 1980), reduce vagal tone 
(Lee, Ismay & Lumbers, 1980) and augment sympathetic 
outflow (Zimmerman, 1980). These effects tend to minimise 
the reflex reduction in heart rate caused by the rise in 
blood pressure due to angiotensin II. The possibility that 
ketanserin causes resetting of baroreceptors has been 
investigated by studying its effects on changes in heart 
rate caused by pressor agents and hypotensive drugs. In 
the spontaneously hypertensive rat, ketanserin potentiates 
hypotension caused by sodium nitroprusside (Smits, Van 
Essen & Strukker-Boudier, 198 7). This suggests that the 
antihypertensive effects of ketanserin may be partly due 
to resetting of the baroreflex. However, in man acute 
ketanserin administration does not affect the heart rate 
responses to drug induced hypo- or hypertension (Berdeaux 
et al., 1987). Chronic oral ketanserin does not alter the 
heart rate responses to infused alpha-1 agonist or 
angiotensin II in hypertensive patients (Donnelly et al.,
1987). Thus it is unlikely that either the reduction in
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heart rate br antihypertensive effects of ketanserin are 
due to resetting of the baroreflex.
e) Is the reduction in heart rate caused by ketanserin
due to a direct effect on the sino-atrial node?
Another possible mechanism for the reduction in heart 
rate caused by ketanserin is by delaying repolarisation of 
the sino-atrial node, as seen with some class III
antiarrhthmic drugs such as melperone (Millar & Vaughan 
Williams, 1983). The evidence for ketanserin having class 
III antiarrhythmic activity is presented in section 4.3.3.
4.3.3 Electrocardiographic QT and QTc intervals.
Ketanserin prolongs the action potential and effective 
refractory period in dog purkinje cells and guinea pig 
papillary muscle (Saman, Thandroyen & Opie, 1985), 
features typical of a class III antiarrhythmic agent.
These effects appear to be mediated through the
serotonergic type-2 rather than the alpha-1 
adrenoreceptor, as the alpha-1 antagonist prazosin has
virtually no effect in the above in-vitro preparations
(Saman et al., 1985). I have shown that ketanserin causes 
significant prolongation of the QT and QTc intervals in 
normal man in keeping with the above in vitro data. 
Similar findings have subsequently been reported in 
normotensive subjects after acute intravenous ketanserin
(Nadamanee et al., 1987) and in hypertensive patients
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following chronic oral dosing (Waller, Solomon & Ramsay, 
1987; Donnelly et al., 1987). Prolongation of the QT 
interval is due usually to increased action potential 
duration in ventricular myocardial cells. This can be 
caused by class la and III antiarrythmics. Class la 
antiarryhthmics, such as quinidine, procainamide and 
disopyramide, also inhibit the fast sodium channel, 
decreasing the slope of depolarisation in phase 0 (seen as 
prolongation of QRS duration on the surface 
electrocardiogram) and reducing the amplitude of the 
action potential (Vaughan Williams, 1982). With an 
electrocardiograph paper speed of 25mm/sec it was not 
possible to measure accurately QRS duration in my study. 
However, in-vitro, ketanserin does not affect the slope of 
depolarisation in ventricular myocardial cells (Saman, 
Thandroyen & Opie, 1985), or cause prolongation of QRS 
duration after acute intravenous administration (Nademanee 
et al., 1987). Thus, it is likely that ketanserin has 
class III but not la antiarrhythmic activity.
There are many potential pitfalls in measuring QT 
interval. Although the QT interval is thought to represent 
action potential duration, different directions of 
impulses during excitation and recovery may cancel each 
other out on the surface electrocardiogram (Abildskov, 
1976; Vaughan Williams, 1982). Furthermore, drugs which do 
not affect ventricular action potential duration but which 
cause changes in heart rate will tend to cause alterations 
of QT interval (inversely proportional to the change in 
heart rate). To correct for this, it has been advocated
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that changes in QT interval should be assessed by 
calculating regression lines of QT against RR' interval 
for each subject (Kelman, Whiting and Sumner, 1984), as 
global corrections of QT for heart rate such as Bazett's 
formula (QT/square root of the preceeding RR1 interval) 
are inaccurate at low and high heart rates. However, 
Bazett's formula is reasonably accurate when heart rate is 
maintained between 60 and 80 beats/minute (Staniforth, 
1983; Staniforth, 1984). Therefore, in studies in which 
changes in heart rate are small, remaining within the 
above range, calculation of the QTc interval provides 
useful information. However, it is important to consider 
absolute QT interval values, as well as making a 
correction of QT for heart rate.
The change in QT and QTc caused by ketanserin could be 
due to alterations in autonomic nervous outflow. When 
heart rate is fixed by cardiac pacing, atropine causes a 
reduction in QT interval in man (Yanowitz, Preston & 
Abildskov, 1966). However the prolongation of QT interval 
caused by ketanserin was not accompanied by an increase in 
cardiac parasympathetic tone. Reduction of sympathetic 
nervous activity through the right stellate ganglion 
causes prolongation of the QT interval. This is seen 
acutely during right radical neck dissection when the 
sympathetic outflow is disrupted (Otteni et al., 1983). 
The left side of the sympathetic nervous system has the 
opposite effect (Yanowitz et al., 1966). Left stellate 
ganglionectomy has been used as a treatment for 
prolonged QT interval (Otteni et al., 1983). Changes in
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sympathetic nervous outflow cannot be excluded as a 
possible cause of prolonged QT after ketanserin.
The prologation in QT interval caused by ketanserin was 
not accompanied by any reduction in serum potassium, a
stimulus which is known to prolong the QT interval
(Surawicz and Knoebel 1984).
Prolongation of the QT interval may be associated with 
life threatening cardiac arrhythmias, ventricular
tachycardia or polymorphous ventricular tachycardia
(torsades de pointes). It is not known if there is a
critical threshold for QT interval for ventricular 
arrhythmias (Surawicz & Knoebel, 1984). Prolongation of 
the QT interval by 20ms caused by the cholesterol lowering 
agent probucol did not increase premature ventricular 
complexes (Browne et al., 1984). However, the combination 
of the class III antiarrhythmic agent sotalol with
hydrochlorthiazide, disopyramide or tricyclic
*
antidepressants has been reported to cause syncope and
polymorphous ventricular tachycardia (McKibben et al.,
1984). The QTc in these cases was markedly prolonged
(>580ms). In view of these findings it seems sensible to 
advise that ketanserin should not be used in combination 
with potassium loosing diuretics, or other drugs known to 
prolong action potential duration.
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4.3.4 Effects of ketanserin on the renin-angiotensin- 
aldosterone system and plasma cortisol.
There is in-vitro evidence that serotonergic type-2 
receptors localised on adrenal zona glomerulosa cells may 
play a role in the regulation of adrenal steroidogenesis. 
Ketanserin inhibits the increased production of 
aldosterone and corticosterone caused . by serotonin 
(Williams et al., 1984) and angiotensin II (Rocco et al.,
1985) in isolated rat zona glomerulosa cells? this 
inhibition appears to be mediated through serotonergic 
type-2 antagonism (1.9 ). and not by alpha-1
adrenoreceptor antagonism, as the alpha-1 antagonist 
prazosin does not inhibit serotonin-induced
steroidogenesis (Williams et al., 1984). Serotonergic 
neurones in the central nervous system also may play a 
role in the regulation of steroidogenesis. The serotonin 
precursors tryptophan 5-hydroxytryptophan increases plasma 
aldosterone in healthy subjects (Modlinger et al., 1979? 
Shenker et al., 1985b)? there is good evidence that the 
rise in plasma aldosterone is mediated centrally as it is 
potentiated by peripheral decarboxylase inhibition with 
carbidopa (Shenker et al., 1985b). However, the rise in 
plasma aldosterone caused by 5-hydroxytryptophan is not 
affected by pretreatment with either ketanserin or 
methysergide (Shenker et al., 1985a), suggesting that this 
effect of 5-hydroxytryptophan is not mediated through 
serotonergic type-1 or -2 receptor sites. Central 
serotonergic neurones may also play a role in the
page 154
regulation of plasma cortisol (1.9). The centrally acting 
serotonin agonist M-chlorophenylpiperazine and the 
serotonin precursor tryptophan increase plasma cortisol in 
healthy subjects (Modlinger et al., 1979? Mueller et al.,
1985). In some circumstances, serotonergic neurones may
have a central action in the regulation of
adrenocorticotrophic hormone release? ketanserin
%
diminishes the adrenocorticotrophic hormone response to
hypoglycaemia in man (Prescott et al., 1984). However the
drug does not affect basal plasma levels of
adrenocorticotrophic hormone (Gordin, Mustajoki & 
Pelkonen, 1985). I found that, in-vivo, ketanserin caused 
no changes to either basal plasma aldosterone, or to the 
increase of plasma aldosterone in response to infused 
angiotensin II. Basal plasma cortisol was also unaffected
by chronic oral ketanserin. Acute intravenous ketanserin
also does not alter plasma cortisol (Gordin et al., 1985). 
These findings do not support a major role for the 
serotonergic type-2 receptor in the regulation of plasma 
aldosterone or cortisol in healthy man. Furthermore, it is 
unlikely that the reduction in blood pressure caused by 
ketanserin is due to inhibition of adrenal 
steroidogenesis.
Serotonin and its precurser tryptophan increase plasma
renin in rats (Meyer and Hertting, 1974) and man
(Modlinger et al., 1979) respectively. Also, in man,
non-selective serotonergic blockade with cyproheptidine 
inhibits the rise in renin caused by sodium depletion 
(Epstein and Hamilton, 1977). These effects are thought to
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be mediated through central serotonergic neurones. Acute 
intravenous administration of ketanserin tends to increase 
plasma noradrenaline, renin and angiotensin II (Reimann et 
al., 1985? Wenting et al., 1982? Zoccali et al, 1983? 
Zabludowski et al., 1984). However, these changes are 
probably due to a reflex increase in sympathetic nervous 
activity in response to the acute reduction in blood 
pressure, rather than a specific pharmacological effect of 
ketanserin. Chronic oral ketanserin has variable effects 
on basal plasma catecholamines, renin and aldosterone. 
Fagard et al., (1984) found an increase in plasma 
noradrenaline and adrenaline, a reduction in plasma renin 
and angiotensin II, and no change in plasma aldosterone 
during the chronic treatment of hypertensives with 
ketanserin. However in a similar study (Woittiez et al.,
1986) no changes in basal catecholamines, renin or 
aldosterone were found. I found that short-term oral 
ketanserin did not affect basal plasma renin or 
angiotensin II in normotensive subjects? normal feedback 
inhibition of renin secretion by infusion of angiotensin 
II was also maintained. Therefore, it is unlikely that the 
serotonergic type-2 antagonist ketanserin reduces blood 
pressure by inhibiting the renin-angiotensin-aldosterone 
system.
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4.4 Effects of the serotonergic type-2 antagonist
ritanserin in patients with untreated essential
hypertension
4.4.1 Serotonin induced and spontaneous platelet 
aggregation.
Ritanserin, given in a dose of lOmg twice daily for 4 
weeks, caused inhibition of serotonin-induced platelet 
aggregation in whole blood in patients with untreated 
essential hypertension. Serotonin-induced platelet 
aggregation is thought to be mediated through the 
serotonergic type-2 receptor (1.4.2). Therefore, in 
keeping with its receptor binding profile (Leysen et al.,
1985), ritanserin is an effective serotonergic type-2 
antagonist.
Ritanserin had no significant effects on spontaneous 
platelet aggregation in whole blood. This form of 
aggregation is thought to be mediated largely through 
release of adenosine diphosphate from red blood cells
(4.1.2). The serotonergic type-2 antagonist ketanserin 
also does not affect adenosine diphosphate-induced 
platelet aggregation, in platelet rich plasma (De Clerck 
et al., 1982; Zannad et al., 1985). Thus it is unlikely 
that the serotonergic type-2 receptor site plays a role in 
modulating adenosine diphosphate-mediated platelet 
aggregation.
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4.4.2 Blood pressure.
The highly selective serotonergic type-2 antagonist 
ritanserin caused no significant change in blood pressure 
when in single oral doses of 10 and 20mg to patients with 
essential hypertension. In contrast, ketanserin (40mg), a 
drug with serotonergic type-2 and alpha-1 antagonistic 
properties (Leysen et al., 1981), caused a significant 
reduction in supine mean arterial pressure in the same
group of patients. It has been shown that lOmg of
ritanserin causes significant alteration of sleep patterns 
in man (Idzikwski & Mills, 1986). Ritanserin 20mg has been 
found to increase somnolence in young healthy subjects 
(Barone et al., 1986). Therefore, the doses of ritanserin 
which I chose to study have been previously shown to have 
central effects in man.
There were no significant changes in blood pressure 
during 4 weeks of ritanserin lOmg twice daily in patients 
with untreated essential hypertension. Ritanserin had no 
detectable effects on forearm blood flow or vascular 
resistance either at rest or after ischaemia. Furthermore, 
ritanserin did not cause any change in body weight or 
venous haematocrit suggestive of counter-regulatory 
responses to vasodilatation. Measurement of
serotonin-induced platelet aggregation showed that 
adequate doses of the drug had been given, causing
serotonergic type-2 antagonism (4.4.1). These results, of 
both acute and chronic dosing with ritanserin, do not 
support a major independent role for the serotonergic
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type-2 receptor in the regulation of peripheral vascular 
tone and arterial blood pressure in patients with 
essential hypertension. The conclusions from animal 
studies are similar. Acute ritanserin administration 
inhibits the rise in blood pressure caused by serotonin in 
the pithed rat, but does not attenuate the pressor 
response to noradrenaline (Conolan, Quinn & Taylor, 1986). 
In the same animal preparation, ketanserin is less potent 
in inhibiting serotonin induced vasoconstriction than 
ritanserin, but does inhibit noradrenaline induced 
vasoconstriction. In anaesthetised rats, acute ritanserin 
administration causes only a very small reduction in blood 
pressure compared to ketanserin (Conolan et al., 1986). In 
the spontaneously hypertensive rat chronic oral 
ritanserin, given in a dose that antagonises the pressor 
response to serotonin, has no effect on basal or stressed 
blood pressure (Gradin et al., 1985).
Serotonergic antagonists which lower blood pressure 
include methysergide and ketanserin. Detailed discussion 
of the mechanism of ketanserin's antihypertensive effects 
is given in section 4.3.1; it is far from clear that 
ketanserin reduces blood pressure by its action at the 
serotonergic type-2 receptor. Methysergide is a 
non-selective serotonergic type-1 and -2 antagonist with 
partial agonist activity. It acts centrally, reducing 
blood pressure by decreasing sympathetic nervous outflow; 
it has no peripheral effects on the cardiovascular system 
(Antonaccio & Taylor, 1977).
Ritanserin is the first serotonergic type-2 antagonist
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to be studied which is virtually devoid of activity at 
other receptor sites which play a role in cardiovascular 
homeostasis (Leysen et al., 1985). Ritanserin differs from 
ketanserin in that it has greater serotonergic type-2 
receptor binding affinity, it is a non-competitive 
antagonist, and it has a longer duration of action; 
ritanserin is also more lipophilic than ketanserin, and 
therefore should penetrate the blood brain barrier more 
readily (Leysen et al., 1985). It is unlikely that any of 
these differences explain the contrasting effects of 
ritanserin and ketanserin on blood pressure. However, 
ritanserin is virtually devoid of alpha-1 receptor binding 
affinity compared to ketanserin (Leysen et al., 1985). 
This difference probably explains the lack of effect of 
ritanserin on blood pressure compared to ketanserin, both 
in patients with essential hypertension and in the rat.
4.4.3 Heart rate.
Serotonergic neurones may be involved in the regulation 
of heart rate (1.6). In animal studies, serotonin has a 
central action, increasing heart rate by inhibiting reflex 
bradycardia (Lin & Chern, 1979; Tadepalli, 1980). 
Therefore, serotonergic type-2 antagonists might cause a 
reduction in heart rate. Although ketanserin causes a 
reduction in heart rate, it is not clear that this effect 
is due to serotonergic type-2 antagonism; it is possible 
that ketanserin reduces heart rate by central alpha-1 
adrenoreceptor antagonism (4.3.2). In contrast to
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ketanserin, the serotonergic type-2 antagonist ritanserin 
is virtually devoid of alpha-1 adrenoreceptor binding
affinity (Leysen et al., 1985). There were no significant
alterations in heart rate in patients with essential
i
hypertension after either acute or chronic oral dosing 
with ritanserin. These findings do not support a major 
independent role for the serotonergic type-2 receptor in 
the regulation of heart rate in man.
4.4.4 Venous compliance.
Serotonin causes constriction of large veins in-vitro 
(Fenuik et al., 1985; Victorzon, Tapparelli &
Muller-Schweinitzer, 1986). Serotonin-induced
venoconstriction appears to be mediated through both 
serotonergic type-1 and -2-like receptors. The 
serotonergic type-1 receptor agonist
5-carboxamidotryptamine causes contraction of isolated 
human and dog saphenous veins (Fenuik et al., 1985;
Victorzon et al., 1986). The serotonergic type-2
antagonists ketanserin and spiperone cause only partial 
antagonism of serotonin induced venoconstriction in the 
same preparations. However the situation may be more 
complex than this. Serotonin and serotonin type-1 agonists 
both inhibit noradrenaline release from sympathetic nerves 
in human saphenous vein (Gothert et al., 1986). This
suggests that serotonin may act through a serotonergic 
type-l-like receptor to inhibit the venoconstrictor 
effects of the sympathetic nervous system.
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It has not been clearly established that serotonin plays 
a role in the regulation of venous tone in-vivo. I have 
shown that forearm venous compliance in patients with 
essential hypertension was not significantly altered by 
chronic administration of the serotonergic type-2 
antagonist ritanserin. This does not support a major 
independent role for the serotonergic type-2 receptor in 
the regulation of venous tone in man.
4.4.5 Electrocardiographic QRS and QT intervals.
Chronic oral ritanserin caused prolongation of the QT 
interval without affecting the QRS duration, features 
consistent with class III antiarrhythmic activity (Millar 
& Vaughan-Williams, 1983). Hypokalaemia can cause
prolongation of the action potential duration, measured as 
an increase in QT interval on the electrocardiograph 
(Surawicz & Knoebel, 1984). However, the prolongation of 
QTC interval caused by ritanserin was not accompanied by 
any reduction in serum potassium. The prolongation of QTc 
interval was very similar to that caused by ketanserin
(4.3.3). Both of these drugs are serotonergic type-2 
antagonists, suggesting that serotonergic type-2 
antagonism is the mechanism by which ketanserin and 
ritanserin prolong QTc. Further studies are required to 
determine whether the electrophysiological effects of 
ritanserin are due to a direct effect on the heart as with 
ketanserin (4.3.3), and whether the degree of QTc 
prolongation is dose dependent. The significance of
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increased QTC interval duration, and pitfalls in 
interpretation are discussed in section 4.3.3 .
4.4.6 Psychological function.
Serotonin precursors and serotonin agonists that cross 
the blood brain barrier can cause anxiety and depression, 
effects mediated through the serotonergic type-2 receptor 
(Leysen, 1984). Therefore, there is interest in the 
possible effects of serotonergic type-2 antagonists as 
anxiolytics. The serotonergic type-2 antagonist ritanserin 
is lipid soluble and readily crosses the blood brain 
barrier. I found no significant changes in hostility, 
anxiety or depression scores, measured on the Multiple 
Affect Adjective Check List, or alertness and 
tranquillity, measured by visual analogue scales, after 
single oral doses of ritanserin were given to patients 
with essential hypertension. Ritanserin in an acute oral 
dose of up to 20mg has been shown to be well tolerated in 
young healthy subjects, with no significant changes in 
psychological function found on a self-reporting symptom 
questionnaire (Barone et al., 1986). Ritanserin lOmg daily 
causes significant increase in slow wave sleep, at 1 and 
14 days in healthy subjects (Idzikwski & Mills, 1986). I 
found no evidence of day-time sedation, measured by visual 
analogue scale and digit substitution test, or change in 
mood, measured by visual analogue scales, after chronic 
oral ritanserin administration to patients with essential 
hypertension. Therefore, serotonergic type-2 antagonism
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does not seem to cause significant sedation or clinically 
important changes in mood in patients with normal 
psychological function. However, it is possible that quite 
different psychological effects might be seen after 
ritanserin in patients who present with mood disorder such 
as anxiety or depression. It has been shown that 
ritanserin lOmg daily for 2 weeks reduces symptoms in 
patients with anxiety disorders (Ceulemans et al., 1985).
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4.5 Effects of the serotonergic type-2 antagonist
ketanserin in adult atopic asthma
A single oral dose of ketanserin 40mg did not affect
significantly resting bronchomotor tone in adult atopic
asthmatic patients. Although there was a tendency for
ketanserin to attenuate the reduction in forced expiratory
volume and forced vital capacity caused by exercise, 95%
confidence limits show that it is unlikely that the drug
has any major acute effect in preventing exercise induced
bronchoconstriction in adult atopic asthmatic patients.
The drug was given in a dose which has been shown to
inhibit serotonin induced platelet aggregation (De Clerck
& Xhonneux, 1985). In an open study, other investigators
found no significant change in resting bronchomotor tone
or attenuation of exercise induced asthma in 7 patients
given lOmg ketanserin intravenously (So, Lam & Kwan,
1985). In contrast, patients with chronic obstructive
airways disease have been shown to increase their FEV^
after intravenous ketanserin; patients with the most
severe disease appeared to recieve the most benefit
(Cazzola et al., 1987).
In exercise induced asthma the maximal reduction in 
airways function occurs within 15 minutes of exercise
(Rubinstein et al., 1987). Bronchoconstriction after 
exercise is due to decreased mucosal temperature, caused 
by heat and water loss to air which has not been fully
warmed and humidified during its passage into the airways 
(Strauss et al., 1978? Deal et al., 1979). The site of
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airways obstruction in exercise induced asthma is 
heterogeneous in terms of small or large airways (McFadden 
et al., 1977).
Ketanserin has both serotonergic type-2 and alpha-1 
adrenoreceptor antagonist activity (4.3.1). Inhalation of 
the alpha-1 antagonist prazosin has no effect on airways 
resistance in asthma (Barnes, Ind & Dollery, 1981). 
Similarly, inhalation of the alpha-1 agonist phenylephrine 
has no effect on airways function in asthmatic subjects 
pretreated with an inhaled beta-blocker and atropine 
(Thomson, Daniel & Hargreave, 1982). Thus the alpha-1 
adrenoreceptor probably does not play a major role in the 
regulation of airway function in asthma in man.
Serotonin is present in large quantities in the dense 
granules of platelets (Da Prada & Pletscher, 1969) and 
during platelet aggregation this potential
bronchoconstrictor is released. Platelet aggregation has 
been claimed to be directly involved in mechanisms of both 
allergen (Knauer et al., 1981) and exercise induced asthma 
in man (Johnson et al., 1984), using elevated levels of 
platelet factor 4 as a marker of aggregation. However 
other workers (Durham et al., 1984) have measured
circulating concentrations of both beta-thromboglobulin 
and platelet factor 4 after exercise, allergen and 
methacholine induced bronchoconstriction, and could not 
find evidence of enhanced platelet aggregation. Although 
platelet activating factor causes bronchoconstriction in 
the guinea pig, associated with accumulation of platelets 
in the pulmonary vasculature, other platelet aggregating
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agents such as adenosine diphosphate and thrombin do not 
cause bronchoconstriction despite similar platelet 
accumulation in the lungs (Robertson & Page, 1987). It is 
not firmly established that enhanced platelet aggregation 
causes bronchoconstriction, or that exercise or allergen 
induced bronchoconstriction are associated with enhanced 
platelet aggregation.
Animal studies suggest that serotonin can cause 
bronchoconstriction by three separate mechanisms (1.10) ; 
by a direct action on serotonergic type-2 receptors in 
respiratory smooth muscle (Cohen et al., 1985; Colebatch, 
Olsen & Nadel, 1986), by potentiating the action of the
vagus (Sheller et al., 1982), and by inhibition of the
nonadrenergic-noncholinergic neural system (Bai, Macklem & 
Martin, 1986). How ever, the bronchoconstrictor effects of 
serotonin demonstrated in these animal models may result
from the use of supraphysiological concentrations of the
monoamine; although large amounts of serotonin circulate 
stored in platelets, very small quantities are likely to 
be present in the free state in plasma (Molyneux & Clarke,
1985). Furthermore, there may be differences in response 
between species. Indeed, inhaled serotonin has no effect 
on pulmonary function in healthy subjects or adult 
asthmatics, even when administered in supraphysiological 
concentrations (Tonnesen, 1985; Cushley, Lee & Holgate,
1986) .
The asthmatic patients showed no significant reduction 
in sitting blood pressure after ketanserin 40mg, but this 
is not an unexpected response to any antihypertensive
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agent given to normotensive subjects. Ketanserin did not 
affect the pressor response or rise in heart rate caused 
by exercise. In contrast, chronic oral ketanserin 
attenuates the rise in systolic blood pressure and heart 
rate in patients with essential hypertension (Hedner et 
al., 1987).
The lack of any major effect of ketanserin on airways 
function suggests that serotonin is unlikely to be an 
important mediator affecting resting bronchomotor tone or 
causing exercise induced bronchoconstriction in adult 
atopic asthma, although a small beneficial effect of 
ketanserin on exercise-induced bronchoconstriction could 
not be excluded. Further studies of chronic dosage and 
inhaled serotonergic antagonists are required to clarify 
this issue. While oral ketanserin does not appear to have 
immediate clinically relevant beneficial effects in adult 
atopic asthma, it may prove useful as a safe alternative 
antihypertensive agent in patients with this condition.
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Appendix 1: Visual analogue scale questionnaire
(18 factor)
Instructions: Please rate the way you feel in terms of 
the descriptions below. Regard the lines as representing 
the full range of each symptom. Rate your feelings as they 
are at the moment. Mark clearly and perpendicularly across 
each line.
Alert  ____________ __  Drowsy
Calm ______ '______ - Excited
Strong ___________ _________ Feeble
Muzzy  ________________ Clear headed
Well co-ordinated _____________. Clumsy
Lethargic _______ Energetic
Contented  _____  . Discontented
Troubled _____ ________________ Tranquil 1
Mentally slow  ___________.______ Quick witted
Tense _____________________ Relaxed
Attentive __________ . Dreamy
Incompetent ____ _______ ________  Proficient
Happy ______________ _ Sad
Antagonistic ____________________  Friendly
Interested .   . Bored
Withdrawn __      Sociable
Depressed  ____  ____ _ Elated
Self centred . ____ _____ Outward going
(10cm lines)
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Calculation of alertness and tranquillity scores from 
the 18 factor visual analogue scale (Herbert, Johns ' & 
Dore, 1976) are made by calculating the sum of [distance 
from the first to the second word (mm) for each visual 
analogue scale multiplied by the individual factor 
loading]. .
Alertness: Scales Factor loading
Quick-witted/Mentally slow
Alert/Drowsy
Attentive/Dreamy
Energetic/Lethargic
Proficient/Incompetent
Strong/Feeble
Clear headed/Muzzy
Well co-ordinated/Clumsy
Elated/Depressed
Outward-going/Self-centred
Interested/Bored
0.878
0.865
0.864
0.856
0.826
0.793
0.775
0.759
0.592
0.591
0.539
Tranquillity: Scales Factor loading
Tr a nqui11/Tr oub1ed 
Calm/Excited 
Contented/Discontented 
Relaxed/Tense 
Happy/Sad
Friendly/Antagonistic 
Sociable/Withdrawn
0.823
0.798
0.785
0.782
0.744
0.701
0.648
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Appendix 2: Multiple Affect Adjective Check List
Anxiety, depression and hostility scores are calculated 
as the number of "plus words" minus the number of "minus 
words" selected by the patient from the Multiple Affect 
Adjective Check List (Zuckerman & Lubin, 1965).
Anxiety
Plus words (n=ll)
Afraid, Desperate, Fearful, Frightened, . Nervous, 
Panicky, Shaky, Tense, Terrified, Upset, Worrying
Minus words (n=10)
Calm, Cheerful, Contented, Happy, Joyful, Loving, 
Pleasant, Secure, Steady, Thoughtful
Depression
Plus words (n=20)
Alone, Awful, Blue, Destroyed, Discouraged, Forlorn, 
Gloomy, Hopeless, Lonely, Lost, Low, Miserable, Rejected, 
Sad, Suffering, Sunk, Terrible, Tormented, Unhappy, Wilted
Minus words (n=20)
Active, Alive, Clean, Enthusiastic, Fine, Fit, Free, 
Gay, Glad, Good, Healthy, Inspired, Interested, Lucky, 
Merry, Peaceful, Safe, Strong, Whole, Young
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Hostility
Plus words (n=16)
Angry, Bitter, Cruel, Disaggreeable, Discontented 
Disgusted, Enraged, Furious, Irritated, Mad, Mean
Offended, Outraged, Stormy, Unsociable, Vexed
Minus words (n=12)
Aggreeable, Amiable, Cooperative, Friendly
Good-natured, Kindly, Polite, Sympathetic, Tame, Tender 
Understanding, Willful
fcVTavERjam:
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Appendix 3; Visual analogue scale questionnaire
(6 factor)
Instructions: Please rate the way you feel in terms of 
the descriptions below. Regard the lines as representing 
the full range of each symptom. Rate your feelings as they 
are at the moment. Mark clearly and perpendicularly across 
each line.
Alert
Well co-ordinated 
Tense 
Incompetent 
Happy 
Withdrawn
Drowsy
Clumsy
Relaxed
Proficient
Sad
Sociable
(10cm lines)
